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Parkinson’s disease (PD) is a neurodegenerative disease that results, in part, from
the progressive loss of dopaminergic (DA) neurons in the Substantia Nigra pars com-
pacta (SNpc). Several groups have shown that human Pluripotent Stem Cell (hPSC)-
derived dopaminergic neuron Progenitor Cells (DAPCs) can generate mature DA neu-
rons and improve motor function following intrastriatal transplantation in animal mod-
els of PD. This has now evolved to the point that the first in human hPSC-based DA
neural transplants are being undertaken or are being planned in patients with PD. How-
ever, prior to undertaking larger-scale clinical studies, animal experiments are needed
to adequately assess the safety of the therapies. Key safety concerns with such therapies
for PD and other Central Nervous System (CNS) disorders include the risk that the
implanted cells could proliferate and form space-occupying masses and/or migrate to
off-target sites within the CNS and/or induce major neuroinflammation. In addition to
considering the potential risks, it is also important to monitor the long-term viability
and differentiation capacity of implanted cells, as to be effective, they must differenti-
ate into the appropriate phenotype and persist in the brain. Monitoring viability and
biodistribution of the DAPCs over time requires non-invasive imaging techniques. In
this project, a bimodal imaging strategy based on Bioluminescence (BLI) and Magnetic
Resonance Imaging (MRI) to monitor the safety of the human Embryonic Stem Cell
(hESC)-based therapy in immunocompromised nude rats has been investigated. BLI
is the preferred technique for monitoring viability and proliferation in vivo, but spatial
resolution is poor, meaning that it cannot be used to assess intracranial biodistribution.
However, this can be overcome by labelling cells with Iron Oxide Particles (IOPs) so
Abstract
that they can be imaged using MRI, a technique that provides very high spatial res-
olution. RC17 hESCs were transduced with bicistronic Luciferase-ZsGreen lentiviral
particles and directed to differentiate to DAPCs. Expression of DAPC markers was
assessed to confirm the success of the differentiation. Furthermore, a group of RC17
hESCs were differentiated into DAPCs and labelled using Micron-sized Particles of Iron
Oxide (MPIOs) to be visualized using MRI. DAPCs expressing Luciferase-ZsGreen or
labelled with MPIOs were transplanted in the striatum of nude rats (n = 6 per group).
DAPCs were tracked in vivo using BLI and MR imaging modalities. Transgene silencing
in differentiating DAPCs accompanied with signal attenuation due to animal growth,
rendered the BLI undetectable by week 2 post intrastriatal transplantation. However,
MR imaging of MPIO-labelled DAPCs showed that transplanted cells remained at the
site of injection for over 120 days. Post-mortem histological analysis of DAPC trans-
plants demonstrated that labelling with either Luciferase-ZsGreen or MPIOs did not
affect the ability of cells to differentiate into mature dopaminergic neurons. Impor-
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Parkinson’s Disease (PD) was first described by Dr. James Parkinson over 200 years
ago as a “shaking palsy” that he described as “Paralysis agitans” (DeMaagd and Philip,
2015). Today, PD is the second most common progressive neurodegenerative disorder,
affecting 1% of the population over 65 years old. The disease is strongly associated with
increased age and likely to become more prevalent as life expectancy increase (Foltynie
et al., 2004).
Currently, 4.6 million people suffer from PD worldwide and the European Parkin-
son Disease Association (EPDA) has estimated that the annual European cost of the
disease is approximately 14 billion Euros. The number of people in the UK with PD is
estimated to have increased by 27% between 2009 and 2020 (about 162,000 individuals)
(DeMaagd and Philip, 2015). Typically, PD appears in the 6th decade of life, although
about 20% of patients that are classified as “young-onset”, develop PD before age 50
(Mhyre et al., 2012).
1.1.1 Diagnosis and symptoms
Patients with PD are clinically diagnosed with both motor and non-motor systems. The
noticeable motor symptoms including altered gait, bradykinesia (slowness of move-
ment), resting tremors, muscle rigidity, and postural instability, usually occur when
about 60–80% of DA neurons in the SNpc have degenerated (Parkinson, 1817; Twelves
et al., 2003). Typically, the non-motor symptoms such as sleep disorders, depression,
cognitive dysfunction, and pain are also important to identify, as early diagnosis of PD
could be crucial for effective treatment (Schrag et al., 2015).
1. Introduction
Although all patients will not necessarily experience all PD symptoms in the same
order, the typical patterns of progression are nevertheless defined in different stages
based on symptoms development. During the initial stages, mild symptoms such as
changes in gait and posture will occur, but as the disease progresses, more significant
motor abnormalities will appear, and patients typically need assistance with their daily
activities (Gómez-Esteban et al., 2007). During the final stages, more severe and lim-
iting symptoms prevent the patients from undertaking any movement at all and there
can be difficulties with speech and swallowing; in 25-30% of cases, dementia has been
reported (Hakim and Mathieson, 1979; Aarsland et al., 2003). Currently, PD is di-
agnosed on the basis of clinical features. The UK Parkinson’s Disease Society Brain
Bank has formalized some criteria for PD with a diagnostic accuracy of up to 90%.
The bradykinesia is the most common feature which has the strongest correlation with
deficiency of dopamine in PD patients.
Figure 1.1: Clinical diagnosis of Parkinson’s disease using SPECT imaging of
[99mTc]TRODAT-1. [99mTc]TRODAT-1 is a dopamine transporter imaging agent. Left
image shows the histology of the brain to indicate the striatum consisting of Caudate Nu-
cleus (CAUD) and the Putamen (PUT). The middle image is the SPECT image of a normal
brain with a typical degree of [99mTc]TRODAT-1 signal. The right image shows a lower level
of [99mTc]TRODAT-1 signal in a PD patient in the early stages of the disease that indicates
dopaminergic neuronal loss, usually with a more pronounced decrease in the putamen rather
than in the caudate (Herscovitch, 2014).
The other classic symptoms are hypophonia (soft voice), micrographia (small hand-
writing) and rigidity (stiffness), which usually affect the upper limbs in the initial
stages. Clinical imaging approaches are also available to help diagnose PD (Jankovic
and Poewe, 2012). The commonly used imaging techniques are MRI, Positron Emis-
sion Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT)
(Wang et al., 2012). The nuclear imaging techniques, PET and SPECT typically use
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radioactive dopamine ligands to assess dopamine metabolism (Smith et al., 2012; Si-
monson et al., 2007). A reduction in tracer uptake, or asymmetric uptake in the dorsal




PD is characterised by selective degeneration of melanised dopaminergic A9 neurons
in the (SNpc) and disruption of the nigrostriatal pathway. The dopaminergic neurons
projects axons into the putamen and caudate nucleus that form the striatum in pri-
mates to release dopamine (Figure 1.2). The putamen is important for modulation of
planning and movement by stimulation of the motor cortex while the caudate nucleus
is implicated in cognitive processes (Parkkinen et al., 2011).
Figure 1.2: The nigrostriatal pathway and projection of dopamine neurons into
striatum. Signals that control body movements travel along neurons that project from the
substantia nigra to the caudate nucleus and putamen (collectively called the striatum). These
"nigro-striatal" neurons (i.e., dopaminergic neurons) release dopamine at their targets in the
striatum. In Parkinson’s patients, dopamine neurons in the nigro-striatal pathway degenerate
for unknown reasons (Bethesda, 2001).
In the DA neurons of the normal adult brain, L-Dopa is synthesized from the
amino acid, tyrosine, by the enzyme Tyrosine Hydroxylase (TH) that take place in the
cytoplasm. L-Dopa is further converted to dopamine by Dopa Decarboxylase (DDC)
(Hamanaka et al., 2016). Dopamine is then stored in cytoplasmic vesicles using a
3
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Figure 1.3: Dopamine neurotransmitter signalling in the brain. The schematic fig-
ure illustrates the biosynthesis of L-Dopa from Tyrosine using TH and further metabolism
of Dopamine neurotransmitter by Dopa Decarboxylase (DDC). Realising of Dopamine from
presynaptic neuron could be resulted in activation of D1 and D2 receptors in the postsynaptic
neuron. D1 receptor signal through G protein to activate Adenylate Ayclase (AC) and forma-
tion of cAMP and further stimulation of Phosphoinositide 3-kinase (PKA) while D2 receptor
could inhibit this pathway.
Vesicular Monoamine Transporter (VMAT). Release of dopamine neurotransmitter in
the presynaptic neuron results in activation of D1 and D2-type dopamine receptors
in the postsynaptic neuron. The D1 receptor is coupled to Gαs proteins which can
activate Adenylyl Cyclase (AC) to raise intracellular cAMP concentrations, leading to
activation of the phosphoinositide 3-kinase (PKA) pathway; this, in turn, activates
the related transcription factors in the postsynaptic neuron. In contrast, the D2-type
receptor inhibits AC and blocks the PKA signalling pathway (Figure 1.3) (Girault and
Greengard, 2004).
1.1.2.2 Lewy bodies
In the brain of Parkinson’s patients, the degeneration of DA neurons is accompanied by
deposition or accumulation of Lewy bodies which are mainly misfolded and insoluble
aggregates of α-Synuclein (Mahul-Mellier et al., 2020). α-Synuclein protein is mainly
found at the presynaptic terminals of neurons and has a critical role in modulation
of synaptic vesicle dynamics to release neurotransmitters. Usually, the α-Synuclein
inclusions are originate in the SNpc which is the main location of cell loss in PD
patients (Hijaz and Volpicelli-Daley, 2020). Also, the spread of Lewy bodies in the
cortex causes the stepwise degeneration of neurons corresponding to an intensification
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of disease, associated with the appearance of motor symptoms (Meade et al., 2019).
During the late stage of PD, the presence of Lewy bodies was confirmed in the frontal
cortex of patient’s brains; this could explain why dementia is not uncommon in the late
stages of PD (Springer and Kahle, 2011; Spillantini et al., 1998).
In PD cases that have a known genetic basis, it has been established that oligomeri-
sation of α-Synuclein is a common feature (Table 1.1). For instance, mutations in
SNCA, the gene that encodes α-Synuclein, result in the proteostasis, misfolded and
over-expression of α-Synuclein (Park et al., 2018). Mutations in ATP13A2 (PARK9)
and LRRK2 are linked to lysosome dysfunction and/or defective autophagy, leading
to reduced α-Synuclein degradation (Zimprich et al., 2004; Spataro et al., 2019). In
addition, Parkin, PINK1, and DJ-1 have roles in the inducing apoptosis, and hence the
indirect formation of Lewy bodies. Loss-of-function mutations in Parkin and PINK1
result in mitophagy (a cellular process to clear damaged mitochondria) which is asso-
ciated with mitochondrial dysfunction (Park et al., 2018; Hu and Wang, 2016). DJ-1
encodes a putative oxidant known to increase cellular Reactive Oxidative Stress (ROS)
in DA neurons (Ariga et al., 2013). VPS35 gene mutations can result in mitochondrial
fragmentation which leads to neurodegeneration in PD patients. Table 1.1 describes
the main genes implicated in PD.
Table 1.1: The main genes known to cause PD, their encoded protein and mode of transmission
(Lansbury and Brice, 2002; Park et al., 2018).
Gene Role Transmission
α−Synuclein (SNCA) Presynaptic protein Dominant
LRRK2 (PARK8) Kinase Dominant
VPS35 Involved in the transport of proteins from Dominant
endosomes to the Golgi
ATP13A2 Lysosomal protein involved in transportation Recessive
across lysosomal membrane
Parkin (PARK2) Subunit of the E3 ubiquitin ligase Recessive
PINK1 Mitochondrial kinase Recessive
DJ1 (PARK7) Ubiquitin ligase Recessive
1.1.3 Aetiology and epidemiology
Aetiology of PD is poorly understood, but as mentioned above, it is believed that
certain genetic mutations are related to dopaminergic cell death (Table 1.1) (Tanner
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et al., 1999). These genetic mutations are well documented and can be inherited or can
occur through exposure to environmental neurotoxins (Nandipati and Litvan, 2016).
The main environmental neurotoxins that are recognized as a potential cause of PD are
MPTP (N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine), pesticides (such as Rotenone,
Paraquat and Maneb), and metals (such as iron and manganese) (Nandipati and Litvan,
2016). There is also an inflammatory component to PD, as suggested by animal exper-
iments, and by the presence of activated microglia in the SNpc of PD patients. The
activated microglia caused apoptosis by releasing inflammatory cytokines and inducing
cell stress (Lecours et al., 2018).
The incidence of PD is associated with different risk factors such as age, sex and
ethnicity (Wright Willis et al., 2010). The global age prevalence of PD onset is cate-
gorised as “early” and “late” depending on whether symptoms appear before or after
the age of 50. PD is rare before the age of 50 and increases sharply after 80 years of
age (Van Den Eeden et al., 2003).
The other associated PD risk factor is sex, as several studies have shown that
PD is twice as common in men than in women. The protective effects of female sex
hormones and more exposer of males to environmental risks might explain this differ-
ence. Geography and race are also PD risk factors but the reasons for this are unclear
(Wright Willis et al., 2010). For instance, the incidence of PD in Hispanics is 16.6
per 100,000 persons, compared to 13.6 per 100,000 in non-Hispanic Whites, 11.3 per
100,000 in Asians, and 10.2 per 100,000 in Blacks (Van Den Eeden et al., 2003). These
differences in PD prevalence could be due to differences in lifestyle and diet between
each population (Abbas et al., 2018).
1.1.4 Current therapies for PD
Currently, there is no cure for PD, and mainstay treatments focus on providing symp-
tomatic relief (Jankovic and Aguilar, 2008). However, there is optimism that stem cell
therapy could provide a cure for future PD patients by replacing the DA neurons that
are lost as a result of the disease (Section 1.2) (Lindvall and Björklund, 2004).
1.1.4.1 Pharmacological approach
The dopamine replacement drug, L-3,4-dihydroxyphenylalanine (L-Dopa), which is the
precursor of dopamine, is the most effective drug to treat Parkinson’s symptomatically
and all patients receive this treatment over time (Schapira, 2005). Unlike dopamine,
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L-Dopa is able to cross the Blood Brain Barrier (BBB) and is then converted into
dopamine by the DA neurons, thereby restoring dopamine levels in the central nervous
system. However, after an initial period of dramatic benefit (about 5 years), the lim-
itation and side effects of L-Dopa become increasingly problematic. “Dopa-resistant”
symptoms, such as postural abnormalities, speech impairment, autonomic dysfunc-
tion, and/or “drug related” side effects especially development of motor fluctuations
and dyskinesias have been reported (Huot et al., 2013; Widnell, 2005; Thanvi and Lo,
2004). In most PD patients who have received L-Dopa orally, peripheral dopa de-
carboxylase inhibitors (particularly Catechol-O-methyltransferase (COMT) inhibitors)
such as carbidopa, or benderizine are administrated to decrease side effects and im-
prove the activity of L-Dopa in the central nervous system (Vassiliou et al., 2019). In
addition, developing the new sustained-release formulation of L-Dopa and continuous
delivery (via mini pumps subcutaneously or tubes percutaneously) of the drug could
overcome the problems associated with the short half-life of L-Dopa, inconsistency in
BBB transportation and gastrointestinal absorption (van Wamelen et al., 2018).
Dopaminergic receptor agonists such as bromocriptine, and pergolide are able to
target and stimulate the dopamine receptors in the brain and help improve the motor
symptoms (Brooks, 2000). Dopamine mimetic receptors have longer half-lives compared
to L-Dopa and could delay consuming L-Dopa in patients if used in the early stages of
PD development (Perez-Lloret and Rascol, 2010).
Another type of drug used in PD patients are inhibitors of dopamine degrada-
tion. Oxidation via Monoamine Oxidase type B (MAOB) is the main mechanism for
dopamine clearance in the synapses. Inhibitors of MAOB such as Selegiline and Rasag-
iline have been found to effectively increase the concentration of synaptic dopamine
and are helpful in patients with fluctuations in motor symptoms, especially when used
in combination with L-Dopa (Schapira, 2011; Cereda et al., 2017).
1.1.4.2 Neurotrophic factors-based therapies
A vast body of experimental studies suggests that the lack of specific Neurotrophic
Factors (NTFs), the secreted proteins that play a critical role in the development, sur-
vival, protection, and maturation of neurons, contribute to the pathophysiology of PD
(Rodrigues et al., 2014). Two of the dopaminergic NTFs, namely Glial cell line-Derived
Neurotrophic Factor (GDNF) and Neurturin (NRTN) have shown great potential in
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promoting axon regeneration following damage and protection of nigrostriatal DA neu-
rons in vitro (Sullivan and O’Keeffe, 2016). However, the delivery of NTFs to the correct
locations in the brain is still a practical challenge because they cannot pass the BBB
and will undergo rapid bio-metabolism by endogenous enzymes in vivo (Domanskyi
et al., 2015).
A recently published clinical trial using a new infusion protocol for GDNF was
conducted by a group in Bristol (UK CRN 12085). During the course of the trial,
patients were administrated GDNF via a skull-mounted port every 4 weeks using a
bilateral intra-putamenal convection-enhanced delivery (CED) (Whone et al., 2019). As
the outcome of trial, the extent of benefit in the experimental group was not significantly
greater than in the placebo due to the fact that the NTFs need to be delivered more
repeatedly.
Gene therapy could be a potential way to bypass the issue of localized delivery
of NTFs and is an approach that is being actively explored. Recent studies show
that incorporation of therapeutic genes into brain cells using recombinant viral vectors
(Adeno-Associated Viral (AAV) or Lentiviral (LV) vectors), stimulate over expression of
NTFs (Sullivan and O’Keeffe, 2016). In this regard, assessing the safety and tolerability
of AAV-GDNF is one of the ongoing Phase 1 clinical trials for advanced PD (NIH trial
No. NCT01621581).
1.1.4.3 Deep brain stimulation
Deep Brain Stimulation (DBS) is a surgical option for advanced PD patients whose
symptoms are no longer controlled using medication. DBS involves the surgical im-
plantation of an electrode in the brain, usually in the globus pallidus internus or sub-
thalamic nucleus, without any loss of brain tissue (Montgomery Jr. and Baker, 2000).
A pulse generator which is connected to brain electrodes (is placed under the skin of the
chest or stomach area) is able to electrically stimulate specific brain targets resulting
in the mitigation and dramatic improvement of PD symptoms such as dyskinesia and
motor fluctuation for up to about 5 years (Limousin and Foltynie, 2019).
DBS requires high levels of expertise as it is a major surgery in the brain which
is usually associated with complications such as intracranial bleeding, infection, or
misplacement of the electrode (Rezai et al., 2004). DBS cannot stop the Parkinson’s





Cell transplantation is a therapeutic approach that has generated great interest during
recent decades. Current advances in our understanding of the mechanisms and molec-
ular pathways involved in PD, make cell therapy a great candidate to improve the
regeneration of dopaminergic neurons (Barker et al., 2015). Particularly, PD is an ap-
propriate neurodegenerative disorder to be considered for cell replacement therapy due
to the focal degeneration of a small proportion of DA neurons, making it a relatively
easy target. The main objective of cell transplantation is to achieve neurochemical or
structural brain repair in PD by replacing the lost cells with DA neurons (Parmar,
2018). In addition, through cell therapy, DA will be secreted locally in a more physio-
logical way that could overcome the unregulated release of DA across the whole brain
which is currently associated with the pharmacological approaches for PD treatment
(Parmar, 2018).
There are several available cell candidates capable of generating DA neurons for
PD treatment including Fetal Ventral Mesencephalic (FVM) cells, induced Pluripotent
Stem Cells (iPSCs), Embryonic Stem Cells (ESCs); Mesenchymal stromal Cells (MSCs),
Neural Progenitor Cells (NPCs), and human parthenogenetic Embryonic Stem Cells
(hpESCs)that are used in clinical trial.
1.1.4.4.1 Fetal ventral midbrain cells
The idea of replacing the degenerated DA neurons in PD was introduced in the
1970s. Several different cell types have been evaluated in clinical trials, including reti-
nal pigmented epithelial cells, porcine fetal ventral midbrain tissue, adrenal medullary
cells and carotid body cells (Björklund and Lindvall, 2017). In 1987, the first clinical
trial suggested that grafted immature dopaminergic cells derived from the midbrain of
aborted fetuses could replace lost DA neurons, restore connectivity as well as reduce PD
symptoms (Brundin et al., 2000; Piccini et al., 1999). In this trial, the fetal tissue was
transplanted unilaterally or bilaterally into the putamen or caudate-putamen and the
patients were on an immunosuppressive regime only for one year. Additionally, long-
term follow-up trials have provided strong evidence of graft survival and derivation of
functional DA neurons for 24 years with no sign of neuroinflammation (Kefalopoulou
et al., 2014; Li et al., 2016). However, further transplantation studies supported by the
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National Institute of Health (NIH) in the US found that more than 50% of the treated
individuals developed side effects which was mainly graft-induced dyskinesia (Barker
et al., 2013). Due to the inconsistent results obtained in different trials, a European
group set out to define factors associated with positive graft outcomes and conducted
an open trial called TRANSEURO that was initiated in 2009 (Barker et al., 2015). In
this trail the patients in the earlier stages of the PD were included in the experimental
group because earlier studies had shown very low effectiveness of cell administration
for patients in the late stage of disease. 11 patients received bilateral grafts in Cam-
bridge or Lund over 3 years and the last patient was grafted in 2018. Hopefully, the
outcome of this trial will be fully released in 2021 (Barker et al., 2019). However, the
low availability of human Fetal Ventral Midbrain (hFVM) tissue resulted in the cancel-
lation of more than 80 grafting surgeries during the TRANSEURO trial (Barker et al.,
2017). Major shortcomings of hFVM tissues and ethical concerns as well as reported
side effects make this kind of clinical transplantation unfeasible for treating larg group
of patients.
1.1.4.4.2 Neural stem cells
Primary Neural Stem Cells (NSCs) reside in a particular zone of the brain which
is called the “neurogenic niches”. These cells permit neurogenesis throughout life as
they are self-renewing, multipotent cells (Chou et al., 2015). They can be obtained
from fetal, neonatal and adult brains or by the directed differentiation of PSCs. Proto-
cols have been established to isolate NSCs from the adult rat striatal Sub-Ventricular
Zone (SVZ) and Sub-Granular Zone (SGZ) of the hippocampus in order to differentiate
them into specialised Neural Progenitor Cells (NPCs) (Lois and Alvarez-Buylla, 1993;
García-Verdugo et al., 1998). The autologous transplantation of NSC-derived NPCs
has shown promising behavioural improvements in rodent models of PD. To date, only
one trial involving autologous human NSC transplants has been reported (Levesque
et al., 2010). This study was carried out on an individual PD patient and demon-
strated the safety and efficacy of using NSC-derived DAPCs. However, procuring adult
NSCs residing deep within the brain would require an invasive biopsy, which would not
be very feasible due to safety concerns. Furthermore, poor growth potential, unstable
phenotype upon repeated passages, and poor survival after transplantation were re-
ported for these cells (Courtois et al., 2010; Ramos-Moreno et al., 2012). Also, clinical
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trials aimed at assessing the safety and efficacy of these cells are still ongoing (Table
1.2).
1.1.4.4.3 Mesenchymal stromal cells
Mesenchymal Stromal Cells (MSCs) are adults stromal cells that were initially
identified in bone marrow. MSCs can also be isolated from various other sources,
including umbilical cord, adipose tissue and peripheral blood (Joyce et al., 2010). Self-
renewal and multipotency capacity of differentiation into ectodermal linage make MSCs
a good candidate for PD treatment (Chen and Chopp, 2006; Hayashi et al., 2013). In-
terestingly, MSCs are able to secrete immunomodulatory cytokines (such as Interleukin
6 (IL-6), Prostaglandin E2 (PGE2)) that regulate the intensity of the immune response;
and trophic factors (such as GDNF, Brain-Derived Neurotrophic Factor (BDNF), and
Nerve Growth Factor (NGF)) that not only have anti-apoptotic and neuro-regenerative
effects, but also decrease oxidative stress and stimulate tissue regeneration (Caplan and
Correa, 2011). For this reason, MSCs could limit the neuroinflammatory process which
can occur following cell transplantation into the brain. Encouraging results obtained
in experimental PD models have led to clinical trials using MSCs (Kumar et al., 2016).
One of the pioneering studies which was conducted in 2010 involved transplanting au-
tologous MSCs through stereotactic surgery. The patients were followed for a period
of 36 months and clinical improvement was observed in 3 out of 7 patients without any
serious adverse effects (Inden et al., 2016). Later, a pilot clinical study revealed the
feasibility and efficacy of allogeneic MSC transplantation over 12 months in PD patients
in early stages of disease (Venkataramana et al., 2012). However, the long-term safety
and sustainability of this therapeutic strategy needs to be clarified (Mendes Filho et al.,
2018). Other clinical trials involving MSCs for the treatment of PD have not published
any results so far.
1.1.4.4.4 Human parthenogenetic embryonic stem cells
Human parthenogenetic Embryonic Stem Cells (hpESCs) are pluripotent cells that
are derived from the chemical activation of unfertilized oocytes. In 2014 the US Food
and Drug Administration (FDA) cleared the hpESC line used for investigational clin-
ical use (Turovets et al., 2011). hpESCs bypass the ethical concerns associated with
hFVM tissue or hESCs because no fetus or viable embryo is used in their derivation,
but nevertheless, they show the typical characteristics of ESCs such as pluripotency
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and teratoma formation after injection into immunodeficient animals (Wang et al.,
2018). In addition, the de novo mutations in hpESCs are much lower compared to
iPSCs which reduced the potential risk of tumorigenicity (Barker et al., 2016). In
order to use hpESCs in a clinical trial, the stem cells were differentiated into NSCs
(Garitaonandia et al., 2018). Animal studies involving rodent and non-human primate
models of PD have shown that hpNSCs are able to differentiate into TH+ neurons and
promote behavioural recovery without any uncontrolled proliferation of the implanted
cells (Garitaonandia et al., 2018; Gonzalez et al., 2016). However, the first clinical trial
involving hpNSCs in PD was just aiming to assess the short-term safety and efficacy
and has not been completed yet.
1.1.4.4.5 Pluripotent stem cells
Two main PSCs, ESCs and induced Pluripotent Stem Cells (iPSCs) have gained
prominence over the past few years for transplantation as they are less ethically con-
tentious compared to FVM (Medvedev et al., 2010; Amit et al., 2000).
The first mouse ESC line was isolated in 1980s from preimplantation mouse em-
bryos (Evans and Kaufman, 1981) and later in the 1998s, human ESCs were isolated
from the inner cell mass of the blastocyst by the Thomson group (Thomson et al.,
1998). hESCs are pluripotent and self-renewing cells that are able to differentiate into
any cell type and represent a breakthrough for the study of human development and
disease (Thomson et al., 1998). However, harvesting hESCs involves destruction of the
human embryo, which is ethically controversial (Lo and Parham, 2009).
iPSCs are pluripotent and indefinitely self-renew and are generated via reprogram-
ing of differentiated somatic cells. The ectopic expression of four genes, OCT4, SOX2,
KLF4, and c–Myc, in both embryonic and adult murine fibroblasts was first reported
in 2006 by Yamanaka, who used lentiviral vectors to over-express those genes (Taka-
hashi and Yamanaka, 2006). OCT4, SOX2, Nanog, and LIN28 were used to generate
patient specific iPSCs from individuals with genetic diseases (Liu et al., 2013). The
major advantages of using iPSCs in clinical application is that the cultured cells would
have an identical genome, theoretically minimising the risk of immune-rejection and
increasing the chance of integration into the patient’s tissues, while also circumventing


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.2 Pluripotent stem cell therapy for PD
The two most common sources of PSCs, namely ESCs and iPSCs, are the cell types
that have been most rigorously assessed in regard to their safety and efficacy in PD
therapies. Extensive research by different groups around the world have been conducted
to differentiate PSCs into functional neural dopaminergic cells in vitro as these are the
promising specialized cell sources for transplantation in PD patients (Figure 1.4) (Harris
et al., 2020).
1.2.1 Neurodevelopment of midbrain DA neurons
DA neurons also known as Ventral Midbrain (VM) dopaminergic neurons are crucial for
basic motor and non-motor behaviours. During the early development and regionaliza-
tion of the neural tube, the position of cells along the dorsal-ventral and rostral-caudal
axes is instructed through various signalling centres (Kiecker and Lumsden, 2012). In
the neural tube, the gradience of WNT1, FGF8, and SHH signalling pathways provide
the required positional information for development of the Isthmus organizer (IsO) and
Floor Plate (FP) (Liu and Joyner, 2001). IsO specifies the boundary between the mid
and hindbrain using OTX2 and GBX2 transcription factors. The DA neurons are gener-
ated from radial glia-like cells of the FP along the ventral midbrain (Martinez-Barbera
et al., 2001). Extensive studies of transcriptional factors during early brain develop-
ment have revealed that expression of LMX1A and its downstream effector MSX1 in
the mesodiencephalon ventricular zone, are the two earliest genes which determine DA
identity along the dorsal-ventral axis. Expression of FOXA1 and FOXA2markers in FP
also regulate the development and maturation of midbrain DA neurons (Prakash et al.,
2006; Zetterström et al., 1996). In addition to these markers, EN1, EN2, and LMX1B
also influence DA differentiation. The expression of FOXA2, OTX2, and LMX1A genes
was shown in the early progenitor neurons of the most caudal part of the ventral mid-
brain and is sustained through the maturation of midbrain DA neurons (Zetterström
et al., 1996). However, these three markers are also expressed in the rostral domain of
the ventral midbrain that gives rise to the glutamatergic Subthalamic Nucleus (STN)
neurons. Also, PITX2 and BARHL1 were shown to be expressed in the rostral domain
along with FOXA2, OTX2, and LMX1A (Kee et al., 2017).
In the post-mitotic stage of DA progenitor development, the expression of Nurr1 is
initiated which is important in the long-term differentiation and survival of mature DA
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Figure 1.4: Available PSC sources currently be used in the clinical cell therapy for
PD. DA neurons can be differentiated from ESCs isolated from preimplantation blastocysts.
Somatic cells such as fibroblasts can be reprogrammed into iPSCs and further differentiate into
DA neurons for stereotactic injection (Figure is modified from (Parmar, 2018)).
neurons (Hebsgaard et al., 2009). Critically, Nurr1 is the key regulator of dopamine syn-
thesis through induction of TH, Dopamine Transporter (DAT), Vesicular Monoamine
Transporter 2 (VMAT2) and L-aromatic amino acid Decarboxylase (DDc) (Saucedo-
Cardenas et al., 1998). The PITX3 transcription factor is also expressed in the post
mitotic DA progenitors and induces the expression of Nurr1, thereby promoting the
terminal differentiation of DA neurons. Members of the neurotrophin family, including
GDNF, BDNF, Neurotrophin-3 (NT-3), and Neurotrophin-4 (NT-4) are crucial in the
later stage of DA neuron maturation and outgrowth (Jacobs et al., 2009; Nunes et al.,
2003).
1.2.2 Strategies for generating hPSC-derived DA neurons
Few years after the first hESCs were isolated by Thompson (Thomson et al., 1998), a
study describing the spontaneous differentiation of neural cells generated from hESCs
was published (Itskovitz-Eldor et al., 2000). Some of the neural cells that were gen-
erated from this system expressed TH, but their frequency was quite low. However,
the observation that TH-expressing neurons could be derived from hESCs in culture
attracted a great deal of interest due to the possibility that they could be used to treat
PD (Klein et al., 2019).
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The first protocols for directing the differentiation of hESCs to DA neurons in-
volved sub-culturing hESCs on murine stromal feeder cells or fetal midbrain cells with
or without supplementation of growth factors such as FGF8 and SHH. Although these
protocols were quite successful in vitro and resulted in the differentiation of relatively
high numbers of TH neurons, the neurons did not survive following grafting into 6-
OHDA–lesioned rats. In addition, tumour formation was frequently reported following
engraftment, which was thought to be due to non-synchronised and inefficient differen-
tiation of DA neurons in vitro and the fact that the injected cell population contained
undifferentiated hESCs (Perrier et al., 2004; Zeng et al., 2004; Roy et al., 2006; Son-
ntag et al., 2007). Greater understanding of the signalling pathways regulating brain
development in the embryo inspired new protocols to drive DA neuron differentiation
more effectively. In 2009, a group at the Sloan-Kettering institute reported neural
induction through the inhibition of BMP and TGFβ signalling pathways (Chambers
et al., 2009). Follow up studies by this group resulted in an optimised protocol for
developing Floor plate cells from hESCs by supplementation of the culture medium
with the ventralisation signalling factor, SHH (Fasano et al., 2010).
Further studies by Kirkeby et al., 2012 and Kriks et al., 2011, resulted in the gen-
eration of Floor plate-derived midbrain DA progenitors from hESCs that co-expressed
OTX2, LMX1A, and FOXA2 (Kirkeby et al., 2012; Kriks et al., 2011).These initial
reports also showed that a Dual-SMAD inhibition protocol, through the addition of
Noggin and SB431542 to inhibit BMPs and to block the down-stream pathways of
Lefty, Activin and Transforming Growth Factor β (TGFβ), resulted in TH expression
in vitro. Importantly, following engraftment into 6-OHDA lesioned rodents the progen-
itor cells restored motor function in the absence of tumour formation. These studies
demonstrate the feasibility of hESC-derived DA neurons for PD treatment. Later, dif-
ferent groups undertook follow up studies to compare the functionality of the grafted
hPSC-derived DA progenitors with hFVM grafts that had shown some efficacy in clin-
ical trials (Chen et al., 2016; Hallett et al., 2015; Niclis et al., 2017). The study by
Grealish et al., 2014, become an important landmark in this field, as this report showed
similar efficacy and correct target-specific innervation of hESC-derived DA neurons and
restoration of DA neurotransmission in the striatum compared with human FVM grafts
using PET imaging in vivo (Grealish et al., 2014).
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The promising results obtained from assessing the potential of hPSC therapies in
animal models of PD has led to increased focus on improving differentiation protocols
and developing them under Good Manufacture Practice (GMP) condition in order to
move hPSCs therapies to the clinical setting for the benefit of PD patients (Section
1.2.3) (Barker et al., 2017).
The functionality of mature DA neurons arising from hPSC-derived DA progenitor
cells was analysed using a primate model of PD. The survival of grafted iPSC-derived
DA precursor cells in the lesioned primate brain; their maturation into DA neurons
capable of secreting dopamine; and extensive innervation were confirmed in studies by
Hallett et al., 2015 and Kikuchi et al., 2017. These positive effects were seen regard-
less of using iPSC from healthy donors or individuals with PD (Kikuchi et al., 2017).
The benefit of using iPSCs generated from the patient would be to exclude the neces-
sity of using immunosuppressants post grafting. Another new approach that has been
proposed to reduce the need for immunosuppressants is to graft Major Histocompat-
ibility Complex (MHC)-matched allogeneic iPSCs (Morizane et al., 2002). However,
long-term graft rejection is still uncertain in this approach, as a study by Badin et al.,
2019 shows long term rejection following engraftment of MHC-matched iPSC-derived
neurons in a primate model (Aron Badin et al., 2019).
In 2014, the G-FORCE PD organisation (http://www.gforce-pd.com) was formed
in order to develop stem cell-based therapy for PD. In 2018, the first human trial
was initiated in Japan using iPSC-derived DA progenitors from healthy donor to
assess the functionality and safety of the grafted cells ( https://www.cira.kyoto-
u.ac.jp/e/pressrelease/news/180730-170000.html).
1.2.3 The importance of preclinical studies in developing optimal clin-
ical trial regimes for PD using hPSCs
hPSC-based therapies have the potential to dramatically change how PD patients are
treated, because hPSCs can generate DA neurons that are lost in PD. Generally, hPSC
therapies for PD involve directing the differentiation of hPSCs to Dopaminergic Pro-
genitor Cells (DAPCs) in vitro and implanting these specialised cells into the brain
where they undergo further differentiation to mature DA neurons. Although much
progress has been made (Table 1.2), safety and efficacy of stem cell therapies in pre-
clinical models needs to be addressed to increase the likelihood that all PD patients can
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benefit from these promising therapies. To assess safety, it is important to determine
whether the cells generate tumours and/or cause other adverse effects, such as neuroin-
flammation. To assess efficacy, the viability and functional activity of the cells needs
to be monitored, as well as the extent and persistence of any therapeutic response.
In order to develop a safe and functional cell transplantation study, one early de-
cision that needs to be made is which source of pluripotent cells to use: hiPSCs or
hESCs? The risk of genetic abnormalities and teratoma formation is higher with iP-
SCs compared to hESCs which is the consequence of genetic instability due to genetic
manipulation (Liang and Zhang, 2013). In addition, significant cost is associated with
testing the safety and efficacy of different clonal iPSC lines for each individual patient
prior to grafting (Couture and Carpenter, 2015). The only advantage of iPSCs com-
pared to ESCs is that the risk of eliciting an immune response is expected to be lower
for iPSCs. However, a clinical report by Li et al., 2016 suggests that allogenic neural
transplants with 6-18 months of immunosuppression could survive more than 20 years
in the brains of PD patients. Therefore, hESCs appear to have several advantages over
iPSCs and have been selected for use in the forthcoming STEM-PD trial (Li et al.,
2016). The choice of hESC lines is also important because it is known that hESC lines
differ in their propensity to generate specific lineages (Allegrucci and Young, 2007).
Studies by Kirkeby et al., 2017 and Nolbrant et al., 2017 showed that for producing
a cell product for a PD clinical trial, the most appropriate clinical grade hESC lines
are the RC17 line from Roslin Cells, and the HS980 line from the Karolinska Institute.
These cell lines fulfil the important criteria of being free of oncogenic mutation and
fully GMP-derived as well as generating highly pure populations of DA progenitor cells
in vitro that later differentiate into mature DA neurons in vivo (Kirkeby et al., 2017;
Nolbrant et al., 2017).
The next point towards achieving a safer and more efficient PD therapy is optimiz-
ing the patterning of hESCs. Several neural induction methods have been described for
hESC differentiation that involve culturing the cells under adherent conditions, or in
suspension (i.e., as neurospheres). Although these protocols demonstrate the presence
of the ventral midbrain neural progenitor cells, the overall efficiency for generating a
large and homogeneous population with precisely patterned neurons is variable (Sec-
tion 1.2.2) (Kirkeby et al., 2012). A published nature protocol which was developed
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by Parmar’s group at Lund University was utilised in this study to obtain high purity
DAPCs from undifferentiated RC17 hESCs. The protocol is relatively short and by
day 16 of differentiation, almost 90% of the cells have differentiated to caudal ventral
mid-brain progenitors that are able to give rise to mature DA neurons and express
TH. Generation of high yields of differentiated DAPCs is relatively important to di-
minish the risk of contamination of the transplanted population with undifferentiated
hESCs or non-DAPCs that can increase the risk of tumour formation and/or make
the therapy less efficient. In addition, the protocol excludes the neurosphere phase
by shifting the protocol entirely to adherent differentiation in order to diminish batch
to batch variation also making the process user friendly and more easy to adapt to
GMP (Nolbrant et al., 2017). In line with this point, generating hPSC-derived DAPCs
in sufficient numbers for clinical use using the best-available standard protocols is pro-
hibitively expensive. Current methods for generating hPSC-derived DAPCs necessitate
expensive recombinant extra-cellular matrix (ECM) substrates and require re-plating
steps during the differentiation process. This renders the scale-up process both labour-
intensive and very costly, posing a barrier to translation. To address this, our group
developed a molecularly engineered protein-based hPSC culture substrate that can be
easily and cheaply produced. The substrate comprises a recombinant protein nanofiber
carrying a cell-adhesive protein domain. The nanofiber consists of assemblies of two
Ig domains, ‘Z1Z2’, from the human protein titin, which have been molecularly fused
into a four-domain tandem (Z1Z2) (Hill et al., 2019). Our preliminary data have shown
that one of our current Z1Z2-based substrates, can support the differentiation of hP-
SCs to DAPCs at high yield, and their subsequent differentiation to TH-expressing DA
neurons (manuscript in preparation, Figure A.1 in appendix).
Another important parameter that can be assessed using preclinical studies is to
determine the most suitable differentiation stage of dopaminergic cells for grafting.
Recent studies indicate that injecting DA cells at the progenitor stage, rather than
more differentiated DA cells, improves the survival and reinnervation of the graft,
allowing it to ameliorate the behavioural deficits. Grafting DA progenitors provides
sufficient time for the cells to become adapted to the brain microenvironment and
then further maturate to TH+ cells in response to local signalling factors. Another
benefit of transplanting DA progenitors is that following implantation, these cells show
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much higher viability than more mature DA neurons that could improve the efficacy
of transplantation (Morizane et al., 2002).
Figure 1.5: Schematic illustration of sites within the rat and human brain used for
the engraftment of PD stem cell therapies. The schematic illustrates coronal sections of
grafting sites including rat and human striatum together with Substantia nigra pars compacta,
Lateral Ventricles (LV).
The advantage of grafting DA progenitors over more immature neural stem cells is
that in vitro studies have indicated that the progenitors have a very low proliferation
rate, which is further reduced following implantation, diminishing to nearly 0% after
2 weeks. This means that transplanted progenitors are likely to be less tumorigenic
and therefore safer (Qiu et al., 2017; Liao et al., 2014; Yang et al., 2008). Preclinical
studies are also important to find the best site of administration for the cells. There
are various sites in the human and rat brain that could be used for grafting cells as
a PD cell therapy: lateral ventricles, the striatum (in rat) or caudate nucleus and
putamen (in human) and the SNpc (Figure 1.5). Current approaches in clinical trials
are mostly focussed on reconstructing the nigrostriatal pathway by transplanting cells
into the SNpc. These methods attempt to possibly direct the axonal outgrowth of
grafted cells into the striatum to re-stabilise the lost dopaminergic circuitry (Backlund
et al., 1985; Lindvall et al., 1987; Madrazo et al., 1987). However, the survival of the
grafted cells in the SNpc is less compared to intra-striatal grafts (Grealish et al., 2014).
In rodent models of cell therapy for PD, placing neural progenitors into the striatum is
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more common compared to grafting directly into the SNpc (Nikkhah et al., 1994b,a).
In rodents, reaching the striatum is much more practical through drilling the skull to
inject cells. Also, the survival, innervation and maturation rate for progenitor cells is
more when they were injected into striatum (Boronat-García et al., 2017).
Following cell implantation, tracking the biodistribution and fate of transplanted
cells and determining their effect on the host brain is essential for assessing their safety
and efficacy. Key safety concerns include the risk that the cells could form tumours,
mal-differentiate, migrate to the wrong target site, or induce neuroinflammation. To
be effective, the administered cells need to survive, mature into DA neurons of the
right phenotype at high efficiency, innervate the host striatum, display physiological
functionality (i.e., show pacemaker potentials, release dopamine), and normalise motor
control. At present, cell biodistribution and fate is assessed in rodent PD models using
histological analyses at the study endpoint. A drawback with this approach is that it
does not allow the cells to be tracked over time in a single animal, instead requiring
groups of animals to be culled at multiple time points. Moreover, it is difficult to
accurately assess the biodistribution of administered cells across the whole brain from
histological sections. Regarding the therapeutic efficacy of transplanted cells, this is
typically monitored in rodent PD models using behavioural tests, the most common
being the amphetamine-induced rotation assay. Amphetamine induces a pronounced
rotation directed ipsilateral to the lesion and lasting about 2-hour in rats bearing a
unilateral lesion of the nigrostriatal dopaminergic pathway. Implantation of DAPCs
into the lesioned striatum leads to a compensation of this rotation (Herman et al., 1993).
A problem with this test, however, is that it has previously shown poor correlation
between the rate of amphetamine-induced rotations and the number of DA neurons
in the lesioned side of the brain, making it difficult to quantify the extent of recovery
following cellular therapy on an individual animal basis (Tronci et al., 2012). Therefore,
to accurately assess safety and efficacy, non-invasive imaging strategies are needed
that allow the biodistribution and fate of the cells, along with their therapeutic and
pathological effects to be assessed in individual animals longitudinally (Section 1.3). A
further advantage of this approach is that it obviates the need to cull animals at multiple




1.2.4 Application of animal models of PD
In recent years, different animal models have been used to recapitulate PD. Reserpine
was one of the first pharmacological agents used to induce a reversible loss of DA neu-
rons in the SNpc (Carlsson et al., 1957). Reserpine is able to prevent the uptake of
neurotransmitters via blocking the vesicular monoamine transporter. However, there
is no nigral dopaminergic cell degeneration using reserpine (Colpaert, 1987; Duty and
Jenner, 2011). Later on, neurotoxins that could ablate DA neurons became more pop-
ular. Currently, one of the toxins that is extensively used in cell transplant and gene
therapy studies using rodent models is 6-Hydroxy-Dopamine (6-OHDA). This neuro-
toxin penetrates into the cytoplasm of the cells through catecholamine transporters
and inhibits mitochondrial complexes I and IV to generate paraquinone and hydrogen
peroxide (Tieu, 2011). 6-OHDA is administered directly into the brain as it is not
able to cross the BBB. The site of injection can be the terminal area of the striatum,
substantia nigra, or nigrostriatal dopaminergic tracts in the medial forebrain bundle
(Cannon and Greenamyre, 2010). Bilateral 6-OHDA lesioned animals develop severe
movement impairment that affects their feeding and drinking ability, so in most studies,
unilateral 6-OHDA lesioned animals are preferred, and this is the most commonly used
PD model. Also, the ipsilateral hemisphere can be used for assessing behaviour and
can serve as a control (Jagmag et al., 2016).
The compound N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) has been
shown to cause permanent Parkinson symptoms by destroying nigral cells (Liu et al.,
2008). MPTP is metabolized into MPP+ via glial cells (mainly astrocytes) using
Monoamine Oxidase B (MOB) which can rapidly demolish dopaminergic cells in the
SNpc (Jagmag et al., 2016). MPTP has been used in mice and monkey animal models
but rats are not sensitive to this neurotoxin as the expression of monoamine oxidase
B is lower in rats comparing to mice and monkey. Currently, exposure to MPTP is
widely used to generate a non-human primate model of PD which is associated with
immunoreactivity to α-Synuclein (Porras et al., 2012).
Some of the endotoxins, such as lipopolysaccharide, can stimulate inflammation in
the substantia nigra which results in the death of dopaminergic neuron. This endotoxin
could be used to create PD models, but it causes a high death rate in animals (Koprich
et al., 2017). Moreover, this PD model is associated with a high degree of variability
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because the level of inflammation and cell death can differ considerably between animals
(Liu and Bing, 2011).
Genetically modified animals have recently been established to mimic PD. PD
Modelling via genetic modification is preferable in mice as the new findings suggest
that PD genes and its pathological events are likely to mirror human PD (Breger and
Fuzzati Armentero, 2019). In this method, the PD transgene construct such as A30P
α-Synuclein and A53T α-Synuclein, will be delivered into desired region of the brain
(striatal or intranigral injection) to robustly induce transgene expression throughout
the lifetime of the animal (Dawson et al., 2010). The transgenes are typically in-
troduced using viral systems, such as lentivirus, recombinant Adeno-Associated Virus
(rAAV), and Herpes Simplex Virus (HSV), according to the purpose of the study and
the transgene structure. However, there are significant difficulties associated with using
transgenes vectors such as generating sufficient quantities of high-titer vector, random
integration into host genome resulted in mutagenesis and oncogenesis. (Koprich et al.,
2017).
1.3 Imaging techniques to track stem cell
Stem cell therapy for neurodegenerative diseases is a growing field that is moving to-
ward clinical trials. However, human cell therapy needs innovative and breakthrough
methods to analyse cell migration, biodistribution and the viability of transplanted
cells, and monitor how the stem cells differentiate and integrate into the host tissue
to reconstruct brain function (Sakthiswary and Raymond, 2012). Many labelling, his-
tological, and imaging techniques have been developed to assess both the safety and
efficacy of stem cell therapies (Scarfe et al., 2017). Traditional approaches to track
stem cells, such as fluorescence imaging of histological sections, requires animals to be
culled in order to explore survival and differentiation of grafted cells. On the other
hand, non-invasive imaging strategies such as BLI, MRI, PET, and SPECT enable the
cells to be monitored longitudinally in the same animal (Jiang et al., 2011). To increase
the likelihood that stem cell therapies will be successful in clinical trials, neuroimaging















































































































































































































































































































































































































































































































































































































































































The key parameters that should be assessed in order to determine safety and effi-
cacy are migration, tumorigenicity, immunogenicity, survival, differentiation, innerva-
tion, and functionality of grafted cells (Heslop et al., 2015). Table 1.3 lists the available
imaging modalities for stem cell tracking in vivo (Zheng et al., 2017).
1.3.1 Bioluminescence imaging
Bioluminescence imaging (BLI) is a non-invasive optical imaging technique that offers
very high sensitivity, enabling even small numbers of cells to be detected in vivo. BLI
involves the detection of light emitted following the ATP-dependent enzymatic reaction
of a luciferase enzyme and an appropriate substrate in the cells. In order to perform
BLI, cells are genetically modified to express luciferase reporter gene (Zhao et al.,
2005). So as to label cells of interest, the genes encoding the transcription of luciferase
enzymes should be introduced into the genome of cells, usually using a lentiviral vector
to facilitate integration into the host genome. The labelled cells with an integrated
luciferase gene can be administrated into the animals and will be tracked by BLI. The
oxidation process by luciferin requires ATP and oxygen that are only be found in live
cells (Figure 1.6).
Figure 1.6: Simplified oxidation reaction of light generation luciferin. The diagram
is showing ATP and luciferin as substrate for luciferase to generate light which only happen in
the viable cells.
There are several kinds of luciferase that can be used in BLI including firefly lu-
ciferase (Photinus pyralis, Fluc), Renilla luciferase from North American sea pansy
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(Renilla reniformis, Rluc), and Gaussia luciferase from marine copepod (Gaussia prin-
ceps, GLuc) (Kim et al., 2004). The exogenously administrated substrate is luciferin
in the case of Fluc and coelenterazine in the case of Rluc or GLuc. Fluc is the most
commonly used luciferase for BLI, due to its brightness and stronger signal for detec-
tion by imaging. The Fluc emits light at red shifted 530–640 nm and peaks at 562
nm wavelength which is not so readily absorbed by endogenous chromophores such as
melanin, and haemoglobin compared to Rluc and Gluc, which emit light at around 480
nm that can be readily absorbed by endogenous chromophores (Conway et al., 2020;
de Almeida et al., 2011). Furthermore, luciferin has “slow glow” kinetics which emits
light around 15 minutes after administration and takes around 2 hours to be cleared
after administration. Coelenterazine, has “fast flash” kinetics and is rapidly cleared
from body. Also, the substrate, luciferin, can readily reach all bodily tissues including
the brain, allowing for while body biodistribution. (Couillard-Despres et al., 2011).
Thus, Fluc is an ideal tracking agent to monitor cell survival (Kruttwig et al., 2010).
However, the spatial resolution of BLI is lower compared to other non-invasive imaging
systems such as MRI. Furthermore, the tissue penetration depth is about 1 cm which
makes it difficult to use in large animals (Table 1.3) (Sutton et al., 2008).
1.3.2 Magnetic resonance imaging
One of the important methods for non-invasive and real-time tracking of stem cells that
offer high spatial and temporal resolution images is Magnetic resonance imaging (MRI).
Gadolinium (III) (Gd3+) is a heavy metal MRI contrast agent which is used in animal
and clinical experiments (Wahsner et al., 2019). In many tracking methods, there is a
problem of low uptake of (Gd3+) contrast agent by cells (Caravan et al., 1999). In those
cases, transfection agents or coupling of the contrast agent to a membrane peptide are
available to increase the rate of cell uptake (Estelrich et al., 2015). Manganese is another
useful contrast agent which is being used more to study brain function. Manganese is
an attractive contrast agent in MRI particularly to study neural activity of transplanted
cells as it can enter the cells quite conveniently via calcium/sodium exchanger channels
or magnesium binding sites on the nucleic acids or proteins (Silva and Bock, 2008).
Arguably, the most useful MR contrast agents available for cell tracking are iron
oxide particles. These are biocompatible as they are typically coated with hydrophilic
polymers, including low molecular weight carboxydextran and they generate a much
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higher signal than other MR contrast agents, allowing smaller numbers of cells to be
detected (Unterweger et al., 2018). Also, compared to manganese or gadolinium, the
paramagnetic metal per mole is highly increased in iron oxide particles, which helps to
increase the MRI signal-to-noise ratio (Feng et al., 2018).
Iron oxide particles have been classified according to the overall size of the particles
as follows: 1) Ultra-Small Superparamagnetic Iron Oxide Nanoparticles (USPIONs)
with diameter less than 50 nm, 2) Superparamagnetic Iron Oxide nanoparticles (SPI-
ONs) (100 nm range) and, ultimately, 3) Micron-sized Particles of Iron Oxide (MPIO)
with a diameter usually higher than 1 µm (Estelrich et al., 2015).
Many studies have shown that SPION labelling of stem cells has no adverse effect
on the survival, migration, and cell function in vitro (Wahajuddin and Arora, 2012).
More importantly, in vivo imaging suggests that the labelled cells can be visualised
through MRI up to several weeks after transplantation (Zhu et al., 2006). The two
formally approved SPIONs used for stem cell labelling were subsequently removed from
the market in 2009 because of economic considerations.
In addition to SPIONs, MPIOs are also available as MR contrast agents and have
been used to track a variety of cell types such as neural progenitor cells, mesenchymal
stromal cells, macrophages and tumour cells in vivo using MRI (Shapiro et al., 2004).
MPIOs are multicore microspheres embedded in a carboxyl-modified polystyrene matrix
and can be internally loaded with fluorescent dyes, thereby enabling them to be detected
on histological samples using confocal fluorescence microscopey (Taylor et al., 2014).
MPIOs are now commonly used in preclinical imaging and cell tracking as they are
biocompatible and simply require incubation in the culture media for 24 hours before
cell administration to be uptaken via spontaneous endocytosis by cells without the
need for complexation with transfection agents or potentially harmful electroporation
(Shapiro et al., 2005). Furthermore, MPIOs more efficiently package iron due to their
bigger volume, facilitating their detection with MRI.
However, there are several limitations associated with stem cell labelling using
magnetic contrast agents. Dilution of label due to stem cell proliferation after grafting
is one of the common issues, resulting in reduction of MR signal over time (Zheng et al.,
2017). In addition, the dead cells can be engulfed by immune cells, especially microglia
in the central nervous system, which could lead to false signals on MRI; therefore, it
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cannot reveal changes stem cell survival and microenvironment (Margel et al., 2007).
1.3.3 PET and SPECT
Positron Emission Tomography (PET) and Single Photon Emission Computed To-
mography (SPECT) are both nuclear medicine imaging techniques that represent a
promising imaging modality in experimental and clinical stem cell tracking (Margel
et al., 2007). In these techniques, a radiotracer, such as 11C, 13N, 15O, 18F, 89Zr, and
111In is used to label stem cells in order to detect transplanted cells in the host tissue.
The PET camera is able to image with relatively high spatial resolution by detecting
positron emitting radioisotope (Patrick et al., 2020). SPECT is very similar to PET;
however, SPECT uses gamma emitting radioisotopes which are generally less sensitive
than those used in PET imaging and the technique is less quantitative (Gleave et al.,
2011). SPECT tracers are usually cheaper than PET tracers due to SPECT radioiso-
topes being more readily available (Kaneta, 2020). The most widely used isotopes in
PET imaging are fluorine-18 (18F), and copper-64 (64Cu) half-lives of 110 minutes and
12.7 hours, respectively. Another isotope that has a longer half-life for PET scanning
is 89Zr-oxine, with a half-life of about 3 days (Margel et al., 2007; Zheng et al., 2017).
The SPECT radiotracers such as 99mTc-HMPAO, 99mTc-ECD, 123I-IBZM, and 123I-
ioflupane have half-lives of about 6 to 12 hours and are normally used to investigate
brain diseases (Martí-Bonmatí et al., 2010).
1.3.4 Assessment of the safety and efficacy of cell transplants using
non-invasive techniques
To determine which strategies for manufacturing hPSC-based therapies for PD are
safest and most effective, we need to be able to track the fate of the cells longitudinally
in vivo. Safety and efficacy data are essential for assessing the risk: benefit ratio of
hPSC-based therapies so as to identify those that are most appropriate for clinical use
(Heslop et al., 2015). To assess safety, it is important to determine whether the cells
generate tumours and/or cause other adverse effects, such as neuroinflammation. To
assess efficacy, the viability and functional activity of the cells needs to be monitored,
as well as the extent and persistence of any therapeutic response (Goldring et al., 2011).
BLI is the preferred technique for monitoring viability and proliferation in vivo, due
to the fact that it only detects living cells. However, the spatial resolution achievable
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with BLI is low, meaning that it cannot be used to assess intracranial biodistribution
(Puaux et al., 2011). This can be overcome by labelling cells with iron oxide particles
(IOPs) so that they can be imaged using magnetic resonance imaging (MRI), provid-
ing very high spatial resolution. MRI enables brain anatomy to be monitored in fine
detail allowing an accurate way to visualise tumour formation and biodistribution of
transplanted cells (Kraitchman et al., 2008; Stroh et al., 2019).
In order to assess the functionality of the administered cells, measuring dopamine
synthesis using PET imaging is the most commonly used non-invasive imaging tech-
nique. The tracer 6-[ 18F]DOPA which is taken up by DA neurons is being clinically
developed for this purpose [189]. In addition, to determine whether the administered
cells induce inflammation in the host brain, using the PET tracer [18F] DPA-714, a
ligand for the 18 kDa Translocator Protein (TSPO) that is upregulated in activated
microglia, astroglia and macrophages has been used (Arlicot et al., 2012).
1.4 Aim of the study
A key aim of this study, was to assess the potential of a bimodal BLI/MR imaging
strategy to track hESC-derived DAPCs in vivo in terms of their viability, biodistribu-
tion, and tumourigenicity. In addition to evaluating the effectiveness of the imaging
modalities themselves, we also investigated whether the labels used for tracking in-
cluding, namely, firefly luciferase for BLI and iron oxide particles for MR imaging,
affected the differentiation potential of the cells and/or their immunogenicity following





The cell line which has been used in this project is the human embryonic stem cell
(hESC) line RC17 (female; passage number 24). RC17 is a clinical grade line obtained
from Roslin Cells Ltd (Scotland, UK). As per the description notes by the supplier, the
provided cell batch by Roslin CT had already been assessed using karyotyping to show
normal chromosome complement and the sex of the cells; phenotyping (through FACS
analysis using SSEA4 surface marker); absence of microorganisms and mycoplasma.
The cells were used after passaging only 3 to 4 times and it was assumed that in this
short time-frame, it would be unlikely that the cell population would contain many
cells with an abnormal karyotype. The undifferentiated ESCs were checked for OCT4
and Nanog expression prior to them being differentiated into dopaminergic neurons.
The cells were also routinely assessed for the presence of mycoplasma.
2.2 Maintenance of hESCs
RC17 cells were thawed, frozen, expanded, and passaged according to the instructions
of the supplier, as described below, using xeno-free media and reagents. Cell culture
procedures were performed using sterile culture reagents in a Class II safety cabinet.
2.2.1 Plate coating
To prepare coated plates for undifferentiated cell line, laminin 521 (0.5 µg/cm2). (Bio-
lamina) was mixed in PBS (+Ca2+/+Mg2+) in a polypropylene conical tube and added
to the tissue culture treated plate (Corning Costar). Plates were shaken thoroughly
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to ensure homogeneous coating. For urgent cell plating, coating was performed by in-
cubating the plates at 37°C for 2 hour. For slow coating, the plate was wrapped in
parafilm and stored at 4°C for 1–7 day. Plates coated at 4°C, were placed at 37°C for
1–2 hour before use.
2.2.2 Thawing and freezing
Cryovials were removed from the liquid nitrogen tank and placed in a water bath
(37°C) until partially defrosted. The cell suspension was then transferred to a 15
ml conical tube containing 10 ml of wash which consisted of DMEM/F12 (Gibco)
supplemented with 10% Human Serum Albumin solution (Irvine Scientific). After
centrifugation 250×g for 3 minutes) the supernatant was discarded, and the cell pellet
resuspended in fresh StemMACS iPS-Brew XF media (StemMACS™), and then seeded
in the coated dishes. In order to increase the yield of recovery of the cells, 10 µM of
Y-27632 dihydrochloride (StemMACS, Miltenyi) (ROCK inhibitor) was added to the
medium of the seeded cells for the first 24 hour after plating. In order to freeze down
the cells, the plate was washed once with PBS (without Ca2+/ Mg2+) and incubated
for 4 minutes in Versene solution (Thermo Fisher Scientific). Versene was neutralised
using wash medium and the cells were gently collected after only one wash. Trituration
was avoided to ensure that cells were frozen and passaged as small clumps, rather than
as single cells. Cell pellets were collected by centrifuging at (250×g for 3 minutes.
Cell pellets were resuspended in CryoStor CS10 (StemCell Technology) freezing media
and 1 ml of cell suspension was transferred into cryovials. The cryovials were stored
in freezing containers (Mr Frosty) filled with 2-propanol at -80°C overnight to ensure
freezing occurred, and the day after, were transferred to a liquid nitrogen tank.
In order to freeze down the cells, the plate was washed once with PBS (without
Ca2+/ Mg2+) and incubated for 4 minutes in Versene solution (Thermo Fisher Scien-
tific). Versene was neutralised using wash medium and the cells were gently collected
after only one wash. Trituration was avoided with both cell lines to ensure that cells
were frozen and passaged as small clumps, rather than as single cells. Cell pellets were
collected by centrifuging at 250 × g for 3 minutes. Cell pellets were resuspended in
CryoStor CS10 (StemCell Technology) freezing media and 1 ml of cell suspension was
transferred into cryovials. The cryovials were stored in freezing containers (Mr Frosty)
filled with 2-propanol at -80°C overnight to ensure freezing occurred at a rate of , and
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the day after, were transferred to a liquid nitrogen tank.
2.2.3 Passaging
Undifferentiated cells were expanded on Laminin 521-coated cell culture plates in the
StemMACS iPS-Brew XF media which was pre-warmed to room temperature. The
cell medium was changed every day, and when the colonies reached 70-80% confluency,
they were incubated for 4 minutes in Versene solution (Thermo Fisher Scientific) and
passaged as small clumps. After 3 minutes 250×g centrifugation, the supernatant was
discarded, and cells gently re-suspended in an appropriate amount of StemMACS iPS-
Brew XF medium supplemented with 10 µM Y-27632 for the first 24-hour after seeding.
To avoid disrupting the small cell clumps during the replating process, trituration was
avoided. Cells were always maintained at 37°C under 5% CO2.
2.2.4 Embryoid body formation
In order to make Embryoid Bodies (EBs), the undifferentiated colonies of hESCs (70-
80% confluent) were incubated with Accutase (Stem Cell Technologies) for 5 minutes or
until partial detachment. 1x106 single cells were suspended in 5 ml APEL 2 (Stem Cell
Technologies) media, supplemented with 10 µM of Y-27632 and added into a well of an
AggreWell800 plate (Stem Cell Technologies) containing approximately 300 microwells
per well with a diameter of 800 µm which was pre-treated with AggreWell rinsing so-
lution (Stem Cell Technologies). AggreWell plates were centrifuged at 100×g for 3
minutes to deposit the cells in the microwells and incubated at 37°C for 24-hours, dur-
ing which time spherical aggregates of deposited spheroids were formed. The medium
of the AggreWell was changed every 2 days until day 10, when spheroid aggregates
were collected by firmly pipetting in the AggreWell plate. EB culture was initiated by
seeding spheroids into Matrigel (Corning)-coated cell culture plates for another 10 day
with medium being changed every other day.
2.3 Generation of hESC reporter line
The pHIV Lentivirus was used to transduce the undifferentiated cells. The construct
encodes a 9320 bp bicistronic element encoding firefly luciferase (luc2) and ZsGreen
(via an IRES link) under the control of the constitutive promoter, Elongation Factor
α (EF1α). A schematic showing the vector is provided in Figure A.2.
In order to transduce cells, colonies of undifferentiated RC17 cells were dissociated
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into small clumps (as they would have very poor survival by seeding as single cells)
consisting of about 5-10 cells using Versene solution for 4 minutes. After 3 minutes
centrifugation at 250×g, cells were counted using a haemocytometer and seeded at a
density of 5x104 cells per well in laminin 521-coated twelve-well plates, in a volume
of 500 µl iPS-Brew supplemented with 10 µM Y-27632 per well (to promote cell at-
tachment and inhibit anoikis). Cells were incubated overnight and transduced on the
following day. Three Multiplicity Of Infections (MOIs) including 5x104, 15x104, and
25x104 viral particles/µl were tested in order to determine the best concentration for
transduction. To enhance the transduction efficiency and virus-cell interaction, the
medium was supplemented with Polybrene (Sigma Aldrich) at a concentration of 10
µg/ml. After 24-hour, the medium was replaced with 1 ml of fresh iPS-Brew and cells
were cultured routinely, with the medium being changed daily.
2.4 Labelling cells with Micron-sized particles of iron ox-
ide
The 1 µm fluorescent Micron-sized Particles of Iron Oxides (MPIOs) (Bangs Beads
laboratories, catalogue No. MESY002) with the fluorophore ‘Suncoast yellow’ incor-
porated (exciting maximally at 540 nm and has its greatest emission at 600 nm) were
used for direct labelling of DAPCs. The MPIOs of stock concentration 5×106/µl were
diluted to 1×106/µl in B27 basal medium. The DAPCs (1×106 cells on day 15 of dif-
ferentiation) were incubated for 24-hour with the MPIOs at a range of concentrations
from 500-8000 particles/µl. On addition of the MPIOs, the plates were shaken to en-
sure even distribution throughout each well. Cell uptake efficiency was then assessed
by flow cytometry.
2.5 Fluorescence-activated cell sorting
Fluorescence-Activated Cell Sorting (FACS) was used to sort transduced hESCs into
two different populations of “Dim green” and “Bright green” cells. In order to perform
the cell sorting, colonies of RC17 cells were expanded for 4 days until they reached 80%
confluency. Cells were dissociated into single cells using TrypLE (Gibco) and 1×106
cells were harvested. Then cells were resuspended into Iscove’s Modified Dulbecco’s
Medium (IMDM), no phenol red (Gibco) in round-bottom glass tubes for sorting. A
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group of non-transduced cells were used as a baseline control. Sorting was performed
using the BD FACSAria (BD Biosciences) flow sorter. The Brightgreen-sorted cells were
collected in the iPS-Brew culture medium and seeded with the supplementation of 10
/µM Y-27632 on laminin 521-coated cell culture plates (Corning Costar) for routine
expansion.
2.6 Flow cytometry analysis
2.6.1 ZsGreen labelled cells
Cells were dissociated as single cells using TrypLE (Gibco) and resuspended in PBS
and finally were transferred into round-bottom glass tubes in ice until analysed. Cells
were analysed by BD FACScalibur (BD Biosciences), using 488 nm laser and eGFP
fluorescence detector to visualise ZsGreen expression. Each analysis was based on
10,000 to 20,000 events and the negative control was non-transduced RC17 cells. Flow
cytometry output was analysed using Flowing Software (TURKU Bioscience).
2.6.2 MPIO labelled cells
Following the 24-hour incubation of DAPCs with MPIOs, cells were treated with min-
imal volumes of Accutase (Stem cell Technologies) (75 µl/cm2) at 37°C for 10 minutes
to obtain a single cell suspension. Cells were triturated and removed from the wells
on addition of PBS and subsequently centrifuged at 250×g for 3 minutes. The su-
pernatant was removed, and the pellet was resuspended in 1 ml PBS. Cells were then
re-centrifuged to remove residual particles that had not been taken up by cells. The
pellet was then resuspended in a final 1 ml of PBS and kept on ice until analysed. Flu-
orescence was detected using BD FACSCalibur (BD Biosciences). In Flowing software,
doublets and dead cells were excluded from the analysis and the percentage of the cell
population that was positive for fluorescence, i.e., the percentage of the cell popula-
tion that had uptaken MPIOs, was calculated. Graphs were then plotted in Originlab
version 2015.SR1.
2.7 Differentiation of hESCs into DAPCs In vitro
In order to differentiate hESCs into caudalized Ventral Midbrain (VM) progenitors,
a previously published nature protocol was followed (Nolbrant et al., 2017). The
34
2. Materials and methods
Figure 2.1: Schematic overview of dopaminergic progenitor differentiation protocol.
Over 16 days differentiation protocol, DAPCs could terminally differentiate in vitro or
could be grafted for in vivo study (Modified from (Nolbrant et al., 2017))
schematic overview of the protocol steps is shown in Figure 2.1. To optimise the proto-
col, three different concentrations of the small molecule CHIR99021 (GSK-3 inhibitor)
were tested: 0.7, 0.8, and 0.9 µM. The 0.9 µM CHIR99021 was the most effective
concentration which was applied in our experiment.
The entire process of VM progenitor differentiation was on laminin 111 (Biolam-
ina). To prepare laminin 111 coated plates, laminin 111 (1 µg/cm2) was added to a
15 ml polypropylene conical tube containing PBS (+Ca2+/+Mg2+), and after mixing,
was transferred to the cell culture plates and stored at 4°C for 1–7 day. To start the
differentiation process (day 1), when 70% confluent, the undifferentiated Bright green
RC17 cells, were dissociated using Accutase (75 µl/cm2), and 10,000 cells per cm2 were
seeded on Laminin 111-coated culture plates in 250 µl/cm2 differentiation medium
which consisted of: *N2 medium + 10 µM Y-27632 (StemMACS) + 10 µM SB431542
(StemMACS) + 100 ng/ml Noggin (Miltenyi) + 300 ng/ml Shh-C24II (Miltenyi) and
CHIR99021 (0.7, 0.8, and 0.9 µl depending on the condition) (StemMACS). On the fol-
lowing days, day 2, day 4, and day 7, the old medium was removed and replaced with
250, 300, 350 µl/cm2 of fresh differentiation medium respectively without Y-27632. On
day 9, the medium was replaced with 400 µl/cm2 of N2 medium + 100 ng/ml FGF8b
(Miltenyi). On day 11, cells were replated using Accutase (75 µl/cm2) and were seeded
on laminin 111-coated plates at a density of 800,000 cells/cm2. In this step the medium
components were: **B27 medium + 10 µM Y-27632 (StemMACS) + 20 ng/ml BDNF
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(Miltenyi) + 0.2 mM L-Ascorbic Acid (AA) (Sigma-Aldrich) + 100 ng/ml FGF8b (Mil-
tenyi). On day 14, the old medium was replaced with 600 µl/cm2 fresh media which
comprised all components which were used on day 11, apart from Y-27632. Table 2.1
describes the timing, media composition, and corresponding volumes for differentiation
of DAPCs. On day 16, patterning of VM progenitors was completed and cells were
either (i) cryopreserved; (ii) used for transplantation, or (iii) further differentiated into
mature DA cells in vitro.




Medium composition (growth factors to be freshly added




N2 complete: N2*0 basal medium, Y-27632 (10 µM), SB431542
(10 µM), Noggin (100 ng/ml), Shh-C24II (300 ng/ml)
and CHIR99021
(0.7,0.8, 0.9 µM depending on the condition).
250
2
N2 complete: N2 basal medium, SB431542 (10 µM), Noggin
(100 ng/ml), Shh-C24II (300 ng/ml) and CHIR99021 (0.7,0.8, 0.9 µM
depending on the condition).
250
4
N2 complete: N2 basal medium, SB431542 (10 µM), Noggin
(100 ng/ml), Shh-C24II (300 ng/ml) and CHIR99021 (0.7,0.8, 0.9 µM
depending on the condition).
300
7
N2 complete: N2 basal medium, SB431542 (10 µM), Noggin
(100 ng/ml), Shh-C24II (300 ng/ml) and CHIR99021 (0.7,0.8, 0.9 µM
depending on the condition).
350
9 N2 complete: N2 basal medium, FGF8b (100 ng/ml). 400
11
B27 complete: B27∗∗ basal medium, Y-27632 10 µM, BDNF
(20 ng/ml), Ascorbic acid (0.2mM) and FGF8b (100ng/ml).
570
14
B27 complete: B27 basal medium, BDNF (20 ng/ml), Ascorbic
acid (0.2 mM), FGF8b (100 ng/ml).
600
*N2 basal medium, 40 ml of which consists of: 19.6 ml DMEM/F12 (Thermo Fisher Sci-
entific), 19.6 ml of neurobasal CTS medium, 0.4 ml N2 supplement (Thermo Fisher Scientific)
(final concentration, 1% (v/v)), 0.4 ml L-glutamine (Thermo Fisher Scientific) (final concentra-
tion 2 mM) and 80 µl of penicillin-streptomycin (Thermo Fisher Scientific) (final concentration,
0.2% (v/v)).
**B27 basal medium, 40 ml of which consists of: 38.7 ml of neurobasal CTS medium, 0.8
ml of B27 supplement without vitamin A (Thermo Fisher Scientific) (final concentration,2%
(v/v)), 0.4 ml L-glutamine (final concentration 2 mM) and 80 µl of penicillin-streptomycin
(final concentration, 0.2% (v/v)).
36
2. Materials and methods
2.8 Differentiation towards mature DA cells In vitro
DAPCs (which were on day 16) were kept in B27 medium + 20 ng/ml BDNF (Miltenyi)
+ 0.2 mM AA (Sigma-Aldrich) + 100 ng/ml FGF8b (Miltenyi) for 5 days and the
medium was replaced every 2 days. On day 21, cells were replated at a density of 155,000
cells/cm2 on laminin 111-coated plates (2 µg/cm2) in the B27 media supplemented with
20 ng/ml BDNF (Miltenyi) + 0.2 mM AA (Sigma-Aldrich) + 10 ng/ml GDNF (R&D
Systems) + 500 µM db-cAMP (Sigma-Aldrich) + 1 µM DAPT (R&D Systems) + Y-
27632 (10 µM). This medium was replaced with 300–500 µl/cm2 (depending on cell
confluency) of fresh medium every 3 days. By day 50, cells were terminally differentiated
into mature DA cells.
2.9 Immunostaining
In order to perform immunofluorescence analysis of cultured cells in the plate, the cell
medium was removed, and cells washed two times with PBS (without Ca2+/Mg2+).
To fix the cells, 4% (w/v) Paraformaldehyde (PFA) (Merck Millipore) was added to
the cells, which were then incubated at room temperature for 15 minutes followed
by washing twice with PBS. To store the plates for the longer term (maximum of 6
months), they were wrapped in parafilm to avoid evaporation and placed at 4°C. To
proceed directly to staining, PBS was removed, and cells were incubated for 20 minutes
in 0.1% (v/v) Triton ×100 (Fisher Scientific) at room temperature. Cells were washed
twice with PBS and blocked using 1% (w/v) Bovine Serum Albumin (BSA) for 30
minutes at room temperature. After BSA incubation, the primary antibodies (make
up to the required concentration using 1:1 volume of 0.1% (v/v) Triton ×100 and 1%
(w/v) BSA) were added to the cells and incubated overnight at 4°C. The primary
antibody solutions were then removed and after 3 washes with PBS, the appropriate
secondary antibodies were added to the cells for 2-hour at room temperature. The
plate was wrapped with aluminium foil to avoid bleaching of secondary antibodies.
For DAPI (Thermo Fisher Scientific) staining, cells were washed 3 times with PBS to
remove the secondary antibodies and DAPI, which was diluted in PBS (1:1000), was
added to the cells for 20 minutes at room temperature. Then, cells were washed with
PBS and plates wrapped in aluminium foil at 4°C until analysis. A full list of primary
and secondary antibodies and the respective dilution factors are listed in Table 2.2.
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Table 2.2: Description of primary and secondary antibodies used in immunofluorescence ex-
periments.
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2.10 RT-qPCR
Cells were washed twice with PBS and a minimum of 5×105 Cells were lysed with
1 ml TRI Reagent (Sigma) for 5 minutes at room temperature. TRI/cell lysate was
transferred into a 1.5 ml microfuge tube and following the addition of 200 µl chloroform
(Sigma), the tube was shaken vigorously for 15 seconds. Samples were centrifuged
1000×g for 15 minutes, resulting in the formation of three separate phases. The clear
top layer that contains the RNA was transferred into a fresh microfuge tube. 100%
Isopropanol (75% of the volume of extracted RNA) was added to the sample, and
following a 10 minutes incubation at room temperature, was centrifuged at 4°C for 10
minutes at 1000×g. The supernatant was discarded, and the pellet was washed with
75% ethanol and centrifuged for 5 minutes at 800×g. The ethanol was removed, and the
pellet was air-dried for a few minutes and then dissolved in 50 µl nuclease-free water. A
NanoDrop (Thermofisher) was used to determine the RNA concentration. To remove
any contaminating DNA, 8 µl of total RNA was treated with 1 µl DNase1 (Promega)
at 37°C for 30 minutes, following which, 1 µl of STOP buffer (Promega) was added and
the solution was incubated at 60°C for 15 minutes and placed on the ice for further use
(or if not used on the same day, was stored at -80°C). To procced to cDNA synthesis,
a maximum of 5 µg of total RNA were added to a solution containing 1 µl of 100 ng/µl
of random hexamers (Qiagen), 1 µl of 10 mM deoxyribonucleotide (dNTP) mix and
molecular biology water up to 14 µl, denatured at 65°C for 5 minutes, followed by a
quick chill on ice. A mix of 5× First Strand Buffer, 0.1 M dithiothreitol (DTT) and 200
U/µl of SuperScript™III-RT (Invitrogen) were then added. The resulting solution was
mixed gently and incubated for 5 minutes at room temperature, followed by incubation
at 50°C for 60 minutes. Afterwards, the reaction was inactivated by heating up to 70°C
for 15 minutes. The solution was stored at -20°C until further use.
qPCR was performed in triplicate using a Bio-Rad CFX system using SYBR Green
JumpStart Taq Ready Mix (Sigma) in total 20 µl per reaction. Each 20 µl reaction
contains 10 µl of Syber Taq, 1 µl of forward primer (6.25 pmols/µl, 1 µl of reverse
primer (6.25 pmols/µl, 1 µl of diluted cDNA (neat cDNA diluted with nuclease-free
water (Gibco) according to amount of initial extracted RNA for each gene, typically,
1/50), and 7 µl of nuclease-free water. The No cDNA Template Control (NTC) were
used to monitor the false positive results.
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Table 2.3: The list of primer sequences.
Genes Size Forward sequences Reverse sequences
GAPDH 119 GTGGAAGGACTCATGACCA GAGGCAGGGATGATGTTCT
FOXA2 114 CCGTTCTCCATCAACAACCT GGGGTAGTGCATCACCTGTT
OTX2 122 ACAAGTGGCCAATTCACTCC GAGGTGGACAAGGGATCTGA
LMX1A 120 CGCATCGTTTCTTCTCCTCT CAGACAGACTTGGGGCTCAC
BARHL1 113 GTACCAGAACCGCAGGACTAAA AGAAATAAGGCGACGGGAACAT
GAPDH was used as the housekeeping gene and a sample of undifferentiated hESCs
were used to determine the gene expression levels relative to the expression in undiffer-
entiated controls. To calculate of relative gene expression the average Cycle Threshold
(CT) values from the three technical replicates were used to analyse the relative gene
expression using the ∆∆CTmethod (Livak and Schmittgen, 2001) (an example of calcu-
lation method for FOXA2 is shown in Equation 2.1). The primer sequences previously
known from (Nolbrant et al., 2017) and ordered from Integrated DNA Technologies
(listed in Table 2.3).
∆CTF OXA2|DAP Cs = CTF OXA2−CTGAP DH
∆CTF OXA2|UNDIF F hESCs = CTF OXA2−CTGAP DH
∆∆CT = ∆CTF OXA2|DAP Cs−∆CTF OXA2|UNDIF F hESCs
Fold Change over Undiff. hESCs = 2−∆∆CT
(2.1)
2.11 Preparation of cells for In vivo administration
Cells were administered intra-cranially via stereotactic injection to 3 groups of rats
(Table 2.4). The first group was administered undifferentiated hESCs that expressed
luciferase and ZsGreen (n=3; positive control for tumour formation); the second group
was administered hESC-derived progenitors that expressed luciferase and ZsGreen
(n=6); the third group was administered hESC-derived progenitors that were labelled
with iron oxide particles (n=6). Modified cells were administered as 2 deposits (each
of 75×103 cells) into the striatum of the right hemisphere. Unmodified cells were ad-
ministered as 2 deposits into the striatum of the left hemisphere and served as control
cell populations.
On the administration days, corresponding cells were washed twice with PBS and
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2 DAPCs DAPCs (Fluc-ZsGreen+) 6 day 91
3 DAPCs DAPCs (MPIO+) 6 day 127
Figure 2.2: Coronal section of rat brain according to bregma. Site of injections were
in the rat striatum which shows by red dots.
dissociated using Accutase for 3 minutes or until partial detachment. The single cell
suspension was collected and centrifuged at 250×g for 3 minutes. Cells were counted
and an appropriate number of cells were diluted in 100 µl of Hanks’ Balanced Salrit So-
lution (HBSS) (Gibco) and stored on ice until transplantation. Single-cell suspensions
were implanted stereotactically using bregma as a reference (Figure 2.2). The skull was
drilled at 0 mm anteroposterior and +/- 1.5 mm mediolateral, with each hemisphere
receiving two deposits of cells using microsyringe (Hamilton) connected to an infusion
pump at a depth of -5.0 and -4.3 mm from dura. The injections were performed by
Pamela Tyers (Roger Barker group; University of Cambridge).
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2.12 Animals
Immune-compromised RNU rats (males, 5-6 weeks old) were purchased from Charles
River and housed in individually ventilated cages under a 12 hour light/dark cycle, with
ad libitum access to standard food and water. All animal experiments were performed
under a licence granted through the UK Animals (Scientific Procedures) Act 1986 and
were approved by the University of Liverpool ethics committee (PPL No, 70/8411).
All procedures (surgical administration of cells and imaging) were carried out under
isoflurane anaesthesia.
2.13 Sectioning and histological analysis
At the experimental endpoint, the rats received an overdose of pentobarbital and were
perfused transcranial with PBS followed by 4% formaldehyde. The brains were har-
vested, postfixed with 4% formaldehyde, equilibrated in 30% sucrose and then embed-
ded using Optimal Cutting Temperature (OCT) embedding medium for frozen tissue
specimens (Agar Scientific). Brains were cryosectioned into 10 µm thick sections using
a cryostat and superfrost plus slides (Thermo Scientific) and stained with Haematoxylin
and eosin (H&E) for morphological analysis or were immunostained and analysed using
fluorescence microscopy. In order to perform immunohistochemistry, the frozen tissue
sections were washed 2 times with PBS to remove OCT medium and incubated for 10
minutes in 0.1% (v/v) Triton×100 and then 30 minutes in 1% (w/v) BSA followed by
primary antibody solution at 4°C overnight. The sections were then washed 3 times
with PBS and incubated with secondary antibody solution (1:500) for 2 hours in the
dark at RT. After removing the secondary antibody solution and performing 2 times
washes (5 minutes each wash), the sections were counterstained with DAPI (1:500) for
10 minutes. After washing with PBS, the section was mounted with fluorescent mount-
ing media (Dako) and cover slipped. (Dr. Chris Hill assisted with brain harvesting.)
2.14 Imaging
2.14.1 Fluorescence microscopy
Imaging was performed using a Leica DM2500 (Leica) fluorescence microscope with the
561 nm, 488 nm, and 405 nm lasers and data were acquired by the Leica Application
Suite (LAS, Leica) integrated software and processed with ImageJ, FIJI.
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2.14.2 Confocal imaging
Confocal imaging was performed using a 3i spinning disk confocal microscope CSU-X1
(Intelligent Imaging Innovations) with a Zeiss autofocus system and Hamamatsu digital
camera using 10×, 20× air or 40× and 63× oil objectives then processed with ImageJ,
FIJI.
2.14.3 Bioluminescence
Bioluminescence (BLI) was carried out with an IVIS spectrum system (Perkin Elmer).
After inducing anaesthesia, the rats’ heads were shaved, and the animals received an
intraperitoneal injection of luciferin at a dose of 150 mg/kg body weight. Data was
acquired 20 minuets post administration of the substrate with a field of view B (6.5 cm),
medium binning, f-stop 1 and exposure time calculated automatically by the acquisition
software, up to a maximum of 5 min. All bioluminescence data was normalised to the
acquisition conditions and are displayed as radiance (photons/s/cm2/str).
2.14.4 Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) data was acquired with a Bruker Advance III con-
sole interfaced to a 9.4T magnet system (Bruker Biospec 94/20 USR). RF excitation
was achieved with an 86 mm resonator and signal detection with a 4-channel phased
array receive-only rat brain coil. Once the injection site was located using scout im-
ages, higher resolution images were acquired with Rapid Acquisition with Relaxation
Enhancement (RARE) sequence. Parameters: echo time (TE)= 38 ms, repetition time
(TR)= 2700 ms, RARE factor= 8, number of excitations (NEX)= 8, field of view
(FOV)= 35×35 mm, matrix size= 350×350 pixels, slices= 20, slice thickness= 500 µm.
(Dr. Arthur Taylor assisted with cell imaging using BLI and MRI; all imaging
experiments were overseen by Prof. Harish Poptani.)
2.15 Statistical analysis
Error bars represent standard deviation (SD) using a minimum number (n) of 3 in-
dependently conducted experiments (n3). SD were calculated using OriginPro 9.0.0
(OriginLab Corporation). Student T-Test was used to evaluate statistical significances
between two groups of samples. The statistical probability is demonstrated in terms
of p-value (p), which was considered “significant” when p<0.05 (*); “very significant”
when 0.01>p>0.001 (**) and “very highly significant” when p<0.001 (***).
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CHAPTER 3
Preparation of Fluc-ZsGreen and
MPIOs labelled DAPCs
3.1 Introduction
3.1.1 Generating DAPCs from RC17 hESCs
The first part of the study was to optimise the in vitro protocol developed by (Nol-
brant et al., 2017) for directing the differentiation of hESCs to DAPCs. Since it is
known that the Glycogen Synthase Kinase inhibitor (GSKi) concentration is crucial
for correct midbrain patterning in vitro, and each cell line may have slightly different
sensitivity to GSK3i levels (Nolbrant et al., 2017), the optimal concentration of the
GSKi (CHIR referred to the chemical form of GSKi) was determined. hESC-derived
DAPCs are usually identified by expression of LMX1A, FOXA2 and OTX2A (Kirkeby
et al., 2012). However, a problem with relying solely on these 3 markers is that their ex-
pression cannot distinguish between progenitors that give rise to Subthalamic Nucleus
(STN) neurons and those that generate mature DA neurons. This can be addressed
by investigating the expression levels of BARHL1, which is only expressed in the STN
progenitors. Investigating how the concentration of CHIR affects BARHL1 expression
enables the optimal concentration of CHIR used in the protocol to be established.
Another question that was addressed in this chapter was whether freeze-thawing
the DAPCs had any effect on the expression levels of the DAPC markers FOXA2,
OTX2A and LMX1A. The reason for doing this was to determine if for future animal
experiments, the DAPCs could be prepared in advance and frozen, thereby facilitating
the planning of the in vivo experiments (Nolbrant et al., 2017).
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3.1.2 Generation of Fluc-ZsGreen RC17 reporter hESC line
The next aim of this chapter was to generate a Fluc-ZsGreen RC17 reporter hESC
line to enable the hESC-derived DAPCs to be detected in rats in vivo. A bicistronic
reporter Fluc-ZsGreen was used for this purpose (Figure A.2) because Fluc enables
non-invasive bioluminescence imaging in vivo, while ZsGreen allows the transduction
efficiency to be assessed in cells in vitro.
It has previously been reported that reporter gene expression can be reduced over
time with passaging (Lippincott-Schwartz and Patterson, 2003; Krishnan et al., 2006).
When generating reporter lines, it is therefore important to investigate whether reporter
gene expression remains stable. Moreover, it is important to consider that the genetic
modification that results from introducing the reporter gene might affect the phenotype
of the cells. In the case of pluripotent stem cells, there is a risk that depending on where
the reporter genes integrate, it could affect the pluripotency of the cells. Pluripotency
of hESCs is assessed by investigating if they can generate derivatives of all 3 embryonic
germ layers: endoderm, mesoderm and ectoderm. This is typically done by either
implanting the cells into mice to see if they can generate teratomas, or by generating
EBs in vitro (Allison et al., 2018). In this study, in compliance with NC3Rs principles,
pluripotency of the hESC reporters was assessed using the EB system.
Following this, it was important to sort the cells using flow cytometry in order to
obtain a pure population of transduced cells that expressed the reporter. It is known
that when pluripotent stem cells are modified to express a reporter gene, and then
differentiated to a specialised cell type, the reporter gene can become silenced (e.g.
cardiomyocyte differentiation of mouse ESC) (Cao et al., 2006). A further aim of this
study was therefore to investigate if expression of the ZsGreen and Fluc reporter genes
was reduced when the cells were differentiated to DAPCs, and then further differenti-
ated to mature DA neurons.
3.1.3 Labelling hESCs-derived DAPCs with MPIOs for MR imaging
In order to enable in vivo cell tracking using MRI, a further aim was to optimise a
protocol to label DAPCs using a contrast agent composed of MPIO. This would allow
the intercranial biodistribution and fate of the DAPCs to be determined by non-invasive
MRI for further investigations (Section 1.3.2).
The objectives of this chapter were as follows:
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1. Optimise the protocol for directing the differentiation of RC17 hESCs to DAPCs.
2. Establish a Fluc-ZsGreen RC17 hESC reporter line.
3. Investigate if reporter gene expression is maintained when the Fluc-ZsGreen hESC
reporter cell line is differentiated to DAPCs and mature DA neurons.
4. Assess the feasibility of using MPIOs to label hESC-derived DAPCs.
3.2 Results
3.2.1 Optimisation of protocol for directing the differentiation of
hESCs to DAPCs
Culturing hESCs of high quality that do not show excessive spontaneous differentiation
is a crucial starting point for generating a high yield of DAPCs. Therefore, the RC17
cells were assessed for the expression of stemness markers, OCT4 and Nanog. The
immunofluorescence results demonstrate that both OCT4 and Nanog expression (red)
in the nuclei (blue) of the undifferentiated colonies of RC17 cells (Figure 3.1).
Figure 3.1: Expression of stemness markers in undifferentiated hESCs. RC17 cells
cultured for 4 days and fixed and immune stained for OCT4 and Nanog (red channel), coun-
terstained with DAPI (blue channel). The confocal immunofluorescent microscopy detects
expression of both markers in the RC17 colonies. Scale bar 100 µm.
To optimise the protocol for differentiating DAPCs from hESCs, the Nolbrant
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(2017) protocol was followed over 16 days (Figure 2.2) using the following three dif-
ferent concentration of CHIR: 0.7, 0.8, and 0.9 µM. The hESCs were differentiated
in parallel and on day 16, cells were fixed and immunostained for the DAPC mark-
ers to assess the success of differentiation and determine the optimum concentration
of CHIR. Immunostaining for co expression of LMX1A/FOXA2 and LMX1A/OTX2
indicated the successful patterning of VM progenitors (Figure 3.2 a&b), but differences
were observed depending on the concentration of CHIR that was used. For instance,
immunostaining revealed a patchy expression of FOXA2 and LMX1A in the presence of
0.7 µM or 0.8 µM CHIR, but a more consistent staining of all markers in the presence
of 0.9 µM CHIR. This suggested that 0.9 µM CHIR is the optimal concentration for
directing the differentiation of RC17 hESCs to DAPCs.
In order to investigate effects of the freeze-thawing, both fresh and frozen cells
which were differentiated into DAPCs using 0.7, 0.8, or 0.9 µM CHIR, were analysed
using qRT-PCR for expression of DAPC marker genes FOXA2, LMX1A, and OTX2A.
The day 16 frozen DAPCs were defrosted and cultured for 2 days in the media that
is used for the cells before freezing to compare with freshly differentiated DAPCs. As
Figure 3.3 shows, in the fresh samples, DAPCs differentiated in the presence of 0.9
µM CHIR showed significantly higher expression levels of all three DAPC markers
compared to those differentiated in the presence of 0.7 or 0.8 µM CHIR (Figure 3.3
a&b&c). In contrast, cells differentiated in the presence of 0.9 µM CHIR that had been
freeze-thawed showed significantly lower expression of DAPC markers.
In order to confirm that 0.9 µM is the optimal concentration for directing the dif-
ferentiation of RC17 hESCs to DAPCs, immunostaining and qRT-PCR was performed
to investigate the expression levels of BARHL1 at the three CHIR concentrations. In
Figure 3.4 (a), the lowest expression of BARHL1 was observed in the progenitors that
were treated with 0.9 µM CHIR. Furthermore, this finding was confirmed by qRT-PCR
(Figure 3.4 b).
3.2.2 Establishing Fluc-ZsGreen RC17 reporter hESC line
The lentivirus carrying the bicistronic Fluc-ZsGreen reporter genes was used to trans-
duce the undifferentiated hESCs. Fluc enables non-invasive bioluminescence imaging
in vivo, while ZsGreen allows the transduction efficiency to be assessed in cells. The
full sequence of the construct is provided in Figure A.2. The following 3 multiplicities
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(a)
(b)
Figure 3.2: Establishing the optimal concentration of CHIR for directing DAPC
differentiation from hESCs. RC17 hESCs were directed to differentiate under the following
CHIR concentrations: 0.7, 0.8 and 0.9 µM. Following 16 days, the cells were fixed and im-
munostained for (a) FOXA2/ LMX1A and (b) OTX2A/ LMX1A, counterstained with DAPI.
At the lower CHIR concentrations of 0.7 and 0.8, patches of unstained cells were observed
within the lawn of DAPCs, whereas more consistent staining was observed in the cells cultured
in the presence of 0.9 µM. The negative controls provided in Figure A.3. (n=3), Scale bar
100 µm.
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Figure 3.3: qRT-PCR data of key DAPCs markers from fresh and defrosted DAPCs
that was differentiated using 0.7, 0.8, and 0.9 µM of CHIR. (a) FOXA2, (b) LMX1A,
and (c) OTX2A are expressed in both fresh and defrosted DAPCs with different expression
levels. Results are given as fold change over undifferentiated hESCs. GAPDH was used as the
housekeeping gene and a sample of undifferentiated hESCs were used to determine the gene
expression levels relative to the expression in undifferentiated controls. Error bars represent
SD, (n=3). p<0.05 (*); 0.01>p>0.001 (**).
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of infections (MOIs) were tested: 1,3, and 5, which corresponded to 5×104, 15×104,
and 25×104 viralparticles/µl, respectively. The aim was to identify the MOI that gave
the highest transduction efficiency without affecting the viability of the hESCs. Phase
contrast microscopy showed that cells transduced with all three MOIs, displayed the ex-
pected morphology of undifferentiated cells, i.e., colonies comprising a dense monolayer
of cells that have a high nuclear: cytoplasmic ratio (Figure 3.5 a). ZsGreen expression
was also detected in hESCs transduced with all three different MOIs. The efficiency of
transduction was determined by measuring ZsGreen expression with flow cytometry.
(a)
(b)
Figure 3.4: Expression of BARHL1 in RC17 hESC-derived DAPCs. (a) Immunostain-
ing and (b) qRT-PCR shows lower expression of BARHL1 in the DAPCs that were treated with
0.9 µM CHIR compared to those treated with 0.7 and 0.8 µM. In (a) BARHL1 is in red and
DAPI represent nuclei is shown with blue colour. In (b) GAPDH was used as the housekeeping
gene and a sample of undifferentiated hESCs were used to determine the gene expression levels
relative to the expression in undifferentiated controls. Error bars represent SD, (n=3), p<0.05
(*), Scale bar 100 µm.
Figure 3.2 (b) shows the dot plots of the cytometry data for the baseline control
with no detected fluorescence, and the transduced cells with ZsGreen expression for the
50
3. Preparation of Fluc-ZsGreen and MPIOs labelled DAPCs
three different MOIs. The cytometry data indicate that for the lowest MOI, ZsGreen
positivity was only 18%, while increasing the MOI to 3 and 5 increased the proportion
of ZsGreen+ hESCs to 35% and 41%, respectively. Also, the similar levels of ZsGreen
expression observed with MOIs 3 and 5 suggested that increasing the concentration
of viral particles beyond this point would be unlikely to increase the transduction
efficacy. Therefore, the undifferentiated RC17 cells that was transduced with MOI 5
were selected for subsequent experiments.
3.2.3 Evaluation of transduced Fluc-ZsGreen+ RC17 reporter line
Given that cytometry data showed that the transduced colonies of RC17 cells were
not homogeneous in regard to expression levels of Fluc-ZsGreen and only about 47%
of cells expressed the ZsGreen (Figure 3.6 a), cells underwent sorting to obtain a pure
homogeneous population with strong expression of the reporters. A group of non-
transduced RC17 cells were used as a baseline control and the transduced cells were
sorted into two different populations of “Dim-green” and “Bright-green” cells (Figure
3.6 b). The Bright-green sorted cells were collected and routinely cultured and passaged
three times to confirm that they maintained their undifferentiated morphology and
high levels of ZsGreen expression through subsequent passages. Figure 3.6 c shows the
morphology of bright-green sorted cells is indistinguishable from non-transduced cells.
To further assess the expression levels of ZsGreen, flow cytometry analysis confirmed
the ZsGreen expression was maintained over multiple passages (Figure 3.3 d).
To assess whether the introduction of the reporter and sorting of cells affected
pluripotency of transduced cells, EB were generated and immunostained for markers
of embryonic germ layer derivatives. The presence of GATA6 (endoderm), Brachyury
(mesoderm) and Nestin (ectoderm) confirmed that the Fluc-ZsGreen+ hESCs remained
pluripotent (Figure 3.7).
3.2.4 Investigating if Fluc-ZsGreen reporter gene expression in main-
tained in hESC-derived DAPCs and mature DA neurons.
A group of Fluc-ZsGreen RC17 cells was differentiated into DAPCs to assess the effect
of transduction on the differentiation patterns and transgene silencing. On Day 16,
the differentiated DAPCs were immunostained for LMX1A+, FOXA2+ and OTX2A+.
As Figure 3.8 a shows, the successful patterning of VM progenitors was confirmed by
51
3. Preparation of Fluc-ZsGreen and MPIOs labelled DAPCs
(a)
(b)
Figure 3.5: ZsGreen expression in RC17 hESCs transduced with a bicistronic Fluc-
ZsGreen construct. (a) The undifferentiated hESCs were transduced using three different
concentrations of viral particles (5, 15, and 25×104 viral particles/µl), corresponding to MOIs
of 1, 3 and 5. The control sample comprised non-transduced hESCs. Following transduction,
the hESCs retained their typical morphology. (b) Flow cytometry fluorescence analysis of
ZsGreen expression showed the percentage of Fluc-ZsGreen+ hESCs could be increased to 41%
by increasing the concentration of lentivirus. Scale bar 100 µm.
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Figure 3.6: Flow-assisted cell sorting (FACS) and evaluation of transduced RC17
hESC Fluc-ZsGreen reporter cells. (a) ZsGreen expression, as measured via flow cytom-
etry, of the control and sorted hESCs. The green fluorescence of the sorted cells is stable for
several passages (b) The transduced colonies of RC17 cells were sorted into two different pop-
ulations of “Dim green” and “Bright green” cells. (c) Phase contrast and immunofluorescent
images of unsorted and bright green cells that were cultured for three passages. (d) Flow cy-
tometry confirmed that ZsGreen expression was maintained in the hESC population, with no
noticeable decreases observed between passages one and three. Scale bar 100 µm.
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Figure 3.7: Embryoid bodies formed from sorted hESCs were shown to be able
to differentiate into all three germ layers. Positive staining for GATA6 (endoderm),
Brachyury (mesoderm) and Nestin (ectoderm) were detected in the spontaneously differentiated
EBs grown from bright green undifferentiated RC17 cells. GATA6, Brachyury and Nestin are
shown in red, ZsGreen in green and nuclei of cells counterstained with DAPI using blue colour.
Scale bar 100 µm.
expression of all DAPCs associated markers. Also, ZsGreen fluorescence intensity was
visible in the progenitors. However, confocal microscopy also revealed that not all cells
expressed ZsGreen after differentiation into DAPCs. To further assess the percentage of
ZsGreen positive DAPCs flow cytometric analysis was performed and revealed that 51%
of these cells expressed ZsGreen, implying a significant loss of reporter gene expression
when compared to undifferentiated hESCs (Figure 3.8 b).
In order to apply DAPCs for transplantation, their ability to differentiate into ma-
ture DA neurons should be first demonstrated in vitro. The key marker for terminally
differentiated DAPCs is TH, which is co-expressed with FOXA2 and OTX2. A group
of VM progenitors were differentiated into mature DA cells according to an established
protocol (Section 2.8). This is a long-term differentiation process and takes about 50
days for cells to give rise to DA neurons. Figure 3.9a shows high expression of FOXA2,
OTX2A and TH in the immunostained cells on day 50 of differentiation. Of note,
ZsGreen was no longer detectable at this differentiation stage (Figure 3.9 b)
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(a)
(b)
Figure 3.8: Differentiated Fluc-ZsGreen RC17 express key markers of DAPCs
and ZsGreen. (a) Confocal microscopy to show the co-expression of FOXA2/LMX1A and
OTX2A/LMX1A in the immunostained Fluc-ZsGreen DAPCs. (b) Flow cytometry showed
that differentiation into DAPCs reduces ZsGreen expression by approximately 47%. Scale bar
100 µm.
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(a)
(b)
Figure 3.9: Differentiation towards mature DA cells: Differentiation towards ma-
ture DA cells. (a) Fluorescence microscopy of mature DA cells on day 50 of differentiation
immunestained for FOXA2 (red), OTX2 (red), and TH (green). (b) No expression of ZsGreen
was detected in the terminally differentiated DA cells that expressed FOXA2 (yellow) and TH
(red). All immunestained samples counterstained with DAPI in blue colour. Scale bar 100 µm.
The strength of the bioluminescence signal was assessed using BLI to determine
the degree of emitted light by Fluc-ZsGreen labelled cells. Three groups of labelled cells
with different seeding density were assessed including undifferentiated hESCs, DAPCs,
and mature DA neurons. Measurement of the light output (bioluminescence) revealed
that the expression of luciferase was strong before differentiation (37 p/s/cell), but was
significantly reduced as cells differentiated towards DAPCs (17 p/s/cell) and extremely
weak when they became mature DA neurons (G1 p/s/cell) (Figure 3.10)
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(a)
(b)
Figure 3.10: BLI of different numbers of Fluc-ZsGreen+ hESCs, DAPCs, and
mature DA cells and the corresponding photon flux. (a) In vitro BLI data shows
increasing of detected Fluc signal by rising the cell number. (b) Fluc is 37 p/s/cell in hESCs
but reduced to 17 p/s/cells in DAPCs. There is significant reduction of signal in mature DA.
Expression data are representative of three independent experiments. Error bars represent SD.
3.2.5 Assessing the feasibility of MPIOs labelling of DAPCs
Following a 24-hour incubation with the MPIOs, the DAPCs cells were examined to
ascertain if cells appeared to have taken up the particles on visual inspection. Cell up-
take efficiency was then quantitatively assessed via flow cytometry. Six concentrations
were explored: 500, 1000, 1500, 2000, 4000 and 8000 particles/µl and the percentage
of cells in the population that had successfully taken up the fluorescent particles and
thus were deemed to be positive, are represented per concentration in Figure 3.11. The
control group was unlabelled DAPCs.
The 1500 particles/µl were chosen to label DAPCs for animal experiment. Flow
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Figure 3.11: Histograms displaying the fluorescence signals detected for MPIOs
labelled DAPCs. MPIOs at following concentrations: (a) 500 particles per µl, (b) 1000
particles per µl, (c) 1500 particles per µl, (d). 2000 particles per µl, (e) 4000 particles per µl,
(f) 8000 particles per µl. Percentage corresponds to the percentage of the population positive
for the signal in each case. Control is in grey colour and selected population of labelled DAPCs
is in red colour.
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cytometry analysis of MPIO-labelled DAPCs suggested that approximately 72% of
DAPCs were labelled with the 1500 particles/µl concentration of MPIOs, as evidenced
by yellow fluorescence originating from MPIOs (Figure 3.12).
Figure 3.12: Fluorescence signals detected of MPIOs labelled DAPCs using FACS
analysis. Yellow fluorescence of unlabelled (blue) and MPIOs-labelled DAPCs (green) shows
that approximately 72% of cells uptake the particles.
3.3 Discussion
In this chapter, optimisation of the protocol to direct differentiation of RC17 hESCs
towards DAPCs on the basis of GSK inhibitor concentration was investigated. Further-
more, feasibility of the lentiviral vector to transduce RC17 hESCs for BLI, and MPIOs
to label DAPCs for MRI tracking have also been evaluated.
Correct patterning of DAPCs is essential to ensure the cells have the potential to
give rise to mature and functional mesencephalic DA neurons upon intracerebral trans-
plantation. Efficient and specific neural induction is dependent on finely controlled
caudalization using GSKi according to the cell line. All VM progenitors co-express
LMX1A+, FOXA2+ and OTX2A+, representing the most caudal triple positive pro-
genitors that generate mature and functional DA neurons. In contrast, triple positive
progenitors in the rostral part of the ventral midbrain give rise to glutamatergic STN
neurons. In this regard, DAPCs can be distinguished from STN progenitors by the
absence of BARHL1 expression, which serves as a further verification of functional
59
3. Preparation of Fluc-ZsGreen and MPIOs labelled DAPCs
DAPCs. Taken together, differentiation should be deemed successful where cells ex-
press LMX1A, FOXA2 and OTX2A, but not BARHL1. Here, it was concluded that 0.9
µM CHIR resulted in significant expression of triple DAPC markers while the BARHL1
expression was minimal.
In addition, the effect of cryopreservation on the differentiated DAPCs was as-
sessed. The data suggest that freezing the cells that were generated under these optimal
conditions reduced the expression levels of the DAPC markers LMX1A, FOXA2 and
OTX2A. Therefore, it was decided that for future animal work, freshly differentiated
DAPCs would be used.
In order to perform preclinical bioluminescent modalities, the Fluc-ZsGreen re-
porter gene was used to label RC17 undifferentiated hESCs. The data indicate that
the integrated reporter gene did not affect hESC pluripotency, nor their ability to dif-
ferentiate to DAPCs and mature DA neurons in vitro. However, the reduction of both
luciferase and ZsGreen were indicated in the DAPCs in vitro followed by transgene si-
lencing in mature DA neurons. The reporter gene silencing in the differentiated cells is
mainly considered as the result of DNA methylation followed by attraction of proteins
that specifically bind to the transgene and block the other factors required for gene
induction (Curradi et al., 2002; Suelves et al., 2016).
Additional assessment in this chapter involved labelling hESC-derived DAPCs us-
ing MPIOs for MRI tracking. Generally, the minimum percentage of loading concen-
tration using iron oxide particles to be detectable by MRI is no less than 50%. From
our data, it is apparent that the optimum concentration of MPIOs is 1500 particles
per µl in order to have at least 50% positive cell uptake. Beyond this concentration,
only about 15% difference was observed using up to 8000 particles per µl. This per-
centage increase could be accounted for by more particles per cell rather than more
cells labelled. Furthermore, no morphological changes or any obvious toxic effects were





An effective strategy for monitoring the proliferation, viability and localisation of im-
planted cells longitudinally is to employ a non-invasive imaging approach comprising
different modalities (Lau et al., 2010). In this study, a bi-modal strategy comprising
BLI and MRI was used to monitor viability, assess intracranial biodistribution, and
monitor tumour formation in vivo following administration of cells into the rat stria-
tum. BLI is the most sensitive live animal imaging technique, enabling relatively small
numbers of transplanted cells to be detected (Section 1.3.1). This technique requires
that the cells express a luciferase reporter, which means that a signal is only emitted if
the cells are alive. An increase in BLI signal over time indicates cell proliferation and
potential tumour formation, whereas a loss of signal suggests that the cells are no longer
viable, or that the reporter is no longer being expressed (Bernau et al., 2014). A draw-
back with BLI, however, is that spatial resolution is poor, which means that it cannot
be used to determine the precise location of the implanted cells and/or any resultant
masses within the brain. MR imaging, on the other hand, has a very high spatial reso-
lution and can accurately map the position of intracranial lesions (Denic et al., 2011).
Moreover, by labelling cells prior to administration with an appropriate contrast agent,
such as iron oxide particles, MRI can be used to plot the biodistribution of the cells over
time (Section 1.3.2). Hoehn and co-workers have shown previously that BLI and MR
imaging can be used to monitor the viability and intracranial biodistribution of hESC-
derived neural stem cells following implantation into the mouse striatum (Tennstaedt
et al., 2015). To the best of our knowledge, this bimodal approach has not previously
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been used to track the tumourigenicity, viability and biodistribution of hESC-derived
DAPCs, following intrastriatal administration into the rat brain. Therefore, in order to
assess the potential of this bimodal BLI/ MR strategy to track hESC-derived DAPCs
in vivo, luciferase-expressing DAPCs and MPIO labelled DAPCs (Chapter 3), were
injected intracranially into rats, and the effectiveness of the bimodal imaging strategy
for tracking the cells was assessed.
The specific objectives of this chapter were to:
1. Assessing the feasibility of using BLI and MRI to detect undifferentiated hESCs
and their derived tumours, respectively.
2. Assessing the feasibility of monitoring the viability and proliferation of FLuc-
ZsGreen+ hESC-derived DAPCs longitudinally using BLI.
3. Assessing the feasibility of tracking the biodistribution of MPIO-labelled DAPCs
longitudinally using MRI.
4.2 Results
Three experimental group were established. The first experimental group consisted of
3 rats, administrated with undifferentiated RC17 hESCs as the control group. The
second and third experimental groups were administrated DAPCs which were labelled
with FLuc-ZsGreen and MPIOs respectively (Table 2.4).
4.2.1 Assessing the feasibility of using BLI and MRI to detect undif-
ferentiated hESCs and their derived tumours, respectively
The purpose of this experiment was to assess the feasibility of using the FLuc reporter
to monitor the viability and proliferation of implanted cells. For this purpose, undif-
ferentiated hESC were implanted into the rat striatum because it has already been
established that undifferentiated hESCs form tumours following intracranial implanta-
tion. A further aim was to assess whether any tumours that formed could be detected
with MRI. To this end, in this experiment, the cells were not labelled with MPIOs.
Three rats had Fluc-ZsGreen+ RC17 hESCs implanted into the right striatum,
and unlabelled hESCs implanted into the left striatum. BLI was performed on the day
of administration (day 0) and day 14. On day 27, both BLI and MR imaging were
performed before sacrificing the animals (Figure 4.1 a).
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(a)
(b)
Figure 4.1: BLI imaging of RC17 hESCs following implantation into the rat brain.
(a) Schematic of injection and experimental timeline of hESC administration and imaging.
(b) BLI of three rats that received undifferentiated hESCs (left hemisphere: non-transduced
cells; right hemisphere Fluc-ZsGreen+ cells). On day 0 only rat 2 exhibited a weak signal (red
arrowhead) which was lost on day 14 and 27. Rat 3 revealed a signal on days 14 that became
more intense by day 27 (red arrowheads).
BLI of animals that received the undifferentiated hESCs on the day of adminis-
tration (day 0), day 14, and 27 post-administration revealed great variability in the
bioluminescence signal. On day 0, only rat 2 displayed a signal, which was weak and
close to background levels (arrowhead) (Figure 4.1 b). This signal was progressively
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Figure 4.2: MR imaging of RC17 hESCs following implantation into the rat brain.
MRI of the brain on day 27 revealed that all rats had developed tumours in both hemispheres
(hyperintense contrast).
lost on the subsequent days. Rat 3 displayed a signal only on days 14 and 27 (arrow-
heads). Due to the weak signal, some non-specific background could be seen around the
periphery of the rats’ head on day 0 (Figure 4.1 b). Figure 4.2 shows the corresponding
MR images of the rat brains on day 27, which was the experimental endpoint. The
MR images displayed a large area of atypical hyperintense contrast surrounding the
injection site, which was present in both brain hemispheres of all animal, representing
tumours of varying sizes irrespective of whether the cells expressed the Fluc-ZsGreen
reporter gene.
4.2.2 Assessing the feasibility of monitoring the viability and prolif-
eration of FLuc-ZsGreen+ hESC-derived DAPCs longitudinally
using BLI
To assess the ability of BLI and MRI to monitor the viability and tumourigenicity of
implanted hESC-derived DAPCs, Fluc-ZsGreen+ RC17 hESCs were differentiated into
DAPCs, and after confirming that the DAPCs still expressed the ZsGreen reporter
(Chapter 3), they were implanted into right striatum. To ensure that the introduction
of the reporter genes did not affect the behaviour of the DAPCs in vivo, unlabelled
cells were injected into the left side of the brain to serve as a control cell population.
Six rats had Fluc-ZsGreen+ DAPCs implanted into the right striatum, and unla-
belled DAPCs implanted into the left striatum. The rats’ heads were imaged at day
1, 14, 28, 56 and 91 for BLI (the last session of BLI was performed on the day of
sacrificing the animals). MRI were performed on day 90 which was the day before
sacrificing the animal (Figure 4.3 a). Although a BLI signal was detected in 4 of the
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(a)
(b)
Figure 4.3: Long-term fate of injected Fluc-ZsGreen+ DAPCs. (a) Schematic of
injection and experimental timeline of DAPCs administration and imaging. (b) BLI of the six
rats that received DAPCs as imaged on days 1, 14, 28, 56, and 91. Most, but not all rats
displayed a signal on the injection day, but this was lost by day 14 and no signal was seen up
at any other time points.
6 rats on day 1 (red arrowheads), no signal could be detected in any of the rats on
the subsequent days. Note that this rat strain can display cycles of thin hair growth,
as seen in some images. In contrast to hESCs (Figure 4.2), administration of DAPCs
resulted in no abnormal MR contrast at the experimental endpoint (day 91, Figure
4.4), with all animals exhibiting a normal brain structure and the needle track being
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Figure 4.4: MR imaging of grafted Fluc-ZsGreen+ DAPCs at the study endpoint.
RARE MRI scans (day 90) of all 6 rats that received DAPCs (left hemisphere: non-transduced,
right hemisphere: Fluc-ZsGreen+). No abnormal features are seen, apart from the needle track
that is still visible in some animals (indicated arrowheads in the first rat only).
the only remarkable feature (red arrowheads in Figure 4.4).
4.2.3 Assessing the feasibility of tracking the biodistribution of
MPIO-labelled DAPCs longitudinally using MRI
To assess the biodistribution of hESC-derived DAPCs with MRI, DAPCs were labelled
with fluorescence MPIOs and injected into the right hemisphere of the rat brain. To
assess whether the introduction of the MPIOs affected the behaviour of the DAPCs in
vivo, unlabelled cells were injected into the right side of the brain to serve as a control
cell population.
Rats implanted with MPIO-labelled DAPCs were imaged only via MRI, as neither
of the hemispheres received cells with the genetic reporter. Figure 4.5 shows Rapid
Imaging with Refocused Echoes (RARE) MRI scans of 6 rats that received MPIOs la-
belled DAPCs (left hemisphere: unlabelled DAPCs; right hemisphere: labelled DAPCs)
as imaged on day 1, 14, 28, 42, 70 and 126 post-surgery (Figure 4.5 a). Hypointense
contrast (red arrowhead), indicative of a reduction in relaxation time as caused by
MPIO labelling, is seen in the right hemisphere throughout the experimental period
in all rats apart from rat 5 (Figure 4.5 b). There was no change in the hypointense
contrast area during the course of MR imaging.
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(a)
(b)
Figure 4.5: Biodistribution of MPIO-labelled hESC-derived DAPCs over time.
(a) Schematic of injection and experimental timeline of DAPC administration and magnetic
resonance imaging. (b) Representative RARE MRI scans of 6 rats that received MPIO-labelled
DAPCs (left hemisphere: unlabelled DAPCs; right hemisphere: labelled DAPCs) as imaged
on day 1, 14, 28, 42, 70 and 126 post administration. Hypointense contrast caused by MPIO
labelling, is seen in the right hemisphere throughout the experimental period (indicated with
an arrowhead in the first image). No abnormal growth is observed in either of the hemispheres.
By scanning through the brain of rat 5 from anterior-to-posterior, it was found that
a hypointense signal was present in the lateral ventricles, rather than in the striatum
(Figure 4.6). In the RARE image the needle track is clearly identified in the MR images,
revealing an injection angle that led to cells being administered to the ventricle (red
arrowheads). Imaging of a different plane reveals hypointense contrast in a different
area within the ventricles (arrowheads in top right image), indicating that the cells
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Figure 4.6: RARE and FLASH MRI scan of grafted MPIOs+ DAPCs in rat5. Red
arrowheads show needle track in the left images and hypointense contrast in the ventricles in
the right images.
migrated and lodged in an unintended site. FLASH images are shown as they provide
better contrast between the brain and MPIOs, facilitating the identification of the
needle track. Note that hypointense contrast is seen in both hemispheres of the brain
of the rat in which cells were mis-injected, which is likely due to the bridged nature of
the fluid-filled ventricles.
4.3 Discussion
The main aim of this chapter was to assess the effectiveness of BLI and MR imaging to
monitor the tumourigenicity, viability and intracranial biodistribution of hESC-derived
DAPCs following stereotactic injection into the rat striatum.
In the animals of the control group that were injected with Fluc-ZsGreen RC17
hESCs, the intensity of BLI signals were different between the three rats of the control
group immediately following injection. The reason for this difference might be a due to
different levels of cell death after injection. Another reason could be due to the effects
of the surgery. There is always a degree of blood clotting at the surgery site, and it
would be expected that this would affect the BLI signal. For instance, if the blood clot
in one animal is greater than another, it would be expected that this would lead to
greater signal attenuation, leading to a reduction in the BLI signal.
MRI was able to detect tumour growth in both the right and left sides of the
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brain, indicating that the growth of the tumours was not dependent on the presence of
the reporter genes. MRI also showed that the largest mass was in the right striatum
of rat 3, which was also the only animal that displayed a signal with BLI. These
results therefore suggest that MRI is more sensitive than BLI for detecting hESC-
derived tumours in the rat brain (Figure 4.1 & Figure 4.2). In most animals, BLI could
only detect Fluc-ZsGreen+ cells shortly after administration and was not effective for
monitoring tumourigenicity and cell viability in the longer term.
The inability to detect cells with BLI likely resulted from a number of factors. First,
at the initial imaging session, the rats were only 6 weeks old. During the intervening
2 weeks before the next imaging session, the rats grew considerably and became more
pigmented (cycles of thin hair growth), causing the intensity of the emitted light to
be reduced; this likely explains why after day 1, BLI could only be detected in a
rat that had developed a large Fluc-ZsGreen+ hESC-derived mass (Figure 4.1 b). An
additional problem was that in comparison with undifferentiated hESCs, we found that
the expression levels of the reporter genes decreased by about 50% in Fluc-ZsGreen+
hESC-derived DAPCs and could not be detected at all in the mature DA neurons
3.10. It is well recognised that ESC differentiation is accompanied by increased levels
of DNA methylation, leading to gene silencing and that the pattern of silencing is cell
type specific (Suelves et al., 2016).
The next factor is the proportion of grafted cells. Bernau et al. found that Fluc+
human foetal neuronal progenitors implanted into the rat striatum could be imaged
with BLI for 3 months. However, in this study, 9×10 5 Fluc+ cells implanted into the
left hemisphere compared with only 1.5×105 cells in our study (Bernau et al., 2014).
The choice of promoter also affects the extent of silencing the reporter gene. A
previous study comparing the activity of five constitutive promoters, EF1α, human β
actin (ACT β), Cytomegalovirus (CMV), Phosphoglycerate Kinase (PGK) and Ubiq-
uitin C (UbC) in differentiating hESCs, reported that EF1α was the most stable, with
expression levels in EBs being reduced to 50% of those in undifferentiated hESCs (Nor-
rman et al., 2010). Our observation that Fluc-ZsGreen expression was undetectable in
the mature DA neurons, both in vitro and in vivo, was unexpected. Tennstaedt et al.
have shown that a EF1α: Fluc-GFP+ neural stem cell line derived from hESCs could
be detected with BLI for 6 weeks following injection into the mouse brain without any
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noticeable decrease in bioluminescence intensity (Tennstaedt et al., 2015). However,
the neural stem cells used in the Tennstaedt study have a different phenotype to hESC
derived DAPCs, and there is no evidence that they differentiate into the DA lineage
(Tennstaedt et al., 2015). Likewise, there is no evidence that the Fluc+ human foetal
neuron progenitors used in the aforementioned Bernau et al. study differentiate into
the DA lineage in the rat brain (Bernau et al., 2014). Indeed, as far as we are aware,
there are no studies that show Fluc expression in hESC-derived DA neurons in vivo
when Fluc is under the control of a constitutive promoter. However, one advantage of
our system is that the loss of signal is due to differentiation. This could be used to
show that the grafted cells have indeed followed the correct pathway post implantation
rather than dedifferentiated back into an ESC-like phenotype.
MR imaging, on the other hand, could detect tumours arising from undifferentiated
hESCs and could monitor the intracranial biodistribution of MPIO-labelled hESC-
derived DAPCs over the full time-course of our experiments. Monitoring of animals
injected for DAPCs labelled by MPIOs using MRI for up to 4 months post implantation
confirmed that DAPCs do not appear to generate tumours, with all rats displaying
normal brain structures at all time points. In 5 out of 6 rats, hypointense contrast
was seen in the right brain hemisphere. This was an expected consequence of the
MPIO labelling, which enabled us to monitor the delivery and intracranial distribution
of DAPCs. The distribution of the administered DAPCs appeared to remain stable
throughout the 4 months that the animals were monitored for, with no obvious change
in the area with hypointense contrast, suggesting that the DAPCs were confined to the
areas into which they were initially deposited.
The micron sized particles used in this study are much larger than nano-sized
particles and contain more iron. Cells labelled with the micron sized particles therefore
provide higher contrast in the MR scanner and it has previously been shown that the
detection of single cells labelled with these particles can be possible (Shapiro et al.,
2005). We therefore feel that it would have been possible for us to detect migrating
cells labelled with the micron-sized beads. However, only about 70% of the injected
cells were labelled with the particles. Therefore, we cannot rule out the possibility
that unlabelled cells might have migrated to other sites within the brain. In rat 5, no
hypointense contrast was observed in the target area. Further analysis of the scans
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revealed that for this animal, the needle had been inserted at an angle, with the cells
delivered to the ventricle leading to them becoming lodged at a different anatomical
location (Figure 4.6). This could be an additional advantage of MRI to show and





In order to track cells in vivo, they need to be labelled with a genetic reporter and/or
nanoprobes. However, both types of labelling technique used in this study, including
the Fluc-ZsGreen bicistronic genetic reporter and MPIOs, can alter the phenotype of
the cells, affect their viability, differentiation potential in the longer term, or render the
cells immunogenic (Crabbe et al., 2010; Kostura et al., 2004).
A study by Limberis et al showed that luciferase causes an immunogenic response
in the mouse (Limberis et al., 2009). This study indicates that tumour cells expressing
luciferase were killed by the host’s immune system, but that unlabelled tumour cells
were not. This transgene immune recognition could be dependent upon different factors,
such as host background, vector dose, and site of injection. If immunogenicity to
luciferase were to occur in an in vivo study, this could make the results unreliable
(Limberis et al., 2009).
Green Fluorescent Protein (GFP) has also been shown to cause apoptosis (Liu
et al., 1999). Some studies have shown that cells labelled with GFP do not survive and
cannot accurately be tracked over time (Ansari et al., 2016; Gambotto et al., 2000).
The immunogenicity response to GFP might be related to the cytotoxicity observed in
some cell types, which can result from elevated levels of Reactive Oxygen Stress (ROS)
observed in various experiments (Jiang et al., 2014; Choy, 2010). However, it is not
clear if ZsGreen, which is a brighter, commercially available GFP, could cause a similar
immune response and toxicity in the longer term in vivo.
In this study RNU athymic rats are being used that lack T cells. The possible
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immune reactivity caused by luciferase and/ or ZsGreen would be expected to be me-
diated by T cells; therefore, it is expected that the reporter gene would be unlikely to
cause an immune response in these particular studies. However, whether there could
be any longer-term toxicity issues caused by the expression of ZsGreen, or whether
the luciferase and/or ZsGreen reporter genes negatively impact on the differentiation
potential of the implanted cells has not previously been explored.
It is documented that iron oxide particle labelling could affect the differentiation
capacities of stem cells. A study by Kostura et al revealed that iron oxide labelling of
mesenchymal stromal cells markedly diminished in vitro differentiation into chondro-
cytes (Kostura et al., 2004). Furthermore, introduction of iron oxide particles into the
CNS induced microglial activation (Wang et al., 2011; Kostura et al., 2004). In fact,
brain exposure to iron oxide particles has been associated with significant activation of
microglia, corresponding to pathological changes such as inflammation, mitochondrial
dysfunction, chromosomal damage, and generation of ROS (Sadeghiani et al., 2005;
Veranth et al., 2007). The RNU rats have functional glial cells, so it is important to
investigate whether the introduction of cells labelled with MPIOs could trigger an im-
mune response in the brain. In addition to the possibility of a glial response induced by
MPIOs, it is also likely that microglia overactivation will be induced by intracerebral
transplantation of the cells themselves. So, it is important in this study to establish if
the MPIO-labelled cells induce an immune response that is greater than that induced
by unlabelled cells (Tomov, 2020).
The specific objectives of this chapter were to use post-mortem samples in order:
1. Assess whether the expression of the Fluc-ZsGreen reporters affect the fate of
hESCs following implantation into the rat brain.
2. Assess the influence of Fluc-ZsGreen and MPIO labelling on the survival and
differentiation capacity of DAPCs following implantation into the rat striatum.
3. Evaluate the immunogenicity of labelled hESC-derived DAPCs following implan-




5.2.1 Investigating the effect of the Fluc-ZsGreen reporter on hESC
fate following implantation into the rat brain
Experiments in Chapter 3 indicated that the introduction of the reporter gene did
not inhibit the ability of hESCs to generate mature DA neurons, nor did it affect
the ability of cells to generate derivatives of the three embryonic germ layers in EBs
derived from the hESC reporter line. Furthermore, experiments in Chapter 4 suggested
that the reporter genes did not affect the ability of the implanted hESCs to form
tumours. However, a question remains as to whether the presence of the reporters has
any noticeable effect on tumour histology. To address this, histological analyses were
undertaken of tumours generated by injecting Fluc-ZsGreen+ hESCs or unmodified
hESCs into the rat striatum. As shown in Chapter 4 (Figure 4.1 a), Fluc-ZsGreen+
hESCs were injected into the right hemisphere, and unmodified hESCs were injected
in the left hemisphere.
At the study end point (day 28) H&E staining was performed on sections of brain
tissue containing the hESC-derived tumour and analysed by a pathologist (Figure 5.1).
By eye, it was possible to identify the tumours as they were more intensely stained
by H&E (Figure 5.1 a). At low power magnification, the area surrounding the injection
site consisted of a large number of tightly packed cells as evidenced by strong nuclear
(haematoxylin) staining in the same area suggesting an abnormal growth of cells (black
arrowheads in Figure 5.1 a). The tumour cells could clearly be distinguished from the
surrounding brain tissue and their position and size correlated well with the MR images
(black arrowheads in Figure 5.1 b). Further analysis of H&E sections at higher power
magnification shows that most of the tumour typically contains neuroepithelial-like
cells in both left and right hemispheres (Figure 5.1 c&d). The normal rat brain tissue
is indicated by blue arrows in Figure 5.1 (c&d). Furthermore, in some parts of both
the left and right hemispheres, vessel-like structures are observed within the tumours
(Figure 5.1 e&f).
Immunofluorescence microscopy revealed that the tumour in both hemispheres
consisted of human cells, as evidenced by positive staining for hNuclei compared to the
area that is outside the tumour region and has no positivity for hNuclei (Figure 5.2a).
In order to determine whether undifferentiated hESCs were present in the tumours,
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Figure 5.1: Histological analysis of tumours derived from undifferentiated hESCs.
(a) H&E staining was performed on frozen sections prepared from the day 27 tumours in rat 1.
Black arrowheads show tumour-like structure in the rat brains. (b) Representative image of MRI
from rat 1 on day 27 which is corelates with the H&E staining showing the tumour structure
in black arrowheads. (c) and (d) high power images of tumour containing neuroepithelial-like
cells (arrowheads) in left and right hemispheres. Blue arrowheads indicate the normal rat
brain tissue. (e) and (f) Vessel-like structures in the tumours have seen in the left and right
hemispheres are indicated by black arrowheads (imaged from rat 2 of control group). Scale bars
are 3mm in (a), 200 µm in (c), (d), (e), and (f).
co-staining was undertaken for hNuclei and OCT4. However, there is no positive ex-
pression of OCT4 suggesting that the cells within the tumours are not undifferentiated
hESCs (Figure 5.2 b). Further immunostaining was performed to investigate which
lineages were present within the tumours. Immunostaining for Brachyury, GATA6
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and β-III-tubulin were undertaken to detect derivatives of mesoderm, endoderm and
ectoderm, respectively. Although Brachyury and GATA6 had been detected in hESC-
derived EBs (Figure 3.7), analysis of the tumours showed that these markers were not
present (Figure 5.2 c). However, there was an abundance of β-III-tubulin staining con-
firming the presence of the ectodermal linage. Furthermore, some of the cells expressed
ZsGreen, suggesting that the ZsGreen might be preferentially silenced in certain lin-
eages but not others. In the vessel-like structures the co-localization of hNuclei and
smooth muscle action αSMA, a marker that indicates blood vessel myofibers, indicates
that they were all derived from the grafted hESCs (Figure 5.2d).
5.2.2 DAPCs express TH in vivo, irrespective of the introduction of
the reporter gene and MPIOs
In chapter 3, it was shown that the DAPC derived hESCs are able to successfully dif-
ferentiate into mature DA neurons, expressing TH in vitro (Figure 3.9). Therefore,
it was anticipated that DAPCs would also mature in vivo. Apart from investigating
the capacity of DAPCs to differentiate into mature DA neurons, here it was examined
whether the labels used for tracking (Fluc-ZsGreen bicistronic vector for BLI and iron
oxide particles for MR imaging) affected the differentiation potential of the cells follow-
ing implantation into the rat striatum. In order to identify this, sections of the right
hemisphere that had been injected with Fluc-ZsGreen+ DAPCs, and sections of the left
hemisphere that had been injected with nontransduced DAPCs, were immunostained
for TH. hNuclei and /or hNCAM (two human specific markers that can not recognise
the mouse proteins) were also used to confirm the identity of the grafted human cells.
Figure 5.3 (a) demonstrates the positivity of hNuclei antigen at the injection site in
both hemispheres suggesting the transplanted DAPCs are still alive and integrated with
the rat brain and displayed neural lineage commitment, irrespective of whether they
had been genetically modified, while there was no positivity for ZsGreen. Importantly,
the areas containing human cells were also positive for TH (red arrowheads in Figure
5.3 a), suggesting maturation of some DAPCs in the rats’ brains within the experimen-
tal period (91 days). The injection sites were also positive for a human-specific NCAM
(hNCAM) antigen (Figure 5.3 b), providing further evidence that human cells had in-
tegrated with the rat brain and displayed neural lineage commitment, irrespective of








Figure 5.2: Immunofluorescence analysis of tumours derived from undifferentiated
hESCs. (a) Representative micrographs of tumours stained for human nuclei and OCT4 coun-
terstained with Dapi. Tumour cells are positive for hNuclei but negative for OCT4, confirming
that all injected hESCs had differentiated in the rat brain. A subpopulation of cells express-
ing ZsGreen can be observed in the tumours formed from Fluc-ZsGreen+ hESCs injected to
the right hemispheres. (b) Images of left and right hemispheres immunostained for GATA6,
Brachyury, and β-III-tubulin revels only expression of β-III-tubulin in hNuclei positive cells
showing that grafted hESCs only differentiated into ectodermal linage. A subpopulation of
cells expressing ZsGreen can be observed in the tumours formed from Fluc-ZsGreen+ hESCs.
(c) Representative of immunestained section for αSMA and hNuclei indicating the presence of
vessel-like structures in the tumour derived from grafted cells. Scale bars correspond to 100
µm.
In the rat brain sections that were transplanted with MPIOs+ DAPCs into the right
hemisphere, and unlabelled DAPCs into the left hemisphere, the immunofluorescence
staining at the injection sites confirmed the presence of human cells that expressed TH,
reinforcing the point that these cells were able to integrate within the rat brain and
differentiated into mature DA neurons, irrespective of the MPIO labelling (Figure 5.4
a). In the right hemisphere, MPIOs were found in the same areas as the administered
human cells and appeared to localise to perinuclear regions. It is also of note that in
some sections MPIOs were observed in extracellular clusters as shown in Figure 5.4 (b).
5.2.3 Intense staining for GFAP is observed surrounding the human
cell implants
As previously mentioned, a previous study showed that the implantation of Fluc+
hESC-derived neural stem cells into the mouse striatum caused marked glial reaction
in the host brain, as evidenced by intense immunostaining for glial fibrillary acidic
protein (GFAP), a marker of reactive astrocytes. To investigate whether Fluc-ZsGreen
or MPIOs contributed to this reaction, immunofluorescence staining was performed
on sections of rat brains that received MPIO-labelled or Fluc-ZsGreen+ DAPCs (left





Figure 5.3: DAPCs integration with the rat brain and TH expression. (a) Immunoflu-
orescence microscopy of the injection sites (left hemisphere: nontransduced, right hemisphere:
Fluc-ZsGreen+). Cells express a human nuclear antigen, showing that the DAPCs survived in
the rats’ brains and expressed TH, suggesting that they matured into DA neurons. Arrowhead
indicates a human cell strongly expressing TH. (b) Immunofluorescence of a similar area but
using an antibody against human NCAM as a means to confirm the human origin of the cells.
In the merged images the TH is white, hNuclei/ hNCAM are red, and Dapi is blue. Scale bars
correspond to 50 µm.
As Figure 5.5 shows the presence of human cells is identified with hNCAM stain-
ing. The intensity of GFAP staining is stronger in the regions that show positivity for





Figure 5.4: DAPCs integration with the rat brain. (a) Immunofluorescence microscopy
of the injection sites (left hemisphere: nonlabelled cells, right hemisphere: MPIOs+ cells). Cells
express human NCAM, showing that MPIO labelled DAPCs survived in the rats’ brains and
TH, suggesting that DAPCs matured into DA neurons. MPIO-specific fluorescence is only seen
in the right hemisphere and tends to be localised near to the cell nuclei. (b) Representative
photomicrographs displaying the clustering and aggregation of MPIOs at the periphery of the
graft (red). In the merged images the TH is white, hNCAM is green, MPIOs are red and Dapi
is blue. Note that the MPIO fluorophore, Suncoast Yellow, is also excited at 405 nm and bleeds
into the Dapi channel. Scale bars correspond to 50 µm.
right and left hemispheres (Figure 5.5 a). Further Immunofluorescence microscopy of
brains from rats that received Fluc-ZsGreen+ DAPCs (left hemisphere: untransduced
control cells, right hemisphere: Fluc-ZsGreen+ cells) also shows the expression of hN-
CAM and increased GFAP staining around the grafted cells both in the right and left
hemispheres (Figure 5.5 b).
Furthermore, qualitative analysis showed an increase in GFAP staining around
the human implants, but no differences in staining intensity were observed around the
implants comprising unlabelled human cells or MPIO-labelled cells (Figure 5.5 a) and





Figure 5.5: Glial reaction at the injection sites. (a) Immunofluorescence microscopy
of brains from rats that received MPIO-labelled DAPCs (left hemisphere: unlabelled; right
hemisphere: labelled). The presence of human cells is identified with hNCAM staining, and the
intensity of GFAP staining is stronger in these areas. MPIOs are only seen in the right hemi-
sphere. (b) Immunofluorescence microscopy of brains from rats that received Fluc-ZsGreen+
DAPCs (left hemisphere: untransduced control cells; right hemisphere Fluc-ZsGreen+ cells).
Scale bars correspond to 100 µm.
5.3 Discussion
In order to assess the safety and efficacy of stem cell therapies in preclinical models,
it is important to be able to track the fate of the cells in vivo. However, before doing
this, it is crucial to assess the suitability of the imaging probes themselves in an in
vivo context. Therefore, the first aim of this chapter was to assess the effects of Fluc-
ZsGreen labelling on the fate of hESCs following transplantation into the rat striatum;
the second aim of this chapter was to investigate the effect of the Fluc-ZsGreen reporter
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gene and MPIOs on hESC-derived DAPCs in terms of viability and their potential to
differentiate into mature DA neurons after introduction into the rat striatum; the third
aim was to explore whether the labelled cells triggered a more severe immune response
than unlabelled cells.
In line with the first aim, H&E histopathological examination of all 3 rats within
the control group showed that the grafted cells spontaneous formed tumours, irre-
spective of whether they expressed the reporter genes or not. Morphologically, the
tumour has abundant neuroepithelial cells as evidenced by the high proportion of cells
expressing the neuronal marker, β-III-tubulin. However, in the EBs that formed from
spontaneous differentiation of hESCs the expression of all three germ layers was evident
(Figure 3.7). The reason for the dissimilar differentiation capacity of hESCs in vitro
compared to within the rat brain in vivo might be due to the effects of the microen-
vironment. Recent research findings documented that implanted stem cells are highly
affected by the three-dimensional structure of their surrounding microenvironment, the
specific extra cellular matrix components, in addition to relevant cytokine signalling,
all of which affect their growth and differentiation (Wan et al., 2015). The other typi-
cal morphological structures within the hESC-derived tumour was myo-epithelium that
stained positively for αSMA. However, it is more likely that these myoepithelial cells
are of neural crest origin, which is also considered to be part of the ectodermal lineage.
Overall, there was no sign of any difference between the tumours in the left and
right hemispheres in terms of morphological structure and marker expression, suggest-
ing the fate of the injected hESCs was not influenced by the presence of Fluc-ZsGreen.
The second aim of this chapter was to assess the viability and maturation of grafted
DAPCs. In order to do this, expression of TH, a marker gene that is expressed in mature
DA neurons (as shown previously in Chapter 3 in vitro) was analysed in the brain sec-
tions containing the injection site. TH+ cells were identified within hNCAM+/hNuclei+
cell populations of labelled and unlabelled human cell cohorts within the rat striatum.
Here, there was no evidence that the bicistronic Fluc-ZsGreen reporter or the MPIOs
inhibited the differentiation of hESC-derived DAPCs into TH+ DA neurons. However,
in both Fluc-ZsGreen and MPIOs labelled cells, not all human cells robustly expressed
TH, likely because a period of >20 weeks is necessary for the maturation of all DAPCs.
In order to explore the glial activity of transplanted cells, the expression of GFAP
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was assessed in the transplanted cells. The transplantation of both labelled and unla-
belled DAPCs elicited a marked glial reaction at the injection site, as expected. How-
ever, there was no notable difference in the scale of glial response, suggesting that
neither Fluc-ZsGreen nor MPIOs increased the glial reaction to the DAPCs. One point
that was noted in some of the immunostained brain sections that were injected by
MPIO+ DAPCs, was the extracellular localisation and aggregation of MPIOs. This
might be due to a level of reported cytotoxicity of iron oxide particles that cause cell




Final discussions and future
perspectives
The main aim of this thesis was to assess the effectiveness of BLI and MR imaging
for monitoring the tumourigenicity, viability and intracranial biodistribution of hESC-
derived DAPCs following stereotactic injection into the rat striatum. Furthermore, the
study investigated whether the introduction of imaging probes, including a bicistronic
luciferase-ZsGreen reporter, and MPIOs, affect the differentiation capacity of trans-
planted cells and graft immunogenicity. To be considered appropriate for use in the
preclinical evaluation of grafted stem cell-derived tissues, it is essential that the integra-
tion of imaging probes has no effect on the differentiation capacity of cells. Transgenic
induction of luciferase is a well-established method for monitoring stem cell-derived
tissues in vivo (Bernau et al., 2014; Peng et al., 2018; Huang et al., 2012); therefore, it
was not expected that the incorporation of this reporter gene would negatively influ-
ence differentiation patterns. In concordance, this study showed that the Fluc-ZsGreen
bicistronic reporter gene successfully labelled hESCs without affecting their differenti-
ation capacity in vitro.
The labelled cells could differentiate into DAPCs and could also further differ-
entiate into mature DA neurons. Furthermore, there was no noticeable difference in
the differentiation ability and immunogenicity between transduced and non-transduced
DAPCs in vivo. However, during the in vivo study, in most rats, BLI could only detect
DAPCs during the first few days after cell transplantation. As discussed in Chapter 4
this was likely due to signal attenuation due to the increasing size of the rats’ head,
and to the silencing of the reporter gene that occurred as the DAPCs differentiated.
6. Final discussions and future perspectives
In vivo silencing is one of the main bottlenecks of luciferase mediated BLI assays, as
the preclinical studies require long-term activity of the transgene. In the discussion of
Chapter 4 the possible reasons of silencing Luciferase-ZsGreen reporter gene used in this
study were discussed in detail, but in brief, the most likely explanation for the silencing
is that the extent of methylation increases as the cells become more differentiated. In
future studies, in order to overcome the limitation of very low BLI signal detection, a
cell type-specific promoter, such as FOXA2, which is expressed in both DAPCs and
mature DA neurons (Domanskyi et al., 2014), could prove more effective than the
EF1 promoter for monitoring viability longitudinally, especially if used with the highly
sensitive AkaLuc luciferase in combination with the substrate Akalumine (Iwano et al.,
2018). The discovery of AkaLuc, a red-shifted alternative to Firefly luciferase and
its luciferin counterpart, AkaLumine-HCL is a significant improvement for live cell
tracking in the brain using BLI. AkaLuc light emission at 677 nm increases tissue
penetration, enhancing sensitivity to near single cell detection and increased absorption
of AkaLumine-HCL across the BBB makes it highly attractive for neuroimaging (Iwano
et al., 2018).
Considering the point of DNA methylation and its effect on silencing the reporter
gene through the process of cell differentiation, quantifying the methylation would give
a good prediction of the gene silencing over the period of the in vivo study. Another
potential improvement on the current study in terms of BL imaging could be switching
to mice instead of rats, thereby reducing signal attenuation. Apart from the aforemen-
tioned problems with the BLI technique, another issue with this modality is that the
spatial resolution is poor and does not allow the position of cells within the brain to
be accurately mapped.
In the present study, four weeks after implantation of undifferentiated hESCs,
MR imaging could detect a cell mass in both cerebral hemispheres, irrespective of
whether the cells had been transduced with the Fluc-ZsGreen reporter. However, no
cell masses were detected at any time point following administration of hESC-derived
DAPCs, suggesting that in contrast to the undifferentiated hESCs, the DAPCs are non-
tumourigenic. Cells labelled with MPIOs could be detected at all time points using
longitudinal MR imaging. In addition, we found that the cells remained at the injection
site and did not appear to migrate to other brain regions. From a safety perspective,
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the lack of migration is important to prevent cells integrating into intact neural circuits,
causing side effects (e.g., epilepsy) (Wijeyekoon and Barker, 2009). Upon investigation
of mature DA neurons that express TH, we reported expression of rodent astrocytes
at the injection site using the GFAP marker. However, no obvious difference in GFAP
expression was observed between the rats injected with labelled and non-labelled cells,
suggesting that the label did not increase the degree of immunogenicity of the cells.
In this study, it is imperative that a high proportion of the grafted cells differentiate
into mature DA neurons to allow restoration of motor dysfunction in PD. Therefore,
in order to show the graft functionality, investigation of other cell populations, mainly
serotonergic neurons in the graft area would be desirable. It is also important to
understand the extent to which DAPCs mature and form synapses with host neurons
following implantation, as this will give some insight into their therapeutic mechanisms.
Few studies have determined the proportion of injected DNPs that generate mature
TH-expressing DA neurons. However, Kriks et al have shown that this is only 10%
and 30% in rats and mice, respectively (Kriks et al., 2011). Furthermore, most studies
tend to focus on recovery of motor function and tend not to assess whether the TH+
neurons form synapses with host neurons. An early study from 1988 showed that
human foetal DA neurons could synapse with host rat neurons, but ultrastructural
analysis of hESC-derived DNPs is lacking (Clarke et al., 1988). This information is
important because limited integration of hESC-derived DNPs might suggest that any
observed recovery of motor function in PD animal models might be due, at least in
part, to other mechanisms, such as the secretion of paracrine factors. In support of
this, mouse ESCs treated with mitomycin C, which are unlikely to generate DNPs
in vivo, were nevertheless able to significantly improve motor function in a mouse PD
model (Acquarone et al., 2015). It is also worth noting that in the most commonly used
PD model, where DA neurons are depleted by administering the chemical 6-OHDA,
re-innervation can occur with time as long as the injury is not too extreme (Stanic
et al., 2003). Thus, it is plausible that paracrine factors derived from administered
DNPs might promote the re-growth of host neurons.
Taken together, the preclinical studies indicate that treating PD patient with
hESCs-derived DAPCs is likely to be a safe and effective therapy, though this tech-
nology requires more maturity in the concept of finding the "universal hPSC line". A
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problem, however, is that the pluripotent stem cell lines can vary considerably in their
ability to generate the required progenitor cells, and different batches of the progen-
itor cells may work better than others. Therefore, to give this exciting therapy the
best chance of working, we need to be able to screen a range of cell lines before they
are used in patients. This will ensure that only the highest-performing cells are im-
planted. A combined BLI/MRI strategy in preclinical models could be effective for
monitoring the viability, biodistribution and tumourigenicity of the different cell lines
in animal models longitudinally. Such a strategy could allow for aspects of the therapy
to be optimized in the animal model prior to clinical application. For instance, the
functional potency of several hPSC lines in generating mature TH+ neurons following
implantation could be explored. Additionally, preclinical studies could help to explore
the potential tumorigenicity of each cell line; the optimal target cell dose to be grafted
in the patients; patient-tolerability and efficiency in reversing the symptoms of the
disease. Furthermore, such preclinical studies would be useful to explore whether the
recovery observed in animal models following cell administration is entirely due to the
cells generating dopaminergic neurons, or whether the cells might also stimulate regen-
eration of host neurons. Also, the idea that the inclusion of specific growth factors,
or cocktails of growth factors to enhance survival of post-implantation differentiation
could be assessed in such a model. Enhancing our knowledge by using an animal model
in this way could help to design the clinical trials more efficiently and mean that the
Parkinson’s disease patients recruited to the forthcoming clinical trials would have the
best chance of experiencing a beneficial outcome.
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Figure A.1: Differentiation of PSCs to DAPCs is comparably efficient when using
ZT-Fn9-10 or Laminin 111 as the culture substrate. Fluorescence micrographs are repre-
sentative of DAPCs at day 16 post-differentiation cultured on Laminin 111 or ZT-Fn9-10. Cells
were stained for ventral midbrain markers FOXA2 (red), OTX2 (red) and LMX1A (green). Dapi
(blue) was used as a nuclear counterstain. Scale bar = 50 µm. Flow cytometry histograms of
FOXA2 and OTX2 expression in DAPCs cultured on Laminin 111 (grey) or ZT-Fn9-10 (purple).
The isotype control profile (white) and gate boundary are shown.
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Figure A.2: Schematic illustration of pHIV bicistronic lentivirus containing firefly
luciferase and ZsGreen reporters. The Vector was generated by Dr Arthur Taylor, Murray
group (Taylor et al., 2020).
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Figure A.3: No primary antibody control immunofluorescence for FOXA2, OTX2A,
and LMX1A in DAPCs. DAPCs incubated with the antibody diluent alone and no primary
antibody, followed by incubation with secondary antibodies and Dapi.There was no signal de-
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Abstract
Purpose: Human pluripotent stem cell (hPSC)-derived dopaminergic neuron progenitor cells
(DAPCs) are a potential therapy for Parkinson’s disease (PD). However, their intracranial
administration raises safety concerns including uncontrolled proliferation, migration and
inflammation. Here, we apply a bimodal imaging approach to investigate the fate of DAPC
transplants in the rat striatum.
Procedures: DAPCs co-expressing luciferase and ZsGreen or labelled with micron-sized particles
of iron oxide (MPIOs) were transplanted in the striatum of RNU rats (n = 6 per group). DAPCs were
tracked in vivo using bioluminescence and magnetic resonance (MR) imaging modalities.
Results: Transgene silencing in differentiating DAPCs accompanied with signal attenuation due
to animal growth rendered the bioluminescence undetectable by week 2 post intrastriatal
transplantation. However, MR imaging of MPIO-labelled DAPCs showed that transplanted cells
remained at the site of injection for over 120 days. Post-mortem histological analysis of DAPC
transplants demonstrated that labelling with either luciferase/ZsGreen or MPIOs did not affect
the ability of cells to differentiate into mature dopaminergic neurons. Importantly, labelled cells
did not elicit increased glial reactivity compared to non-labelled cells.
Conclusions: In summary, our findings support the transplantation of hPSC-derived DAPCs as a
safe treatment for PD.
Key words: Dopaminergic neuron progenitor cells, Human pluripotent stem cell, Parkinson’s
disease, Non-invasive imaging, Bioluminescence, Magnetic resonance imaging
Introduction
Parkinson’s disease (PD) is a neurodegenerative disease that
results in part from the progressive loss of dopaminergic
(DA) neurons in the substantia nigra. Several groups have
shown that human pluripotent stem cell (hPSC)-derived
dopaminergic neuron progenitor cells (DAPCs) can generate
Electronic supplementary material The online version of this article (https://
doi.org/10.1007/s11307-020-01499-4) contains supplementary material,
which is available to authorized users.




mature DA neurons and improve motor function following
intrastriatal transplantation in animal models of PD [1, 2].
This has now evolved to the point that the first in human
hPSC-based DA neural transplants are being undertaken or
planned in patients with PD. However, prior to undertaking
larger-scale clinical studies, animal experiments are needed
to adequately assess the safety of the therapies. Key safety
concerns with such therapies for PD and other central
nervous system (CNS) disorders include the risk that the
implanted cells could proliferate and form space-occupying
masses and/or migrate to off-target sites within the CNS and/
or induce major neuroinflammation [3]. In addition to
considering the potential risks, it is also important to monitor
the long-term viability and differentiation capacity of
implanted cells, as to be effective, they must differentiate
into the appropriate phenotype and persist in the brain.
An effective strategy for monitoring the proliferation,
viability and localisation of implanted cells longitudinally
is to employ a non-invasive imaging approach compris-
ing different modalities, such as bioluminescence (BLI),
magnetic resonance (MRI) and fluorescence imaging [4,
5]. BLI is the most sensitive live animal imaging
technique, enabling relatively small numbers of
transplanted cells to be detected [6]. This technique
requires that the cells express a luciferase reporter, which
means that a signal is only emitted if the cells are alive.
An increase in BLI signal over time indicates cell
proliferation and potential tumour formation whereas a
loss of signal suggests that the cells are no longer viable.
A drawback with BLI, however, is that spatial resolution
is poor, which means that it cannot be used to determine
the location of the implanted cells and/or any resultant
masses within the brain. MR imaging, on the other hand,
has a very high spatial resolution and can accurately map
the position of intracranial lesions [7]. Moreover, by
labelling cells prior to administration with an appropriate
contrast agent, such as iron oxide particles [8] or 19F-
based tracking agents [9], MRI can be used to plot the
biodistribution of the cells over time.
Hoehn and co-workers have shown previously that BLI
and MR imaging can be used to monitor the viability and
intracranial biodistribution of human embryonic stem cell
(hESC)-derived neural stem cells following implantation
into the mouse striatum [10]. To the best of our knowledge,
this bimodal approach has not previously been used to track
the tumourigenicity, viability and biodistribution of hESC-
derived DAPCs, following intrastriatal administration into
the rat brain. A key aim of this study, therefore, was to
assess the potential of this bimodal BLI/MR strategy to track
hESC-derived DAPCs in vivo. In addition to evaluating the
effectiveness of the imaging modalities themselves, we also
investigated whether the labels used for tracking (i.e. a
firefly luciferase, Fluc-ZsGreen bicistronic vector for BLI
and iron oxide particles for MR imaging [4, 11]) affected the
differentiation potential of the cells and/or their immunoge-
nicity following implantation into the rat striatum.
Materials and Methods
hESC Culture and Maintenance
The clinical-grade RC17 hESC line was obtained from
Roslin Cells Ltd., UK. Cells were expanded on laminin 521
(0.5 μg/cm2) (Biolamina) in iPS-Brew XF (StemMACS™).
Cells were passaged as small clumps using Versene, a non-
enzymatic cell dissociation reagent (ThermoFisher Scien-
tific), and 10 μM of Rho kinase (Rock) inhibitor Y-27632
dihydrochloride (StemMACS, Miltenyi) was added to the
medium for the first 24 h after plating. The medium was
changed daily, and cells were maintained at 37 °C under 5 %
CO2.
Generation of hESC Reporter Line and Labelling
with Iron Oxide Particles
RC17 cells were transduced with a lentiviral vector encoding
for the bicistronic expression of the codon-optimised firefly
luciferase (luc2) and ZsGreen (via an IRES link) under the
constitutive promoter elongation factor-α (EF1α). The vector
plasmid was a gift from Bryan Welm (Addgene plasmid
#39196), and the production and titration of viral particles
was carried out using established protocols [11]. In order to
transduce the hESCs, colonies of undifferentiated RC17
cells were dissociated into very small clumps consisting of
about 10–15 cells using Versene for 5 min. After centrifu-
gation, the cells were counted and seeded onto laminin
521 at a density of approximately 2.5 × 104 cells/cm2 in the
presence of 10 μM Y-27632. Cells were incubated overnight
and transduced on the following day with 25 × 104 viral
particles (multiplicity of infection of approximately 5) in the
presence of polybrene (10 μg/ml). After 24 h, the medium
was replaced, and the cells were expanded for 4 days prior to
sorting for ZsGreen expression with a BD FACSAria (BD
Biosciences) flow sorter. The Fluc-ZsGreen+ cells were
collected in iPS-Brew culture medium supplemented with
10 μM Y-27632, seeded on laminin 521 and expanded for
subsequent experiments. To assess bioluminescence activity,
cells were plated at different densities in black 96-well plates
(Thermo Scientific), allowed to settle for 2–4 h and then
incubated with medium containing D-luciferin (150 μg/ml,
Promega) prior to data acquisition with an IVIS spectrum
system (Perkin Elmer).
Micron-sized particles of iron oxide (MPIO) were used as
a label for MR detection of DAPCs. Suncoast Yellow
MPIOs (Bangs Beads, 1.63 μm nominal diameter, Bangs
Laboratories, Inc.) were added directly to the DAPC’s cell
culture medium at a concentration of approximately 1500
particles/μl for 24 h. After the labelling period, cells were
carefully washed with PBS to remove unbound particles,
harvested and then used for in vivo studies. The extent of
MPIO labelling was assessed with a FACSCalibur (BD
Biosciences) flow cytometer.
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Differentiation into Neural Precursors and
Mature Neurons
RC17 cells were differentiated towards mesencephalic
DAPCs or terminally differentiated into mature DA neurons
as previously described [12]. In brief, DAPCs are obtained
after neuralisation, patterning and expansion of the cells for
a period of 16 days whereas DA neurons are obtained via the
maturation of DAPCs for 34 days. Correct caudalization of
progenitors towards a midbrain fate was achieved using
0.9 μM GSK3 inhibitor (CHIR99021).
Cell Implantation and In Vivo Imaging
RNU rats (males, 5–6 weeks old) were purchased from
Charles River and housed in individually ventilated cages
under a 12-h light/dark cycle with ad libitum access to
standard food and water. All animal experiments were
performed under a licence granted through the UK Animals
(Scientific Procedures) Act 1986 and were approved by the
University of Liverpool ethics committee. All applicable
institutional and/or national guidelines for the care and use
of animals were followed. All procedures (surgical admin-
istration of cells and imaging) were carried out under
isoflurane anaesthesia.
Single-cell suspensions prepared in Hanks’ Balanced Salt
Solution were implanted stereotactically into the left and
right hemispheres of the rats’ brains. Using the bregma as a
reference, the skull was drilled at 0 mm anteroposterior and
±1.5 mm mediolateral, with each hemisphere receiving two
deposits of cells at a depth of −5.0 and −4.3 mm from the
dura. Each deposit contained 75 × 103 cells in 0.75 μl of
PBS, delivered with a microsyringe connected to an infusion
pump. The rats were divided into three different experimen-
tal groups as outlined in Table 1.
BLI was carried out with an IVIS spectrum system. After
inducing anaesthesia, the rats’ heads were shaved and the
animals received an intraperitoneal injection of luciferin at a
dose of 150 mg/kg body weight. Data were acquired 20 min
post administration of the substrate with a field of view B
(6.5 cm), medium binning, f-stop 1 and exposure time
calculated automatically by the acquisition software, up to a
maximum of 5 min. All bioluminescence data were
normalised to the acquisition conditions and are displayed
as radiance (photons/s/cm2/str).
MRI data were acquired with a Bruker Avance III
console interfaced to a 9.4T magnet system (Bruker Biospec
94/20 USR). RF excitation was achieved with an 86-mm
resonator and signal detection with a four-channel phased
array receive-only rat brain coil. Once the injection site was
located using scout images, higher resolution images were
acquired with rapid acquisition with relaxation enhancement
(RARE) sequence. Following are the parameters used: echo
time (TE) = 38 ms, repetition time (TR) = 2700 ms, RARE
factor = 8, number of excitations (NEX) = 8, field of view
(FOV) = 35 × 35 mm, matrix size = 350 × 350 pixels, slices =
20, slice thickness = 500 μm.
At the experimental endpoint, the rats received an
overdose of pentobarbital and were perfused transcardially
with PBS followed by 4 % formaldehyde. The brains were
harvested, postfixed with 4 % formaldehyde, equilibrated in
30 % sucrose and cryosectioned for microscopy analysis.
RT-qPCR
Cells were washed twice with PBS, and a minimum of 5 ×
105 cells were lysed with TRI Reagent (Sigma). Total RNA
was extracted according to the manufacturer’s protocol, and
a NanoDrop was used to determine RNA concentration. To
synthesise cDNA, RNA was treated with DNase1 and
reverse transcribed using random hexamers (Qiagen) and
Superscript III reverse transcriptase (Invitrogen). PCR was
performed on a CFX Connect system (Bio-Rad) using
SYBR Green JumpStart Taq Ready Mix (Sigma). The genes
OTX2, FOXA2 and LMX1A were measured to assess
differentiation into DAPCs, with GAPDH being used as a
housekeeping gene. Undifferentiated hESCs were used as a
control. Relative expression levels of target genes between
control and experimental samples were calculated using the
2−ΔΔCt method [13]. Primer sequences are shown in ESM
Table 1.
Immunostaining and Histology
Cells were fixed with 4 % formaldehyde for 20 min,
permeabilised with 0.1 % Triton X-100 for 20 min and
blocked with 1 % bovine serum albumin (BSA) for 30 min.
Cryosections (10 μm) from fixed tissues were permeabilised
and blocked as described above. Primary antibodies were
diluted in 1:1 Triton X-100:BSA according to the dilution
factors in ESM Table 2 and incubated for 24 h at 4 °C.
Secondary antibodies were diluted 1:1000 in 1:1 Triton
X-100:BSA and incubated for 2 h at room temperature. For
immunofluorescence, cells were counterstained with DAPI.
Images were acquired on a 3i spinning disk confocal
microscope CSU-X1 (Intelligent Imaging Innovations) and
processed with ImageJ [14]. For immunohistochemistry,
tissue sections were incubated with 1.4 mM 3,3′-diamino-
benzidine (DAB) and 0.01 % hydrogen peroxide for 15 min,
and images were acquired with a Leica DM IL microscope.
Results
hESC Labelling Does Not Negatively Impact on
Differentiation Towards DAPCs or Mature
Dopaminergic Neurons In Vitro
Flow cytometry analysis of RC17 hESCs 4 days after viral
transduction showed that approximately 47 % of the
population expressed the reporter gene ZsGreen (ESM
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Fig. 1a, b). After sorting, a pure population of hESCs
expressing the reporter was obtained (Fig. 1a, b), herein
defined as Fluc-ZsGreen+ hESCs. Fluc-ZsGreen+ hESCs
maintained expression of ZsGreen over multiple passages
and were morphologically indistinguishable from non-
transduced cells (Fig. 1a, b). To assess whether the
introduction of the reporter affected pluripotency, embryoid
bodies (EB) were generated and immunostained for markers
of embryonic germ layer derivatives. The presence of
GATA6 (endoderm), Brachyury (mesoderm) and Nestin
(ectoderm) confirmed that the Fluc-ZsGreen+ hESCs
remained pluripotent (ESM Fig. 1c).
DAPCs were assessed for the co-expression of the key
markers FOXA2, LMX1A and OTX2 on day 16 of
differentiation. Quantification of mRNA via RT-qPCR
revealed significant upregulation of all these markers
(Fig. 1c), which was confirmed via immunofluorescence
(Fig. 1d). However, fluorescence microscopy also revealed
that not all cells expressed ZsGreen after differentiation into
DAPCs (Fig. 1d). DAPCs were further differentiated into
mature DA neurons and immunostained (differentiation
day 50) to detect the classic DA neuron marker, tyrosine
hydroxylase (TH). Immunofluorescence demonstrated that
the transduced RC17-derived DA neurons expressed TH
(Fig. 1e), but ZsGreen was no longer detectable at this
differentiation stage.
Flow cytometric analysis of DAPCs showed that only 51 %
of these cells expressed ZsGreen, implying a significant loss of
reporter gene expression when compared to undifferentiated
hESCs (Fig. 1f), and complete loss once the cells had matured
to dopaminergic neurons (DAs) (Fig. 1e). Measurement of the
light output (bioluminescence) revealed that the expression of
luciferase corresponded to that of ZsGreen; that is, biolumi-
nescence was strong before differentiation (37 p/s/cell),
significantly reduced as cells differentiated towards DAPCs
(17 p/s/cell) and extremely weak when they became mature
DAs (G1 p/s/cell) (Fig. 1g).
Taken together, these results show that the introduc-
tion of the genetic reporter did not affect hESC
pluripotency nor their ability to differentiate to DAPCs
and DA neurons. However, reporter gene expression was
progressively lost as the cells differentiated towards DA
neurons. Despite the reduction in light emission in
DAPCs, we reasoned that it would still be possible to
detect them in rodents in vivo, enabling their tracking
and assessment of viability/tumourigenicity in the early
post-transplant period, but that it would not be possible
to detect the mature DA neurons.
In Vivo Imaging Reveals Absence of DAPC
Tumourigenicity and Long-Term Intracranial
Distribution
In addition to assessing the ability of BLI and MRI to detect
the implanted cells, a further objective of the in vivo studies
was to investigate whether the presence of either the Fluc-
ZsGreen reporter or the MPIOs affected (i) the
tumourigenicity of the cells, (ii) the ability of the hESC-
derived DAPCs to differentiate into mature DA neurons
in vivo or (iii) the immunogenicity of the human cells. To
this end, three groups of rats were set up. Group 1, which
served as a control group for tumour formation, comprised
of three rats that had Fluc-ZsGreen+ hESCs implanted into
the right striatum and unlabelled hESCs into the left striatum
(Fig. 2a); group 2 comprised of six rats that had DAPCs
derived from Fluc-ZsGreen+ hESCs implanted into the right
striatum and unlabelled cells into the left striatum (Fig. 2d);
group 3 comprised of six rats that had MPIO-labelled hESC-
derived DAPCs implanted into the right striatum and
unlabelled hESC-derived DAPCs implanted into the left
striatum (Fig. 4c).
hESCs and DAPCs Follow Distinct Fates In Vivo,
Irrespective of the Introduction of a Reporter
Gene
Optical imaging of animals that received undifferentiated
hESCs on the administration day and on days 14 and 27 post
administration revealed great variability in the biolumines-
cence signal. On the administration day, just one of the
animals displayed a signal, which was very weak, suggesting
that Fluc expression was not robust enough for sensitive
detection in all animals. Bioluminescence was progressively
lost from this rat but detected in a different animal at a later
time point (ESM Fig. 2a).
MR imaging of these rats at the experimental endpoint
(day 27) displayed a large area of atypical hyperintense
contrast surrounding the injection site, which was present in
both brain hemispheres of all animals (Fig. 2b and ESM
Fig. 2b). Histological analysis of the tissue showed that this
area consisted of a large number of tightly packed cells as
evidenced by strong nuclear (haematoxylin) staining in the
same area (Fig. 2b), suggesting an abnormal growth of cells.
Immunofluorescence microscopy of these samples revealed
that the masses in both hemispheres consisted of human
cells, as evidenced by positive staining for a human-specific
Table 1. Description of the experimental groups
Group Cells implanted in the left hemisphere Cells implanted in the right hemisphere Number of animals Endpoint
1 Undifferentiated hESCs Undifferentiated hESCs (Fluc-ZsGreen+) 3 Day 27
2 DAPCs DAPCs (Fluc-ZsGreen+) 6 Day 91
3 DAPCs DAPCs (MPIO-labelled) 6 Day 127
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nuclear antigen (hNuclei). Interestingly, however, not all
cells in the masses that formed in the right brain hemisphere
(Fluc-ZsGreen+ hESCs) expressed ZsGreen, suggesting that
some of the hESCs lost expression of the reporter (Fig. 2c).
The hESC-derived masses did not display a teratoma-like
tissue architecture when examined by haematoxylin and
eosin staining (data not shown). Instead, many of the cells
expressed β-III tubulin, suggesting that transplantation of
these cells in the rat brain promoted differentiation to
ectodermal lineages (ESM Fig. 2c). The growths were also
negative for OCT4, confirming that cells had differentiated
in the brain (ESM Fig. 2d). Taken together, these results
indicate that undifferentiated hESCs form mass lesions,
irrespective of the introduction of the Fluc-ZsGreen reporter.
For rats implanted with DAPCs (group 2) (Fig. 2d),
four of six animals displayed a bioluminescence signal
on the administration day (Fig. 2e and ESM Fig. 3a),
which was not detectable at the subsequent imaging
points (days 14, 28, 56 and 91). In contrast to hESCs,
administration of DAPCs resulted in no abnormal MR
contrast at the experimental endpoint (day 91, Fig. 2f),
with all animals exhibiting normal brain structures and
the needle track being the only remarkable feature.
Human cells were still present at the injection site in
both hemispheres, as evidenced by hNuclei positivity
(Fig. 3a). Importantly, the areas containing human cells
were also positive for TH, suggesting maturation of some
DAPCs in the rats’ brains within the experimental period
Fig. 1. Effect and stability of the Fluc-ZsGreen reporter gene in hESCs. a Phase contrast and fluorescence microscopy of
the control and Fluc-ZsGreen+ hESCs. Cells were imaged three passages post sorting. b ZsGreen expression, as measured via
flow cytometry, of the control and sorted hESCs. The green fluorescence of the sorted cells is stable for several passages. c
Expression of OTX2, FOXA2 and LMX1A in DAPCs obtained from Fluc-ZsGreen+ hESCs. d, e Fluorescence microscopy of
DAPCs and DAs obtained from Fluc-ZsGreen+ hESCs (differentiation days 15 and 50, respectively). Cells were immunostained
for OTX2, FOXA2, LMX1A and TH. f Flow cytometry shows that differentiation into DAPCs reduces ZsGreen expression
(approximately 47 % of the cells expressing the construct). g BLI of different numbers of Fluc-ZsGreen+ hESCs, DAPCs and
DAs and the corresponding photon flux. Data are representative of three independent experiments. Error bars represent SD,
and the solid line the linear fit of the data. Scale bars in micrographs correspond to 100 μm.
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(91 days). Not all human cells robustly expressed TH,
likely because a period of 920 weeks is necessary for the
maturation of all DAPCs. The injection sites were also
positive for a human-specific NCAM (hNCAM) antigen
(Fig. 3b), providing further evidence that human cells
had integrated with the rat brain and displayed neural
lineage commitment, irrespective of whether they had
been genetically modified.
Fig. 2. Long-term fate of hESCs and DAPCs. a Schematic of injection and experimental timeline of hESC
administration and imaging. b Representative RARE MRI scan (day 27) and corresponding histological section (H&E
staining) of a rat that received undifferentiated hESCs (left hemisphere: non-transduced, right hemisphere: Fluc-
ZsGreen+). Both sides display a large area of hyperintense contrast at the injection site (arrowheads) which was
confirmed to correspond to tightly packed cell nuclei via histology. c Fluorescence microscopy of areas of abnormal
growth in the right hemisphere. In all cases, the growth corresponded to cells of human origin, as evidenced by
expression of a human nuclear antigen. The level of ZsGreen expression was heterogeneous within the growths, with
areas of strong expression (top) and areas where ZsGreen was lost (bottom). Scale bar = 50 μm. d Schematic of
injection and experimental timeline of DAPC administration and imaging. e BLI of two of the six rats that received
DAPCs as imaged on days 1, 14 and 91. Most, but not all, rats displayed a signal on the injection day, but this was lost
by day 14, and no signal was seen at any other time points. The left panel is representative of rats that displayed signal
on day 1, and the right panel representative of rats that did not display a signal on any of the days. Data for the other
rats and time points are shown in the ESM. Note that this rat strain can display cycles of thin hair growth, as seen in
some images. f RARE MRI scans (day 90) of all six rats that received DAPCs (left hemisphere: non-transduced, right
hemisphere: Fluc-ZsGreen+). No abnormal features are seen, apart from the needle track that is still visible in some
animals (indicated arrowheads in the first rat only).
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MPIO Labelling Enables Assessment of the
Intracranial Distribution of Implanted Cells
Flow cytometry analysis of MPIO-labelled DAPCs sug-
gested that approximately 72 % of DAPCs were labelled
with the particles, as evidenced by yellow fluorescence
originating from MPIOs (Fig. 4a). We also detected a shift in
the side scatter of DAPCs after labelling with MPIOs,
providing further evidence for the internalisation of the
particles (Fig. 4b).
Rats implanted with MPIO-labelled DAPCs (group 3)
(Fig. 4c) were imaged only via MR as neither of the
hemispheres received cells with the genetic reporter.
Monitoring of this group for up to 4 months post
implantation confirmed that DAPC implantation does not
lead to tumour formation, with all rats displaying normal
brain structures at all time points. In five out of six rats,
hypointense contrast was seen in the right brain hemi-
sphere (Fig. 4d and ESM Fig. 3b). This was an expected
consequence of the MPIO labelling, which enabled us to
monitor the delivery and intracranial distribution of
DAPCs. Remarkably, the distribution of the administered
DAPCs appears to remain stable throughout the 4 months
that the animals were monitored for, with no obvious
change in the area with hypointense contrast, suggesting
that the DAPCs were confined to the areas into which they
were initially deposited. In one rat, no hypointense contrast
was observed in the target area. Further analysis of the
Fig. 3. DAPC integration with the rat brain. a Immunofluorescence microscopy of the injection sites (left hemisphere: non-
transduced, right hemisphere: Fluc-ZsGreen+). Cells express a human nuclear antigen, showing that the DAPCs survived in the
rats’ brains and expressed TH, suggesting that they matured into DAs. Arrowhead indicates a human cell strongly expressing
TH. b Immunofluorescence of a similar area but using an antibody against human NCAM as a means to confirm the human
origin of the cells. Scale bars correspond to 50 μm.
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scans revealed that for this animal, the needle had been
inserted at an angle, with the cells delivered to the
ventricle leading to them becoming lodged at a different
anatomical location (ESM Fig. 3c).
As observed before, immunofluorescence staining at the
injection sites confirmed the presence of human cells that
expressed TH, reinforcing the point that these cells were able
to integrate within the rat brain and differentiated into
mature DAs, irrespective of the MPIO labelling (Fig. 4e). In
the right hemisphere, MPIOs were found in the same areas
as the administered human cells and appeared to localise to
perinuclear regions.
Fig. 4. MPIO tracking of DAPCs in the rat brain. a Yellow fluorescence of unlabelled and MPIO-labelled DAPCs. b Forward
vs. side scatter plot of unlabelled and MPIO-labelled DAPCs. c Schematic of injection and experimental timeline of DAPC
administration and magnetic resonance imaging. d Representative RARE MRI scans of a rat that received MPIO-labelled DAPC
(left hemisphere: unlabelled, right hemisphere: labelled) as imaged on day 1, 14, 28, 42, 70 and 126 post administration.
Hypointense contrast, indicative of a reduction in relaxation time as caused by MPIO labelling, is seen in the right hemisphere
throughout the experimental period (indicated with an arrowhead in the first image). No abnormal growth is observed in either of
the hemispheres. e Immunofluorescence microscopy of the injection sites. Cells express human NCAM, showing that MPIO-
labelled DAPCs survived in the rats’ brains and TH, suggesting that DAPCs matured into DAs. MPIO-specific fluorescence is
only seen in the right hemisphere and tends to be localised near to the cell nuclei. Note that the MPIO fluorophore, Suncoast
Yellow, is also excited at 405 nm and bleeds into the DAPI channel. Scale bar = 50 μm.
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Intense Staining for GFAP Is Observed
Surrounding the Human Cell Implants
A previous study showed that the implantation of Fluc+
hESC-derived neural stem cells into the mouse striatum
caused marked glial reaction in the host brain, as evidenced
by intense immunostaining for glial fibrillary acidic protein
(GFAP), a marker of reactive astrocytes [10]. To investigate
whether Fluc-ZsGreen or MPIOs contributed to this reaction,
sections from group 2 and group 3 rats were immunostained
for GFAP. Qualitative analysis showed an increase in GFAP
staining around the human implants, but no differences in
staining intensity were observed around the implants
comprising unlabelled human cells or MPIO-labelled cells
(Fig. 5a and ESM Fig. 4a) and cells derived from Fluc-
ZsGreen+ hESCs (Fig. 5b and ESM Fig. 4b). Consistent with
the expression profile of ZsGreen in mature DA neurons
in vitro (Fig. 1e), the expression of ZsGreen in the brain
sections was barely detectable (Fig. 5b and ESM Fig. 4b).
Discussion
Our study assessed the effectiveness of BLI and MR
imaging to monitor the tumourigenicity, viability and
intracranial biodistribution of hESC-derived DAPCs follow-
ing stereotactic injection into the rat striatum. In most
animals, BLI could only detect Fluc-ZsGreen+ cells shortly
after administration and was not effective for monitoring
tumourigenicity and cell viability in the longer term. MR
imaging, on the other hand, could detect tumours arising
from undifferentiated hESCs and could monitor the intra-
cranial biodistribution of MPIO-labelled hESC-derived
DAPCs over the full time-course of our experiments.
The inability to detect cells with BLI likely resulted from
a number of factors. First, at the initial imaging session, the
rats were only 6 weeks old. During the intervening 2 weeks
before the next imaging session, the rats grew considerably
and became more pigmented (see ESM Fig. 3a), causing the
intensity of the emitted light to be reduced; this likely
explains why after day 1, bioluminescence could only be
Fig. 5. Glial reaction at the injection sites. a Immunofluorescence microscopy of brains from rats that received MPIO-
labelled DAPCs (left hemisphere: unlabelled; right hemisphere: labelled). The presence of human cells is identified with hNCAM
staining, and the intensity of GFAP staining is stronger in these areas. MPIOs are only seen in the right hemisphere. b
Immunofluorescence microscopy of brains from rats that received Fluc-ZsGreen+ DAPCs (left hemisphere: untransduced
control cells; right hemisphere Fluc-ZsGreen+ cells). Scale bars correspond to 100 μm.
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detected in a rat that had developed a large Fluc-ZsGreen+
hESC-derived mass (ESM Fig. 2a, rat 3). Bernau et al. found
that Fluc+ human foetal neuronal progenitors implanted into
the rat striatum could be imaged with BLI for 3 months [15].
However, they implanted 9 × 105 Fluc+ cells into the left
hemisphere compared with only 1.5 × 105 cells in our study.
An additional problem was that in comparison with
undifferentiated hESCs, we found that the expression levels
of the reporter genes decreased by ~50 % in Fluc-ZsGreen+
hESC-derived DAPCs and could not be detected at all in the
mature DA neurons. It is well recognised that ESC
differentiation is accompanied by increased levels of DNA
methylation, leading to gene silencing, and that the pattern
of silencing is cell type specific [16]. The choice of promoter
also affects the extent of silencing. A previous study
comparing the activity of five constitutive promoters,
EF1α, human β-actin (ACTB), cytomegalovirus (CMV),
phosphoglycerate kinase (PGK) and ubiquitinC (UbC) in
differentiating hESCs, reported that EF1α was the most
stable, with expression levels in EBs being reduced to ~50 %
of those in undifferentiated hESCs [17]. Our observation that
Fluc-ZsGreen expression was undetectable in the mature DA
neurons, both in vitro and in vivo, was unexpected.
Tennstaedt et al. have shown that a EF1α:Fluc-GFP+ neural
stem cell line derived from hESCs could be detected with
BLI for 6 weeks following injection into the mouse brain
without any noticeable decrease in bioluminescence inten-
sity [18]. However, the neural stem cells used in the
Tennstaedt study have a different phenotype to hESC-
derived DAPCs, and there is no evidence that they
differentiate into the DA lineage [18]. Likewise, there is no
evidence that the Fluc+ human foetal neuron progenitors
used in the aforementioned Bernau et al. study differentiate
into the DA lineage in the rat brain [15]. Indeed, as far as we
are aware, there are no studies that show Fluc expression in
hESC-derived DA neurons in vivo when Fluc is under the
control of a constitutive promoter. In future studies, a cell
type-specific promoter, such as FOXA2, which is expressed
in both DAPCs and mature DA neurons [19], could prove
more effective than the EF1α promoter for monitoring
viability longitudinally, especially if used with the highly
sensitive AkaLuc luciferase in combination with the sub-
strate Akalumine [20]. However, one advantage of our
system is that the loss of signal is due to differentiation. This
could be used to show that the grafted cells have indeed
followed the correct pathway post implantation rather than
dedifferentiated back into an ESC-like phenotype.
Four weeks after implantation of undifferentiated hESCs,
MR imaging could detect a cell mass in both cerebral
hemispheres, irrespective of whether the cells had been
transduced with the Fluc-ZsGreen reporter (ESM Fig. 2b).
However, no cell masses were detected at any time point
following administration of hESC-derived DAPCs, suggest-
ing that in contrast to the undifferentiated hESCs, the
DAPCs are non-tumourigenic. Cells labelled with MPIOs
could be detected at all time points using longitudinal MR
imaging. In addition, we found that the cells remained at the
injection site and did not appear to migrate to other brain
regions. From a safety perspective, the lack of migration is
important to prevent cells integrating into intact neural
circuits causing side effects (e.g. epilepsy) [21].
Previous studies have shown that labelling cells with iron
oxide nanoparticles can inhibit differentiation to specific
lineages [22, 23]. In our study, we did not find any evidence
that the bicistronic Fluc-ZsGreen reporter or the MPIOs
inhibited the differentiation of hESC-derived DAPCs into
TH+ DA neurons. The final aim of our study was to
investigate whether the reporter or the MPIOs increased glial
reactivity to the grafted cells. It is known that the
implantation of cells into the brain induces a glial response
[24], as evidenced by increased numbers of reactive GFAP+
astrocytes surrounding the grafts [10]. Transplantation of
both labelled and unlabelled DAPCs elicited a marked glial
reaction at the injection site, as expected. However, there
was no notable difference in the scale of glial response,
suggesting that neither Fluc-ZsGreen nor MPIOs increased
the glial reaction to the DAPCs [25].
Conclusions
In summary, we have demonstrated that hESC-derived
DAPCs can be labelled with luminescence and contrast-
enhancing reporters for in vivo cell tracking. Following
intracranial transplantation in the rat striatum, our findings
support the safe implementation of DAPC-derived therapies
for the treatment of PD.
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Self-Assembling Proteins as High-Performance Substrates 
for Embryonic Stem Cell Self-Renewal
Christopher J. Hill, Jennifer R. Fleming, Masoumeh Mousavinejad, Rachael Nicholson, 
Svetomir B. Tzokov, Per A. Bullough, Julius Bogomolovas, Mark R. Morgan, Olga Mayans,* 
and Patricia Murray*
modeling of disease, drug discovery, the 
screening of toxicants, and personal-
ized therapies in regenerative medicine 
for conditions like age-related macular 
degeneration and Parkinson’s disease.[3,4] 
Human pluripotent stem cells (hPSCs), 
specifically human embryonic stem cells 
(hESCs) and induced pluripotent stem 
cells (iPSCs), are of critical significance 
in these pursuits.[5] Biomedical applica-
tions of hPSCs require large-scale ex vivo 
culture. Therapeutic uses require, in addi-
tion, xeno-free conditions to avoid risk 
of zoonotic transmission. Meeting these 
combined requirements is challenging 
as hPSCs are typically cultured on costly 
animal-derived substrates of undefined 
and variable batch-to-batch composition. 
In particular, hPSCs are commonly cocul-
tured with mouse fibroblast feeder cells 
or grown on Matrigel, a complex mixture 
of extracellular matrix (ECM) proteins 
secreted by mouse sarcoma cells that con-
sists primarily of laminin, collagen IV, and entactin.[6] Recently, 
substrates based on the recombinant eukaryotic expression of 
ECM proteins such as laminin or vitronectin have been intro-
duced.[7,8] These successfully support hPSC self-renewal,[9,10] 
The development of extracellular matrix mimetics that imitate niche 
stem cell microenvironments and support cell growth for technological 
applications is intensely pursued. Specifically, mimetics are sought that 
can enact control over the self-renewal and directed differentiation of 
human pluripotent stem cells (hPSCs) for clinical use. Despite considerable 
progress in the field, a major impediment to the clinical translation of hPSCs 
is the difficulty and high cost of large-scale cell production under xeno-free 
culture conditions using current matrices. Here, a bioactive, recombinant, 
protein-based polymer, termed ZTFn, is presented that closely mimics human 
plasma fibronectin and serves as an economical, xeno-free, biodegradable, 
and functionally adaptable cell substrate. The ZTFn substrate supports with 
high performance the propagation and long-term self-renewal of human 
embryonic stem cells while preserving their pluripotency. The ZTFn polymer 
can, therefore, be proposed as an efficient and affordable replacement for 
fibronectin in clinical grade cell culturing. Further, it can be postulated that 
the ZT polymer has significant engineering potential for further orthogonal 
functionalization in complex cell applications.
The generation of substrates that preserve pluripotency in 
human stem cells and direct their controlled differentiation 
is intensely pursued.[1,2] Such substrates are of critical value 
to stem-cell-based applications, such as those concerning the 
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but have high purchase costs. Together with the expense 
of clinical grade culture media, this limits the upscaling of 
hPSC expansion (e.g., in large-scale 3D culture systems using 
microcarriers[11]) using these substrates. Chemical substrates 
carrying conjugated peptides are also available, like Synthemax. 
However, in addition to their high cost, their use in therapeutic 
applications might raise potential safety concerns. For example, 
Synthemax is made of carboxylic acid-carrying acrylate, to which 
peptides derived from vitronectin are attached using chemical 
crosslinking.[12] It successfully supports hPSC expansion[12] but 
it has been observed to lead to genetic abnormalities in long-
term cell cultures.[13] In summary, the need for economic and 
safe translational materials persists.
The protein polymer ZT[14] holds promise to meet the need 
for an economical, homogeneous, and functionally adaptable 
cell substrate of controlled composition. ZT exploits the compl-
exation of the protein telethonin (Tel) with the two N-terminal 
immunoglobulin (Ig) domains from titin, Z1Z2, which occurs 
naturally in human sarcomeres. Tel is “sandwiched” between 
two antiparallel Z1Z2 doublets, forming a robust intermolecular 
β-sheet that spans the three components[15] (Figure 1A). Both 
Tel and Z1Z2 can be overexpressed recombinantly in bacteria 
with a high yield. The ZT polymer is based on a Z1Z2–Z1Z2 
fusion tandem (Z1212) that causes the spontaneous propaga-
tive assembly of Z1Z2:Tel complexes.[14] ZT components can 
be readily functionalized by genetically encoding functional 
moieties into the building blocks prior to their assembly. This 
strategy affords exact control on the position and stoichiometry 
of exogenous elements in the polymer. As proof of principle, 
ZT was engineered to display an affinity motif N-terminal to Tel 
that recruited gold nanoparticles to the polymer with nanoscale 
periodicity.[14] Moreover, the isolated Z1 domain showed that its 
CD loop permits the grafting of lengthy peptide motifs without 
causing fold perturbations, serving as an accessible and func-
tional epitope.[16] Thereby, the ZT polymer can allow the incor-
poration of functional moieties in a controllable fashion.
Here, we aimed to exploit the polymeric nature, scaffolding 
capabilities, and ease of production of the ZT polymer to 
develop an economic substrate for culturing hESCs. Specifi-
cally, we aimed to mimic the efficiency of human fibronectin in 
supporting hESC self-renewal in serum-free conditions.[17,18] In 
fibronectin, the small peptide RGD in domain Fn10 is the crit-
ical integrin-binding motif mediating cell adhesion, spreading, 
and migration.[19] Accordingly, RGD peptide mimetics are 
frequently employed as adhesive moieties on substrates for 
cell culture applications.[20,21] hESCs do not attach to RGD 
peptides,[18] but a proteolytic 120 kDa fibronectin fragment con-
taining the complete Fn10 domain successfully supported their 
self-renewal.[18] Building on this knowledge and on the fact that 
fibronectin supports cell attachment with higher efficacy than 
RGD alone,[22] we have assessed the mimetic potential of the 
ZT polymer functionalized with RGD and Fn10 moieties.
First, we established that the ZT polymer remains unaltered 
upon display of exogenous bioreactive motifs. For this, we cre-
ated two functionalized Z1212 variants by genetically fusing DNA 
sequences: 1) a Z1212 tandem carrying the fibronectin GRGDS 
motif in the CD loop of the second Z1 domain (Z1212RGD) 
(Figure 1A,B) and 2) a Z1212 chimera where the Fn10 domain from 
fibronectin had been fused C-terminally to the tandem (Z1212Fn) 
via the same GETTQ linker sequence originally used to join Z1Z2 
doublets[14] (Figure 1C). In Z1212RGD, the GRGDS sequence has 
higher affinity for integrins than the core RGD motif alone, with 
the flanking residues known to enhance cell attachment.[23,24] 
This resulted ultimately in the substitution of four native Z1 resi-
dues for a seven-residue peptide (Figure 1B). For comparison, a 
biologically inactive RGE version[22] was created (Z1212RGE).
The variants Z1212RGD, Z1212RGE, and Z1212Fn proved unde-
manding to produce recombinantly in Escherichia coli cultures. 
Pure, stable, and monodisperse samples of all variants were 
produced in high yields equivalent to the wild type protein Z1212 
(>40 mg L−1 culture) (Figure S1A,B, Supporting Information). 
To test the capability of the variants to self-assemble, and given 
that the Z1Z2/Tel complex is the fundamental assembly unit 
of the ZT polymer, we considered that complexation of Tel by 
modified Z1Z2 samples at the native 2:1 ratio was evidence of 
undisrupted assembly in these variants. Therefore, we produced 
Z1Z2RGD/Tel and Z1Z2Fn/Tel complexes by in cellulo co-expres-
sion, studied their migration in size exclusion chromatography 
(SEC), and measured their molecular mass by SEC-coupled 
multi-angle laser light scattering (MALLS), confirming the 
expected 2:1 association (Figure S1C–E, Supporting Informa-
tion). Next, we mixed the polymerizing Z1212 variants (Z1212RGD, 
Z1212RGE, and Z1212Fn) with Tel and confirmed assembly by 
native-PAGE (Figure S1F,G, Supporting Information) and 
electron microscopy (Figure 1D); the resulting polymers are 
here denoted as ZTRGD, ZTRGE, and ZTFn, respectively. Taken 
together, these results proved that the Z1212 building block 
could be successfully functionalized in both internal (CD loop) 
and external (C-terminus) positions, maintaining its structural 
integrity and its polymerization capability.
The conformation of the RGD motif influences the selec-
tivity and affinity of the integrin receptors it engages and, 
thereby, its efficiency in cell adhesion.[22,24–26] Thus, we studied 
whether the RGD motif inserted in Z1 resembles the motif in 
the native Fn10. In Fn10, the motif is located within the FG 
β-hairpin loop that resembles a distorted type II’ β-turn with 
high intrinsic flexibility.[25,27] To confirm the degree of structural 
mimicry achieved by the loop engineered in Z1, we elucidated 
the crystal structure of Z1212RGD at 3.0 Å resolution (Table S1, 
Supporting Information). The structure confirmed that the fold 
of Z1 is not altered by the inserted sequence, with the struc-
ture closely matching that of wild-type Z1 (rmsd = 0.47 Å to 
Z1 in Protein Data Bank (PDB) entry 2A38[28]) (Figure 1E). The 
inserted SSGRGDSS sequence formed a loop protruding from 
the surface of Z1 as expected, in quasi β-turn conformation and 
with evident signs of flexibility (Figure S2, Supporting Informa-
tion), thereby reproducing the features of the native motif in 
fibronectin. Comparison of crystal structures for modified Z1 
and Fn10 (PDB IDs: 1FNA, 1FNF, and 4MMX) showed that the 
engineered RGD motif locally adopts a similar conformation 
(Figure 1F,G). These data confirm the ability of the introduced 
sequence to emulate the native RGD motif.
We then tested whether the functionalized ZT polymer 
promoted spreading of murine mesenchymal stromal cells 
(mMSC) by comparing the relative efficiency of cell attachment 
to the ZTRGD and ZTFn polymers. For this analysis, we employed 
the clonally-derived mMSC line D1, which tolerates a variety of 
RGD-based substrata.[29–31] We cultured mMSCs on nonadhesive 
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polystyrene plates coated with the ZTRGD, ZTRGE, and ZTFn poly-
mers under serum-free conditions and quantified cell attach-
ment and dispersion. At 2 h culture, mMSCs showed adherence 
to both ZTRGD and ZTFn in a concentration-dependent manner, 
confirming the accessibility of both RGD and Fn10 moieties 
within the polymer (Figure 2A,B). However, consistently more 
Figure 1. The functionalized ZT polymer. A) Crystal structure of the “sandwich” complex formed by two antiparallel Z1Z2 Ig-doublets from titin (blue) 
and Tel (red) (PDB: 1YA5[15]). The CD loop of domain Z1 is boxed. B) Sequence of the native and modified CD loop. The residues introduced are 
colored red. C) Z1212 protein carrying a C-terminally fused domain Fn10 from human fibronectin (PDB: 1FNF,[25] green). Fusion of naturally-occurring 
protein moieties in this chimera uses a GETTQ linker sequence. The native RGD motif located within the FG loop of Fn10 is displayed. D) Transmission 
electron microscopy images of ZTWT, ZTRGD, ZTRGE, and ZTFn polymers postassembly (scale bars correspond to 100 nm). E) Crystal structure of the 
GRGDS modified Z1 domain superimposed on wild-type Z1 (PDB 2A38[28]). F) Superimposition of crystal structures of domain Fn10 from fibronectin 
(PDB codes are given). The conformational flexibility of the RGD loop (colored) is manifest. G) Superimposition of the RGD loop in Z1 (orange) with 
those from Fn10 structures shows that the motif incorporated in Z1 adopts a near-native conformation at the local level (structure 1FNA is excluded 
as its conformation is unique).
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cells attached to ZTFn than to ZTRGD. As expected, the non-bioac-
tive ZTRGE did not support cell attachment. mMSC spreading was 
quantified by calculating the average cell area for all conditions 
(Figure 2C). Spreading was significantly increased on ZTRGD 
and ZTFn compared to the plastic control, but ZTFn showed the 
best performance. In addition, cell profiles were used to deter-
mine the average circularity (or area-to-perimeter ratio), aspect 
ratio (AR), and solidity of mMSCs plated on human plasma 
fibronectin, ZTRGD or ZTFn (Figure 2D). Values were remarkably 
equivalent for cells grown on ZTFn or fibronectin, while differ-
ences were observed in cells plated on ZTRGD. Higher circularity 
and solidity values for mMSCs cultured on ZTRGD correlated 
with a symmetric spreading on this substrate, while the higher 
AR and lower solidity of cells cultured on ZTFn or fibronectin 
indicate anisotropic spreading. By using a competitive inhibition 
assay that employed a linear GRGDS peptide, we confirmed that 
the observed effects on cell attachment are due to the respec-
tive specificities of the engineered ZTRGD and ZTFn polymers 
for integrin binding (Figure S3, Supporting Information). To 
further investigate attachment, we examined the impact of the 
different substrates on cytoskeletal organization and adhesion 
complexes (Figure 2E). Focal complexes were observed on all 
substrates. However, mMSCs plated on fibronectin or ZTFn dis-
played well-developed stress fiber networks, while cells attached 
to ZTRGD exhibited fewer stress fibers and a cortical actin distri-
bution. Taken together, cell adhesion and spreading data indi-
cated that the loop-grafted GRGDS motif was insufficient to 
support effective mMSC attachment, but that the interaction of 
cells with the ZTFn polymer mimicked that of full-length human 
fibronectin.
Figure 2. Murine MSC and human ESC adhesion and spreading on ZT substrates. A) Representative phase-contrast micrographs of mMSCs cultured 
for 2 h under serum-free conditions on nontreated plastic coated with ZT polymers at 10 μg mL−1 (scale bar = 100 μm). B,C) Effect of ZTRGE 
(non-bioactive), ZTRGD, and ZTFn substrates on mMSC adhesion (B) and spreading (C). Cell attachment is expressed as a percentage of the positive 
control (fibronectin at 10 μg mL−1) that was taken as 100%. The average area of cells grown on fibronectin is included for comparison. Statistical 
significance in (B) and (C) is in reference to a nontreated surface (0 μg mL−1). D) Comparisons of the average circularity, aspect ratio, and solidity of cells 
grown on nontreated plastic coated with fibronectin, ZTRGD, or ZTFn, all samples at 10 μg mL−1. E) Representative confocal microscopy images of cells 
stained for F-actin (green), paxillin (red), and DAPI (blue) following attachment to different substrates. Zooms of boxed areas are shown in the upper 
right of the respective image. F) Representative phase-contrast images of HUES7 cells cultured for 2 and 4 h on ZTRGD, ZTFn, and control substrates. 
Scale bar = 100 μm. G) Quantification of cell attachment and spreading is shown by the bar charts. Cell attachment is expressed as a percentage of the 
positive control (Matrigel) that was taken as 100%. H) Comparisons of the average circularity, aspect ratio, and solidity of cells plated on plastic plates 
coated with Matrigel, fibronectin, or ZTFn at 10 μg mL−1. I) Representative confocal microscopy images of cells stained for F-actin (green), paxillin (red), 
and DAPI (blue) following attachment to different substrates. Zooms of boxed areas are shown in the upper right of the respective image. (Error bars 
represent the standard error on the mean (SEM), n = 3. Scale bar = 50 μm if not otherwise stated. Throughout, *p < 0.05, **p < 0.01, and ***p < 0.001).
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To assess the capability of ZTFn to support cell growth in 
potential clinical applications, we then tested this polymer on 
human HUES7 cells, proving that hESCs attach to and prolif-
erate on ZTFn. HUES7 cells neither attach nor spread on mate-
rials functionalized with RGD peptides, but they can be cultured 
on fibronectin or large proteolytic fragments thereof.[18] Accord-
ingly, we confirmed that HUES7 cells did not adhere to ZTRGD 
(Figure 2F) or to the Fn10 domain alone (in the absence of the 
polymerized ZT) (Figure S4, Supporting Information). How-
ever, they attached successfully to the ZTFn polymer. Moreover, 
the extent of HUES7 cell attachment and spreading on ZTFn 
was comparable to that on human plasma fibronectin (both 
substrates used at comparable amounts; Figure S5, Supporting 
Information). Cell attachment and spreading on both fibronectin 
and ZTFn were only moderately lower than those obtained from 
the complex matrix Matrigel (Figure 2G). We concluded that 
the ZTFn polymer comparatively resembled the performance of 
native fibronectin in supporting hESC growth and spreading.
We further compared the effect of ZTFn, fibronectin, and 
Matrigel on cell growth. As our long-term goal is to support the 
clinical application of hPSCs, we focused this test on established 
biological substrates, naturally produced by living cells and com-
posed only of biodegradable, folded protein components that 
have not undergone chemical treatment. We did not employ 
chemical substrates (e.g., Synthemax) as comparative controls 
to ZTFn because of their more distant composition. The results 
showed that, while average cell circularity and solidity were con-
sistent between substrates, the average AR of cells plated on ZTFn 
was significantly higher than that of cells cultured on fibronectin 
and particularly higher than Matrigel, reflecting the asymmetric 
spreading on ZTFn (Figure 2H). F-actin and paxillin staining 
showed that focal adhesions were present in HUES7 cells grown 
on Matrigel and ZTFn, but were less common on fibronectin 
(Figure 2I). Filopodia-like projections were abundant in cells cul-
tured on Matrigel and in some cells grown on fibronectin, but 
cells grown on ZTFn lacked projections and exhibited a geometric 
morphology with well-defined actin stress fibers (Figure 2I). 
Intriguingly, the observed increase in actin filamentation was 
sustained following prolonged culture on ZTFn (Figure S6A, 
Supporting Information). Despite their morphological differ-
ences, cells grown on ZTFn retained an ESC phenotype following 
single cell dissociation as confirmed by nuclear OCT4 and 
NANOG expression (Figure S6B, Supporting Information). Cells 
on all substrates successfully began to form colonies after 24 h 
(Movies S1–S3, Supporting Information) and robustly expressed 
pluripotency markers (Figure S7A, Supporting Information). 
Additionally, focal adhesions were found to contain focal adhe-
sion kinase (FAK) phosphorylated at tyrosine 397 (pY397), 
confirming the activation of signaling pathways downstream of 
integrin engagement (Figure S7B, Supporting Information).
To better characterize the molecular mode of action of ZTFn, 
we set out to identify the integrins it engages. As fibronectin 
attachment is largely dependent on α5β1 and αVβ3,[32] we tested 
first the involvement of these integrins in HUES7 cells plated 
on ZTFn. While we detected α5β1 in focal adhesions (Figure 3A), 
we did not detect αVβ3 (Figure S8A,B, Supporting Informa-
tion). Unexpectedly, targeting the αV subunit alone produced 
robust focal adhesion-like staining, as did an antibody against 
subunit β5 unique to the αVβ5 heterodimer (Figure 3B). Thus, 
we concluded that HUES7 cell attachment to ZTFn is mediated 
by αVβ5 and α5β1 integrins present in cell adhesion complexes 
(Figure 3C). After 2 days of culture, the cells continued to engage 
αVβ5 (Figure S9, Supporting Information). On the contrary, cells 
grown on Matrigel and fibronectin were negative for both αV 
and β5 adhesion-specific staining (Figure S8B, Supporting Infor-
mation). Currently, there is no robust evidence for the binding 
of αVβ5 to fibronectin; therefore, its engagement by ZTFn was 
unexpected. Integrin αVβ5 is a well-characterized receptor of the 
RGD motif in the somatomedin-B domain from vitronectin.[33,34] 
Accordingly, αVβ5 mediates hPSC attachment to vitronectin,[35,36] 
and attachment of hiPSC lines IMR90 and Gibco episomal line 
to the synthetic vitronectin-based peptide acrylate, Synthemax.[12] 
In agreement with our finding, we observed that the morphology 
of cells grown on ZTFn strikingly emulated that of cells grown 
on vitronectin (Figure S10, Supporting Information). Both cells 
cultured on vitronectin and ZTFn also displayed increased stress 
fiber formation and large focal adhesions containing FAK pY397 
(Figure S10, Supporting Information). The larger size of focal 
adhesions formed on the ZTFn substrate caused the cells to 
migrate more slowly in comparison to Matrigel and fibronectin 
substrates, as a close relationship exists between the size of focal 
adhesions and cell migration speed (Figure 3D).[37] Slow migra-
tion was reproduced by cells cultured on vitronectin (Figure 3D). 
Upon prolonged culture on all substrates, cells formed colonies. 
Colonies grown on Matrigel exhibited α5β1 expression in dis-
tinct fibrillar patterns while expression of this integrin was lost 
on ZTFn (Figure S9A, Supporting Information). Yet, colonies 
grown on ZTFn continued to express αVβ5 (Figure S9B, Sup-
porting Information). It is remarkable to observe that the pres-
entation of the Fn10 domain in the context of the ZTFn polymer 
induces a preferential switch to αVβ5. It can be concluded that 
not only the chemical composition of the bioreactive motif but 
also the geometry of its presentation to the cell is critical for inte-
grin selectivity. This finding adds to the previous observation that 
the specific conformation of fibronectin on different synthetic 
surfaces dramatically influenced integrin binding.[38]
To investigate whether the observed difference in integrin 
engagement affected cell phenotype, we assessed the ability 
of ZTFn to promote survival of single HUES7 cells. We found 
that hESCs maintain a pluripotent phenotype following pro-
longed culture on ZTFn, which supported clonal expansion 
with an efficacy comparable to fibronectin and only moderately 
reduced relative to Matrigel (Figure 4A). Cell proliferation was 
somewhat reduced on ZTFn compared to Matrigel, but was not 
significantly different from fibronectin (Figure 4B). Finally, 
we assessed the ability of ZTFn to maintain the long-term self-
renewal of HUES7 cells. For this, the cells were cultured in 
mTeSR1 medium (without ROCK inhibitor, a compound used 
to extend cell survival[39]) for up to 18 passages. The cells were 
passaged every 5–6 days as clumps containing 50–200 cells; they 
were cultured on ZTFn for ≈4 months in total with no notice-
able negative effects. The cells grew as colonies with typical 
morphologies, including a high nuclear-to-cytoplasmic ratio 
and prominent nucleoli. Cells also retained nuclear expression 
of OCT4 and NANOG (Figure S11A, Supporting Information). 
Relative gene expression analysis of pluripotency markers OCT4, 
NANOG, and SOX2 was used to compare cells cultured on 
Matrigel with those cultured on fibronectin or ZTFn for 1, 5, and 
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10 passages. NANOG and SOX2 transcript levels were found 
to be significantly decreased in cells cultured on fibronectin at 
passage 10 (Figure 4C). Although NANOG expression was also 
downregulated in cells cultured on ZTFn at passage 10 relative 
to Matrigel, expression was significantly higher compared to 
fibronectin (Figure 4C). Cells cultured on ZTFn or fibronectin 
for 13 passages were used to form embryoid bodies that con-
tained derivatives of the three embryonic germ layers in vitro 
(Figure S11B in Supporting Information). Positive staining for 
Brachyury (mesoderm), GATA6 (GATA-binding factor 6, endo-
derm), and Nestin (ectoderm) confirmed that HUES7 cells 
remained pluripotent following their long-term culture on ZTFn.
In conclusion, we show that the ZT polymer is a chimeric 
composite of recombinant human proteins, with high function-
alization capability.[14] Neither loop grafting nor domain fusion 
reduced the bacterial production yield of Z1212 variants, an impor-
tant consideration for large-scale applications. We show that 
the functionalized ZT system is compatible with standard cell 
culture techniques and that it serves as an efficient substrate for 
the long-term self-renewal of pluripotent hESCs, being a viable 
substitute for natural fibronectin and other commonly used 
matrices for hPSC culture. The material is produced in bacteria; 
it is scalable and predictably compatible with 3D culture systems. 
In this regard, the incorporation of natural ECM proteins with 3D 
Figure 3. Integrin engagement and migration of human ESCs on ZTFn. A) Representative pseudocolored confocal microscopy images show paxillin 
(red) and α5 integrin subunit (green) costaining of HUES7 cells following 4 h culture on ZTFn. The fluorescence intensity line scan profile was generated 
from the merged image shown below. Scale bars = 10 μm. B) Staining of αV and β5 integrin subunits (red). The merged images show counterstaining 
for F-actin (green) and DAPI (blue). Scale bar = 50 μm. C) Pseudocolored microscopy images show costaining of α5 (green) and β5 (purple) subunits 
in HUES7 cells cultured on ZTFn. A fluorescence intensity profile is shown for the merged image. Scale bars = 10 μm. D) Box-and-whisker plots of cell 
migration. Boxes show the median (middle line), mean (square), 25th and 75th percentiles (box ends), and 5th and 95th percentiles (whiskers) (n = 80).
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materials using crosslinking is established in the bibliography. 
For example, fibronectin has been photocrosslinked into hya-
luronic acid 3D hydrogels for endothelial cell culture.[40] As the 
ZT polymer is composed of folded protein domains that closely 
resemble those of fibronectin, its incorporation in 3D systems 
via chemical crosslinking can be expected to be an equally fea-
sible goal. In summary, economical substrates of controlled com-
position such as the ZTFn polymer will be essential for further 
advancement in the clinical translation of PSC-based therapies.
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Figure 4. Human ESC clonal culturing and self-renewal on ZTFn. A) Clonogenic survival of cells plated on Matrigel, fibronectin, and ZTFn at a density 
of 2.5 × 103 cm−2. B) Proliferative capacity of HUES7 cells cultured on Matrigel, fibronectin, or ZTFn over 4 days. Error bars represent SEM (n = 4). 
C) Quantitative RT-qPCR analysis of NANOG, OCT4, and SOX2 expression levels in HUES7 cells cultured on fibronectin or ZTFn for 1, 5, and 10 pas-
sages relative to cells cultured on Matrigel. Error bars represent SEM (n = 3).
Publications
131
1807521 (8 of 8)
Keywords
biomaterials, protein engineering, protein self-assembly, self-renewal, 
stem cells
[1] C. M. Madl, S. C. Heilshorn, Annu. Rev. Biomed. Eng. 2018, 20, 21.
[2] Z. Liu, M. Tang, J. Zhao, R. Chai, J. Kang, Adv. Mater. 2018, 30, 
1705388.
[3] R. S. Thies, C. E. Murry, Development 2015, 142, 3614.
[4] Y. Avior, I. Sagi, N. Benvenisty, Nat. Rev. Mol. Cell Biol. 2016, 17, 
170.
[5] Y. Shi, H. Inoue, J. C. Wu, S. Yamanaka, Nat. Rev. Drug Discovery 
2017, 16, 115.
[6] C. S. Hughes, L. M. Postovit, G. A. Lajoie, Proteomics 2010, 10, 
1886.
[7] E. Sanjar, S. Jin, World J. Stem Cells 2015, 7, 243.
[8] Y. Fan, J. Wu, P. Ashok, M. Hsiung, E. S. Tzanakakis, Stem Cell Rev. 
Rep. 2015, 11, 96.
[9] A. B. J. Prowse, M. R. Doran, J. J. Cooper-White, F. Chong, 
T. P. Munro, J. Fitzpatrick, T. L. Chung, D. N. Haylock, P. P. Gray, 
E. J. Wolvetang, Biomaterials 2010, 31, 8281.
[10] T. Miyazaki, S. Futaki, H. Suemori, Y. Taniguchi, M. Yamada, 
M. Kawasaki, M. Hayashi, H. Kumagai, N. Nakatsuji, K. Sekiguchi, 
E. Kawase, Nat. Commun. 2012, 3, 1236.
[11] C. Kropp, D. Massai, R. Zweigerdt, Process Biochem. 2017, 59, 244.
[12] Z. Melkoumian, J. L. Weber, D. M. Weber, A. G. Fadeev, 
Y. Zhou, P. Dolley-Sonneville, J. Yang, L. Qiu, C. A. Priest, 
C. Shogbon, A. W. Martin, J. Nelson, P. West, J. P. Beltzer, S. Pal, 
R. Brandenberger, Nat. Biotechnol. 2010, 28, 606.
[13] J. W. Lambshead, L. Meagher, J. Goodwin, T. Labonne, E. Ng, 
A. Elefanty, E. Stanley, C. M. O’Brien, A. L. Laslett, Sci. Rep. 2018, 
8, 701.
[14] M. Bruning, L. Kreplak, S. Leopoldseder, S. A. Muller, P. Ringler, 
L. Duchesne, D. G. Fernig, A. Engel, Z. Ucurum-Fotiadis, 
O. Mayans, Nano Lett. 2010, 10, 4533.
[15] P. Zou, N. Pinotsis, S. Lange, Y.-H. Song, A. Popov, I. Mavridis, 
O. M. Mayans, M. Gautel, M. Wilmanns, Nature 2006, 439, 229.
[16] M. Bruning, I. Barsukov, B. Franke, S. Barbieri, M. Volk, 
S. Leopoldseder, Z. Ucurum, O. Mayans, Protein Eng., Des. Sel. 
2012, 25, 205.
[17] M. A. Baxter, M. V. Camarasa, N. Bates, F. Small, P. Murray, 
D. Edgar, S. J. Kimber, Stem Cell Res. 2009, 3, 28.
[18] D. M. Kalaskar, J. E. Downes, P. Murray, D. H. Edgar, R. L. Williams, 
J. R. Soc., Interface 2013, 10, 20130139.
[19] A. J. Zollinger, M. L. Smith, Matrix Biol. 2017, 60–61, 27.
[20] L. Perlin, S. Macneil, S. Rimmer, Soft Matter 2008, 4, 2331.
[21] S. L. Bellis, Biomaterials 2011, 32, 4205.
[22] P. Rajagopalan, W. A. Marganski, X. Q. Brown, J. Y. Wong, Biophys. J. 
2004, 87, 2818.
[23] M. D. Pierschbacher, E. Ruoslahti, Nature 1984, 309, 30.
[24] T. G. Kapp, F. Rechenmacher, S. Neubauer, O. V. Maltsev, 
E. A. Cavalcanti-Adam, R. Zarka, U. Reuning, J. Notni, H. J. Wester, 
C. Mas-Moruno, J. Spatz, B. Geiger, H. Kessler, Sci. Rep. 2017, 7, 
39805.
[25] D. J. Leahy, I. Aukhil, H. P. Erickson, Cell 1996, 84, 155.
[26] E. Ruoslahti, B. Obrink, Exp. Cell Res. 1996, 227, 1.
[27] A. L. Main, T. S. Harvey, M. Baron, J. Boyd, I. D. Campbell, Cell 
1992, 71, 671.
[28] M. Marino, P. Zou, D. Svergun, P. Garcia, C. Edlich, B. Simon, 
M. Wilmanns, C. Muhle-Goll, O. Mayans, Structure 2006, 14, 1437.
[29] N. Huebsch, P. R. Arany, A. S. Mao, D. Shvartsman, O. A. Ali, 
S. A. Bencherif, J. Rivera-Feliciano, D. J. Mooney, Nat. Mater. 2010, 
9, 518.
[30] Y. Lei, S. Gojgini, J. Lam, T. Segura, Biomaterials 2011, 32, 39.
[31] M. Mehta, C. M. Madl, S. Lee, G. N. Duda, D. J. Mooney, J. Biomed. 
Mater. Res., Part A 2015, 103, 3516.
[32] M. R. Morgan, A. Byron, M. J. Humphries, M. D. Bass, IUBMB Life 
2009, 61, 731.
[33] J. P. Kim, K. Zhang, J. D. Chen, R. H. Kramer, D. T. Woodley, 
J. Biol. Chem. 1994, 269, 26926.
[34] I. Schvartz, D. Seger, S. Shaltiel, Int. J. Biochem. Cell Biol. 1999, 31, 
539.
[35] S. R. Braam, L. Zeinstra, S. Litjens, D. Ward-van Oostwaard, 
S. van den Brink, L. van Laake, F. Lebrin, P. Kats, R. Hochstenbach, 
R. Passier, A. Sonnenberg, C. L. Mummery, Stem Cells 2008, 26, 2257.
[36] T. J. Rowland, L. M. Miller, A. J. Blaschke, E. L. Doss, A. J. Bonham, 
S. T. Hikita, L. V. Johnson, D. O. Clegg, Stem Cells Dev. 2010, 19, 
1231.
[37] D. H. Kim, D. Wirtz, FASEB J. 2013, 27, 1351.
[38] B. G. Keselowsky, D. M. Collard, A. J. García, J. Biomed. Mater. Res., 
Part A 2003, 66A, 247.
[39] K. Watanabe, M. Ueno, D. Kamiya, A. Nishiyama, M. Matsumura, 
T. Wataya, J. B. Takahashi, S. Nishikawa, S. Nishikawa, 
K. Muguruma, Y. Sasai, Nat. Biotechnol. 2007, 25, 681.
[40] S. K. Seidlits, C. T. Drinnan, R. R. Petersen, J. B. Shear, L. J. Suggs, 
C. E. Schmidt. Acta Biomater. 2011, 7, 2401.
Publications
132
